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PREFACE
This volume is a compendium of articles from the Morbidity and Mortality Weekly
Report (MMWR ) that were prepared on the occasion of the 50th anniversary of CDC,
marked on July 1, 1996. The compendium comprises articles from the MMWR weekly
selected primarily on the basis of their historical merit and interest to public health
practice. For each of the 20 selections, we invited past and/or current CDC experts
(and, in some cases, experts from outside CDC) to write a new editorial note about
some aspect of each article and its relation to the evolution of public health practice.
The topics of these reports span the scope of public health problems addressed
and reported by CDC in MMWR  after responsibility for MMWR  came to CDC in 1961.
The new editorial notes for many of these reports were contributed to by persons who
played key roles in responses to the problems at the time they occurred; we encour-
aged these contributors to share perspectives and details of special historical interest.
We hope the reprinted reports and new commentaries are serviceable not only to local
and state public health officials, who contribute to and use MMWR, but also by public
health and medical practitioners in other settings, schools of public health, and other
academic programs with concentrations in the history and policies of health.
MMWR’s history is intertwined with the evolution of public health in the United
States. In the spring of 1878, Congress passed the first National Quarantine Act requir-
ing U.S. consuls to report sanitary conditions abroad and on vessels bound for U.S.
ports. From these and other sources, the Surgeon General of the Public Health Service
(PHS) was directed to publish weekly abstracts for transmission to PHS medical offi-
cers, collectors of customs, and state and local health authorities. Thus, on July 13,
1878, under the name, Bulletin No. 1, the predecessor of MMWR  was born. The Bulle-
tins  lasted barely 46 issues, but they chronicled such grim and terrifying events as the
great yellow fever epidemic of the Mississippi Valley.
The National Board of Health and its quarantine reports followed the Bulletin. Pub-
lication resumed, however, in 1887 when No. 47 appeared as the Weekly Abstract of
Sanitary Reports. Although only a few pages, it reached 1800 readers and was, ac-
cording to its editor, “greatly appreciated not only by quarantine officers, but by
steamship companies, merchants, and the press.” By 1897, the Abstract  became Pub-
lic Health Reports, a weekly journal devoted to reporting epidemics and morbidity and
mortality, but scientific articles as well. Several federal agencies sponsored this publi-
cation during the first half of the century, and by 1952 MMWR  acquired its present
name, published then by the National Office of Vital Statistics. However, in 1960, CDC
(then the Communicable Disease Center) was given the responsibility, and the first
issue published by CDC appeared on January 13, 1961.
Distributing objective scientific information, albeit often preliminary, to the public
at large, MMWR  has filled that critical time gap between the immediacy of the news
media’s interpretation and the long wait for publication in the scientific journals. In
fact, CDC has published extra issues when health events of national importance re-
quired immediate, scientific, and objective reporting. For example, the 1970–71 na-
tionwide epidemic of bacteremia associated with contaminated intravenous fluids
and the 1976 occurrence of Guillain-Barré syndrome associated with the swine influ-
enza vaccination program demanded immediate reporting to the nation that MMWR 
provided.
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The primary purpose of MMWR  has been to report events of public health interest
and importance to CDC’s major constituents—state and local health departments—
and as quickly as possible. In large part, they are the ones who recognize and report
the data to CDC and, therefore, they should receive the greatest credit for the
MMWR’s role in prevention and control of morbidity and mortality.
Our experiences as Editors of the MMWR  span 3 decades and most of the history
of the MMWR  at CDC. We are proud of the accomplishments of the MMWR  on behalf
of CDC and in the service of public health in the United States and worldwide, and we
are pleased to present this compendium. We hope you find it helpful in the study and
practice of public health.
                                                    Richard A. Goodman, M.D., M.P.H.
                Editor, 1988–1998
                                                    Karen L. Foster, M.A.
                Assistant Editor, 1982–1986;
                Managing Editor, 1988–
                                                    Michael B. Gregg, M.D.
                Editor, 1967–1988
In this compendium, we have corrected typographic inconsistencies and errors published both
in the original reports and in the reprinted reports with new editorial notes. We have changed
text references to page numbers and table and figure call-outs to reflect the pagination of this
volume. Tables and figures appear inconsistent only because we attempted to recreate their
original style and format.
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FOREWORD
CDC. MMWR. Public health. Respect. Timeliness. Efficiency. Protecting the health of
the public. All synonymous. All American. Now global. A source of pride and trust for
us all. The Centers for Disease Control and Prevention.
In 1996, the original CDC celebrated its 50th anniversary. CDC logically began right
after the Second World War at a time when the United States of America began to put
a lot of money and effort into health improvements for its people. The Depression was
over, as was the world’s great war. Such movements as the GI Bill for education, the
beginning of the baby boomers generation, and greatly increased funding for the Na-
tional Institutes of Health were under way. Many new public medical schools were
being founded, and federal legislation (Hill-Burton Act) enabled the construction of
hundreds of needed hospitals, especially in small cities and towns and rural areas. The
booming nation, in an uneasy peace after its largest war, focused inwardly to improve
the lot of its people while it looked outwardly with apprehension toward world com-
munism, especially in the USSR and Red China, and toward the extreme horror of
nuclear war.
World War II literally had brought home the reality of tropical diseases to all Ameri-
cans because of the stationing of troops from all 48 states in the North African and
South Pacific campaigns where malaria, in particular, was such a ubiquitous scourge.
And, of course, yellow jaundice (later known as hepatitis A) was also rampant in many
military arenas. Some believe that Hitler lost the battle of Stalingrad not only because
of the Russian winter, overextended supply lines, and tenacious Russian resistance,
but because hepatitis decimated his German army there.
Beginning the CDC in Georgia was also sensible since the U.S. South was still
home to endemic malaria, intestinal parasites, and many other infectious diseases (I
had both malaria and hookworm, growing up in the neighboring state of Alabama in
the decade of the founding of CDC). The MMWR, established in 1878, became a regu-
lar CDC responsibility in 1961 and now issues its first book of landmark articles. Look-
ing through the landmark article list, all are obviously notable but some are really
stickouts.
1963 and 1978—smallpox. Yes, dear younger readers, there was once such a dis-
ease, and what a terrible scourge it was. Sweden was the first country in the world to
eliminate indigenous smallpox—in 1895. Yet, in 1963 there was an outbreak in Swe-
den from a case brought from Indonesia, telegraphing the interconnectivity of hu-
mans and infectious diseases in our global village. That experience helped stimulate
Sweden to join with the United States to lead in global smallpox eradication, the last
human case being reported in the MMWR  in 1978. Modern public health really began
in 1796, 200 years before the CDC’s 50th anniversary, when Edward Jenner discovered
immunization—cowpox preventing smallpox. And CDC, especially D.A. Henderson
and William F. Foege, deserves more credit than anyone else (except for Jenner, of
course) for eliminating human clinical smallpox from the world. 
It has been wonderfully in the public interest for the CDC to have expanded from its
original “Communicable Disease Center” founding name and mission to a much
broader base—any and all diseases that are preventable. Preventable chemical inju-
ries (poisonings and toxicology) have been a noteworthy focus of CDC work. And, of
course, that most important chemical injury of them all—tobacco toxicity and carcino-
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genicity—following chronic nicotine addiction. CDC called cigarette smoking a nation-
ally notifiable condition in CDC’s 50th year—1996—another landmark.
For the future, there is plenty still on CDC’s plate. Death is normal. But premature
deaths from any and all causes, many of them behavioral, are not normal—like drug
addiction (including alcohol, tobacco and illicit drugs); like violence—injuries, inten-
tional or unintentional (CDC early on pointed out that there is no such thing as an
“accident,” only unintentional injury); like cancers of a wide variety of types that are
known to be preventable; like undesired, unexpected pregnancy and its frequently
harmful consequences. All are significant; all are controversial; all are CDC’s. 
In contrast to the everyday practice of medicine, which is very personal and one-
on-one, public health is for population groups and often controversial by its very na-
ture. Many public health measures, once data are in and truth is known, must be
brought about by law change. We can never expect such necessary coercion to be
uniformly popular, but it is required from time to time. And one can expect the politi-
cians to raise a ruckus (including about budget) with CDC when it tackles particularly
controversial issues (such as firearm injury prevention).
In a sense it is ironic that we may have come full circle with infectious diseases,
especially new or changed, or unknown, or unpredictable, or even unknowable, as
global microbial threats again rear their ugly heads and tempt CDC to take a swing at
them. CDC will swing, and we all will be very proud and comfortable that CDC and its
stellar publication MMWR  are still around, going strong and unequivocally in the pub-
lic’s best interest. Of historic significance, the stellar leader of CDC during 1993–1998,
David Satcher, MD, now travels from his native Alabama through Los Angeles, Nash-
ville, and Atlanta to take on the challenge of becoming the new Surgeon General of
the U.S. Public Health Service and Assistant Secretary of Health of the U.S. Depart-
ment of Health and Human Services. Yet another validation of the mission, scope, and
vitality of our national treasure—the Centers for Disease Control and Prevention.
                                                    George D. Lundberg, M.D.




History of CDC MMWR 1996;45:526–30 (June 28, 1996)
CDC, an institution synonymous around the world with public health, will be
50 years old on July 1. The Communicable Disease Center was organized in Atlanta,
Georgia, on July 1, 1946; its founder, Dr. Joseph W. Mountin, was a visionary public
health leader who had high hopes for this small and comparatively insignificant
branch of the Public Health Service (PHS). It occupied only one floor of the Volunteer
Building on Peachtree Street and had fewer than 400 employees, most of whom were
engineers and entomologists. Until the previous day, they had worked for Malaria
Control in War Areas, the predecessor of CDC (Figure 1), which had successfully kept
the southeastern states malaria-free during World War II and, for approximately
1 year, from murine typhus fever. The new institution would expand its interests to
include all communicable diseases and would be the servant of the states, providing
practical help whenever called.
Distinguished scientists soon filled CDC’s laboratories, and many states and foreign
countries sent their public health staffs to Atlanta for training. Any tropical disease
with an insect vector and all those of zoological origin came within its purview. Dr.
Mountin was not satisfied with this progress, and he impatiently pushed the staff to
do more. He reminded them that except for tuberculosis and venereal disease, which
FIGURE 1. Malaria Control in War Areas, Henry Rose Carter Laboratory — Savannah,
Georgia, 1944
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had separate units in Washington, D.C., CDC was responsible for any communicable
disease. To survive, it had to become a center for epidemiology.
Medical epidemiologists were scarce, and it was not until 1949 that Dr. Alexander
Langmuir arrived to head the epidemiology branch. He saw CDC as “the promised
land,” full of possibilities. Within months, he launched the first-ever disease surveil-
lance program, which confirmed his suspicion that malaria, on which CDC spent the
largest portion of its budget, had long since disappeared. Subsequently, disease sur-
veillance became the cornerstone on which CDC’s mission of service to the states was
built and, in time, changed the practice of public health.
The outbreak of the Korean War in 1950 was the impetus for creating CDC’s Epi-
demic Intelligence Service (EIS). The threat of biological warfare loomed, and Dr.
Langmuir, the most knowledgeable person in PHS about this arcane subject, saw an
opportunity to train epidemiologists who would guard against ordinary threats to
public health while watching out for alien germs. The first class of EIS officers arrived
in Atlanta for training in 1951 and pledged to go wherever they were called for the next
2 years. These “disease detectives” quickly gained fame for “shoe-leather epidemiol-
ogy” through which they ferreted out the cause of disease outbreaks.
The survival of CDC as an institution was not at all certain in the 1950s. In 1947,
Emory University gave land on Clifton Road for a headquarters, but construction did
not begin for more than a decade. PHS was so intent on research and the rapid growth
of the National Institutes of Health that it showed little interest in what happened in
Atlanta. Congress, despite the long delay in appropriating money for new buildings,
was much more receptive to CDC’s pleas for support than either PHS or the Bureau of
the Budget.
Two major health crises in the mid-1950s established CDC’s credibility and ensured
its survival. In 1955, when poliomyelitis appeared in children who had received the
recently approved Salk vaccine, the national inoculation program was stopped. The
cases were traced to contaminated vaccine from a laboratory in California; the prob-
lem was corrected, and the inoculation program, at least for first and second graders,
was resumed. The resistance of these 6- and 7-year-olds to polio, compared with that
of older children, proved the effectiveness of the vaccine. Two years later, surveillance
was used again to trace the course of a massive influenza epidemic. From the data
gathered in 1957 and subsequent years, the national guidelines for influenza vaccine
were developed.
CDC grew by acquisition. The venereal disease program came to Atlanta in 1957
and with it the first Public Health Advisors, nonscience college graduates destined to
play an important role in making CDC’s disease-control programs work. The tubercu-
losis program moved in 1960, immunization practices and the MMWR  in 1961. The
Foreign Quarantine Service, one of the oldest and most prestigious units of PHS, came
in 1967; many of its positions were soon switched to other uses as better ways of
doing the work of quarantine, primarily through overseas surveillance, were devel-
oped. The long-established nutrition program also moved to CDC, as well as the Na-
tional Institute for Occupational Safety and Health, and work of already established
units increased. Immunization tackled measles and rubella control; epidemiology
added family planning and surveillance of chronic diseases. When CDC joined the
international malaria-eradication program and accepted responsibility for protecting
the earth from moon germs and vice versa, CDC’s mission stretched overseas and into
space.
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CDC played a key role in one of the greatest triumphs of public health: the eradica-
tion of smallpox. In 1962 it established a smallpox surveillance unit, and a year later
tested a newly developed jet gun and vaccine in the Pacific island nation of Tonga.
After refining vaccination techniques in Brazil, CDC began work in Central and West
Africa in 1966. When millions of people there had been vaccinated, CDC used surveil-
lance to speed the work along. The World Health Organization used this “eradication
escalation” technique elsewhere with such success that global eradication of small-
pox was achieved by 1977. The United States spent only $32 million on the project,
about the cost of keeping smallpox at bay for 21⁄2  months.
CDC also achieved notable success at home tracking new and mysterious disease
outbreaks. In the mid-1970s and early 1980s, it found the cause of Legionnaires dis-
ease and toxic-shock syndrome. A fatal disease, subsequently named acquired
immunodeficiency syndrome (AIDS), was first mentioned in the June 5, 1981, issue of
MMWR. Since then, MMWR  has published numerous follow-up articles about AIDS,
and one of the largest portions of CDC’s budget and staff is assigned to address this
disease.
Although CDC succeeded more often than it failed, it did not escape criticism. For
example, television and press reports about the Tuskegee study on long-term effects
of untreated syphilis in black men created a storm of protest in 1972. This study had
been initiated by PHS and other organizations in 1932 and was transferred to CDC in
1957. Although the effectiveness of penicillin as a therapy for syphilis had been estab-
lished during the late 1940s, participants in this study remained untreated until the
study was brought to public attention. CDC also was criticized because of the 1976
effort to vaccinate the U.S. population against swine flu, the infamous killer of 1918–
19. When some vaccinees developed Guillain-Barré syndrome, the campaign was
stopped immediately; the epidemic never occurred.
As the scope of CDC’s activities expanded far beyond communicable diseases, its
name had to be changed. In 1970 it became the Center for Disease Control, and in
1981, after extensive reorganization, Center became Centers. The words “and Preven-
tion” were added in 1992, but, by law, the well-known three-letter acronym was re-
tained. In health emergencies CDC means an answer to SOS calls from anywhere in
the world, such as the recent one from Zaire where Ebola fever raged.
Fifty years ago CDC’s agenda was noncontroversial (hardly anyone objected to the
pursuit of germs), and Atlanta was a backwater. In 1996, CDC’s programs are often tied
to economic, political, and social issues, and Atlanta is as near Washington as the tap
of a keyboard (Figure 2).
Adapted for MMWR by Elizabeth W Etheridge, PhD, from her book, Sentinel for Health: A History
of the Centers for Disease Control. Berkeley, California: University of California Press, 1992.
Editorial Note: When CDC’s name changed in 1970, from the Communicable Disease
Center to the Center for Disease Control, CDC scientists were poised to accept new
challenges. The most notable of the agency’s many achievements in the following
10 years was its role in global smallpox eradication, a program that finally succeeded
because of the application of scientific principles of surveillance to a complex prob-
lem. In the realm of infectious diseases, CDC maintained its preeminence, identifying
the Ebola virus and the sexual transmission of hepatitis B, and isolating the hepatitis
C virus and the bacterium causing Legionnaires disease. The Study of the Effective-
ness of Nosocomial Infection Control (SENIC) was the most expensive study the
agency had ever undertaken and proved for the first time the effectiveness of recom-
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mended infection-control practices. Other studies included identification of the asso-
ciation of Reye syndrome with aspirin use, the relation between liver cancer and
occupational exposure to vinyl chloride, and the harmful effects of the popular liquid
protein diet.
The 1980s institutionalized what is considered to be a critically important scientific
activity at CDC—the collaboration of laboratorians and epidemiologists. The decade
began with the national epidemic of toxic-shock syndrome, documentation of the as-
sociation with a particular brand of tampons, and the subsequent withdrawal of that
brand from the market. CDC collaboration with the National Center for Health Statis-
tics (NCHS) resulted in the removal of lead from gasoline, which in turn has markedly
decreased this exposure in all segments of the population. The major public health
event of the 1980s was the emergence of AIDS. CDC helped lead the response to this
epidemic, including characterization of the syndrome and defining risk factors for dis-
ease.
CDC became involved in two very large epidemiologic studies during the 1980s.
First, the Cancer and Steroid Hormone Study conducted in collaboration with the Na-
tional Cancer Institute assessed the risks for breast, cervical, and ovarian cancers as-
sociated with both oral contraceptives and estrogen replacement therapy. Second, at
the request of Congress, CDC undertook a series of studies of the health effects of
service in Vietnam on veterans and their offspring, which led to a landmark contribu-
tion of the laboratory—the development of a serum test for dioxin able to measure the
toxicant in parts per quadrillion. This decade also introduced scientifically based rapid
assessment methods to disaster assistance and sentinel health event surveillance to
occupational public health. Epi Info, a software system for the practice of applied
HISTORY OF CDC
FIGURE 2. CDC headquarters on Clifton Road — Atlanta, 1996
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epidemiology, was introduced and now has been translated into 12 languages for tens
of thousands of users globally. Finally, during the 1980s, NCHS was moved to CDC,
further enhancing CDC’s information capabilities to meet national needs.
The 1990s have been characterized by continuing applications of CDC’s classic
field-oriented epidemiology, as well as by the development of new methodologies.
For example, the disciplines of health economics and decision sciences were merged
to create a new area of emphasis—prevention effectiveness—as an approach for mak-
ing more rational choices for public health interventions. In 1993, the investigation of
hantavirus pulmonary syndrome required a melding between field epidemiology and
the need for sensitivity to and involvement of American Indians and their culture.
Similarly, the response to global problems with Ebola virus and plague underscore the
importance of adapting these new methodologies. Other major CDC contributions to
the world’s health include global polio eradication efforts and efforts to prevent neural
tube defects. Finally, in October 1992, Congress changed CDC’s official name to the
Centers for Disease Control and Prevention, to recognize CDC’s leadership role in pre-
vention. Today, CDC is both the nation’s prevention agency and a global leader in pub-
lic health. As the world enters the new millennium, CDC will remain the agency ready
to address the challenges to its vision of healthy people in a healthy world through
prevention.
Editorial Note by: Stephen B Thacker, MD, MSc, Office of the Director, Epidemiology Program
Office, CDC.
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Notifiable Disease Surveillance and Notifiable Disease Statistics —
United States, June 1946 and June 1996
Surveillance for Notifiable Diseases MMWR 1996;45:530–6 (June 28, 1996)
National surveillance for infectious diseases is used to document the morbidity and
impact associated with these conditions in the United States. This report includes
morbidity data for the weeks ending June 8, 1946, and June 22, 1996, and describes
changes since 1946 both in the procedures for conducting surveillance and in the inci-
dence of selected diseases.
Surveillance Notes
The history of the reporting and tracking of diseases that could pose a risk to public
health in the United States dates back more than a century. In 1878, Congress author-
ized the U.S. Marine Hospital Service (the forerunner of today’s Public Health Service
[PHS]) to collect morbidity reports on cholera, smallpox, plague, and yellow fever
from U.S. consuls overseas; this information was used to institute quarantine meas-
ures to prevent the introduction and spread of these diseases into the United States.
In 1879, a specific Congressional appropriation was made for collecting and publish-
ing reports of these notifiable diseases. The authority for weekly reporting and publi-
cation was expanded by Congress in 1893 to include data from states and municipal
authorities. By 1928, all states, the District of Columbia, Hawaii, and Puerto Rico were
reporting 29 infectious diseases to the Surgeon General. 
Fifty years ago, morbidity statistics published each week were accompanied by the
statement “No health department, State or local, can effectively prevent or control
disease without knowledge of when, where, and under what conditions cases are oc-
curring.” These statistics appeared under the heading “Prevalence of Disease—
United States” in each issue of Public Health Reports  printed by PHS, Office of the
Surgeon General (Division of Public Health Methods) (see pages 12–15). In 1949, the
collection, compilation, and publication of these morbidity statistics was transferred
to the National Office of Vital Statistics, which produced the Weekly Morbidity Report.
In 1952 the publication was renamed Morbidity and Mortality Weekly Report, and re-
sponsibility for the publication was transferred to CDC in 1961.
In 1946, reports of notifiable diseases consisted of summary statistics, transmitted
by telegram each week by all state and some city health officers. The numbers were
tabulated and sent immediately by letter to each site for verification. Data published in
the June 28, 1946, issue of Public Health Reports  were for the week ending June 8,
1946 (see pages 12–15). Today, for most diseases, each state health department enters
individual case reports (rather than summary numbers) into a computer for transmis-
sion to CDC through the National Electronic Telecommunications System for Surveil-
lance; data published in this issue of MMWR  represent cumulative totals reported
through June 22, 1996. Except for New York City and Washington, D.C., morbidity data
from individual cities are no longer published weekly.
Because the reporting frequency varied for different conditions (i.e., weekly,
monthly, or annually), the precise number of conditions considered nationally report-
able in 1946 is unclear. The first list of 41 infectious diseases that all states agreed
should be nationally notifiable to PHS was developed at the first conference of state
and territorial epidemiologists in 1951 (1 ). This group was the forerunner of the Coun-
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cil of State and Territorial Epidemiologists (CSTE), now CDC’s primary collaborator for
determining what is nationally reportable. In 1951, as now, because reporting can be
mandated only at the state level, reporting to CDC by the states was voluntary. Today,
52 infectious diseases are notifiable nationally (2 ); in addition, at the 1995 CSTE meet-
ing, the first noninfectious condition—elevated blood lead levels—was added to the
list of conditions designated as reportable at a national level (3 ). On June 6, 1996,
CSTE added silicosis and acute pesticide poisoning/injuries to the list of nationally
reportable conditions. Also on June 6, CSTE unanimously agreed to include preva-
lence of cigarette smoking in the list of conditions designated as reportable by states
to CDC; this is the first time tobacco has been included and the first time a risk behav-
ior, rather than a disease or illness, has been included (see page 29).
Disease Notes
Comparing reports of notifiable conditions during June 1946 and June 1996 high-
lights some of the differences in the prevalent or common diseases. For example,
50 years ago, in the fundamentally prevaccine era, for the week ending June 8, 1946,
health departments reported 161 cases of poliomyelitis, 229 cases of diphtheria, 1886
cases of pertussis, and 25,041 cases of measles (see page 13–15). Through the week
ending June 22, 1996, a cumulative total of no confirmed cases of polio, one case of
diphtheria, 1419 cases of pertussis, and 263 cases of measles have been reported for
1996. Since 1946, vaccines have been licensed for all four of these conditions: diph-
theria and tetanus toxoids and pertussis vaccine in 1949, inactivated polio vaccine in
1955 and live attenuated vaccine in 1961, and measles vaccine in 1963. Because of the
advent of these and other disease-control strategies, during the past decade public
health authorities have established as targets for the year 2000 eradication of polio
globally and measles elimination in the Americas. Four cases of another vaccine-
preventable disease, smallpox, were reported for the week ending June 8, 1946, and a
total of 337 cases for the entire year of 1946; the last documented cases of smallpox in
the United States occurred 3 years later, in 1949. In 1958, the World Health Organiza-
tion targeted smallpox for global eradication, a campaign that was declared success-
ful in 1980 (4 ). 
Among the 10 nationally notifiable infectious diseases that are most commonly
reportable today, several were unknown in June 1946. The 10 most frequent nationally
reportable infectious conditions in 1994 (the most recent year for which final data are
available) were, in descending order, gonorrhea, acquired immunodeficiency syn-
drome (AIDS), salmonellosis, shigellosis, hepatitis A, tuberculosis, primary and secon-
dary syphilis, Lyme disease, hepatitis B, and pertussis (5 ). Fifty years ago, AIDS and
Lyme disease were unknown. “Infectious hepatitis” (subsequently identified as hepa-
titis A) had just been identified, and morbidity reports for this condition first appeared
in 1947. In 1953, serum hepatitis (subsequently named hepatitis B) was recognized as
a separate entity, although it was included in the general category of hepatitis until
1966, when infectious and serum hepatitis began to be reported separately. Other dis-
eases reported on a weekly basis during 1946 included amebiasis, murine typhus fe-
ver, and tularemia; during the past 10 years, these three conditions were deleted from
the nationally notifiable disease list and are no longer routinely reported to CDC.
Because of the acknowledged underreporting of most diseases (particularly those
typically characterized by clinically mild illness) to this passive surveillance system,
the National Notifiable Disease Surveillance System (NNDSS) does not capture all
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cases of disease nationwide. However, these data are essential for monitoring disease
trends and for determining relative disease burdens. In addition, this same NNDSS—
with origins dating more than a century ago—continues to be used for monitoring the
decline in incidence of vaccine-preventable and other diseases and to detect and
document the appearance of new public health problems.
Reported by: Systems Operations and Information Br, Div of Surveillance and Epidemiology,
Epidemiology Program Office, CDC.
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Introduction to Table V
Premature Deaths, Monthly Mortality, and
Monthly Physician Contacts — United States
MMWR 1982;31:109–10 (March 12, 1982)
Introduction to Table VBeginning with this issue, a new table will appear monthly in the MMWR: “Table V.
Potential Years of Life Lost, Deaths, and Death Rates, by Cause of Death, and Esti-
mated Number of Physician Contacts, by Principal Diagnosis” [see page 18]. By dis-
playing a variety of measures that gauge the importance and relative magnitude of
certain public health issues, this table will call attention to those issues where strate-
gies for prevention are needed. Publication of this table reflects CDC’s increased re-
sponsibility for promoting action to reduce unnecessary morbidity and premature
mortality and continues the MMWR’s tradition of disseminating public health informa-
tion to its readership.
Further improvements in health can be achieved through actions taken by individu-
als as well as by administrators in the public and private sectors to promote a safer
and healthier environment (1 ). To this end, the new table provides information re-
garding areas that provide the greatest potential for health improvement.
Causes of death are listed in Table V in descending order of the potential years
of lost life that are attributed to each cause. In 1980, heart disease, cancer, and
cerebrovascular disease account for 67.9% of all deaths in the United States; motor-
vehicle and other accidents, suicide, and homicide accounted for 8.1% (2 ). In terms of
age at the time of death, the relative importance of causes of death changes remark-
ably; motor-vehicle and other accidents, suicide, and homicide accounted for 40.8% of
the total years of life lost prematurely (before age 65 years); and heart disease, cancer,
and cerebrovascular disease accounted for 37.2%.
“Potential years of life lost before age 65” in the table is estimated for persons
between 1 year and 65 years old at the time of death and is derived by multiplying the
annual number of deaths in each age category by the difference between 65 years and
the age at the mid-point of each category. If deaths of persons older than 65 years
were included, greater weight would be given to natural causes of death, and pre-
mature and preventable causes of death would no longer be distinguishable. If deaths
of persons younger than 1 year were included, causes of death affecting this age
group would be weighted heavily and would therefore contribute a disproportionately
large share of potential years of life lost. However, “Infant mortality” in the table is a
measure of deaths occurring in this age group and “Prenatal care” reflects efforts to
prevent death in this group.
Cause-specific mortality rates, published in the Monthly Vital Statistics Report  by
the National Center for Health Statistics, are estimated from a systematic sample of
10% of death certificates received in state vital statistics offices during a 1-month pe-
riod using the underlying cause of death recorded on the certificate. Because com-
plete information concerning the underlying cause of death is not available when the
sample is taken, estimates for certain causes are biased in the monthly sample but
then are corrected when annual estimates are made. The estimated number of deaths
each month is obtained by multiplying the corresponding estimated mortality rate,
which is computed on an annual basis, by the provisional population estimate for the
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TABLE V. Potential years of life lost, deaths, and death rates, by cause of death, and

















E826-E949)  2,684,850   8,500  43.5  5,156,000
Malignant neoplasms
(140-208)  1,804,120  36,120 184.9  1,990,000
Diseases of heart
(390-398, 402,
404-429)  1,636,510  61,810 316.4  5,168,000
Suicides, homicides
(E950-E978)  1,401,880   4,160  21.3 —
Chronic liver disease
and cirrhosis (571)    301,070   2,730  14.0    100,000
Cerebrovascular
diseases (430-438)    280,430  13,710  70.2    473,000
Pneumonia
and influenza
(480-487)    124,830   3,790  19.4    904,000
Diabetes mellitus




conditions (490-496)    110,530   4,280  21.9  1,824,000
Prenatal care4  2,187,000
Infant mortality4   3,700 11.7/1000 live births     
Estimated monthly
mortality2
1National Center for Health Statistics. Monthly Vital Statistics Report, Vol. 29, No. 13, Septem-
ber 17, 1981. Total potential years of life lost are estimated for persons between 1 year and
65 years old at the time of death and are derived from the product of the number of deaths
in each age category and the difference between 65 years and the age at the mid-point of
each category.
2National Center for Health Statistics. Monthly Vital Statistics Report, Vol. 30, No. 11, Febru-
ary 10, 1982, pp 8-9. Infant deaths and provisional U.S. population from Vol. 30, No. 10, Janu-
ary 15, 1982, p 1. Mortality rates on an annual basis per 100,000 estimated population in the
United States are estimated from the underlying cause of death recorded on a 10% systematic
sample of death certificates taken from all those received in state vital statistics offices during
a 1-month period. The number of deaths each month is estimated from the product of the
corresponding estimated mortality rate and the provisional U.S. population estimated for that
month divided by the number of days that month as a proportion of the total days in the year.
3IMS America. National Disease and Therapeutic Index (NDTI), Monthly Report, October 1981,
Section III. This estimate comprises the number of office, hospital, and nursing home visits
and telephone calls prompted by each medical condition based on a stratified random sample
of office-based physicians (2100) who record all private patient contacts for 2 consecutive days
each quarter.
4“Prenatal care” and “infant mortality” are included in the table because “Potential years of
life lost” does not reflect deaths of children <1 year.
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United States and then dividing by the number of days for that month as a proportion
of the total days in the year.
The measure for morbidity is obtained from the National Disease and Therapeutic
Index (NDTI), a random sample of data from office-based physicians in 19 major spe-
cialities in the continental United States. Each physician in the sample records all his
contacts with private patients for 2 consecutive days each quarter. These contacts
comprise telephone calls (7% of total in 1981); office visits (68%); and patients visited
by the physician in hospitals (22%), nursing homes (1%), and their own homes (1%).
As a result, this measure gives greater weight to those diseases that prompt a visit to
a private physician or required hospitalization. When the physician cannot make a
diagnosis at the time of the visit, the suspected diagnosis or presenting symptom is
recorded. Although misclassification might occur, the potential for this bias is reduced
by using broad categories in the table.
Publication of Table V is an effort to use measures of morbidity and mortality as
reminders of the impact on public health of some of these preventable problems.
However, when data are summarized, their complexity and detail are sacrificed; and
when information is simplified, although the overall effect may be clarified, subtle
issues may be obscured. Therefore, a series of articles exploring different aspects of
preventable problems will be published in the MMWR to complement this table.
These articles will present more detailed analysis of what is known about health status
indicators, risk factors, and other factors affecting public health.
References
1. Healthy People, The Surgeon General’s Report on Health Promotion and Disease Prevention,
1979. Public Health Service, Office of the Assistant Secretary for Health and Surgeon General,
DHEW (PHS) Publication No. 79-55071.
2. National Center for Health Statistics. Monthly Vital Statistics Report, Vol. 29, No. 13, Septem-
ber 17, 1981.
Editorial Note—1997
Robert A Hahn, PhD, MPH, Division of Prevention Research and Analytic Methods (proposed),
Epidemiology Program Office, CDC.
The 1982 addition to the MMWR  of a monthly Table V, “Premature Deaths, Monthly
Mortality, and Monthly Physician Contacts—United States,” employed the measure of
years of potential life lost (YPLL), which was designed to alert the public health com-
munity to the magnitude of “premature,” “preventable,” and “unnecessary”
mortality. In contrast to the traditional measures of crude and age-adjusted mortality,
which treats deaths at all ages equivalently, YPLL weights deaths inversely to age at
death (i.e., deaths at young ages affect the value of YPLL more than deaths at older
ages). Although the measure had been used since 1947 (1 ), the CDC series on YPLL
especially raised awareness about the magnitude of the problem of injury among
youth (2 ), causes of death among infants (e.g., sudden infant death syndrome [SIDS]
and congenital anomalies [3,4 ]), and acquired immunodeficiency syndrome (AIDS)
(5) . YPLL contributed to the establishment of CDC’s Violence Epidemiology Branch in
1983 and CDC’s National Center for Injury Prevention and Control in 1992. Other meas-
ures of years of life lost have been modified to account for the “quality” of life lived
with different types of morbidity and disability. For example, years of healthy life
(YHL) considers activity limitations and perceived health and has been used to estab-
Introduction to Table V 21
lish and monitor national health objectives in the United States for the year 2000 (6 ).
In addition, disability-adjusted life years (DALY) “expresses years of life lost to pre-
mature death and years lived with a disability of specified severity and duration” (7 ).
Measures of YPLL have served primarily as tools for health-care planning, prioritiza-
tion, and administration rather than as instruments of causal research.
An analysis of “potential years of life lost” was first published 50 years ago by Mary
Dempsey (1 ), a statistician at the National Tuberculosis Association, who sought to
indicate the relative youth of decedents from tuberculosis compared with cancer and
heart disease; while crude mortality rates of the latter were far higher, YPLL rates were
more comparable. Many modifications and alternatives to YPLL have been formulated
(8,9 ). Dempsey used life-expectancy-at-birth cutoffs specific to the populations com-
pared; in contrast, some have used a fixed life expectancy for all populations com-
pared, as proposed by Haenszel (10 ). Others have used different age cutoffs, at both
lower age limits (e.g., 0, 1, 15, and 20 years) and upper limits (e.g., 65, 70, 75, and
85 years). The measure including ages 15–70 years has been referred to as potentially
productive years of life lost, on the assumption that these are the productive years of
life (9 ). Another measure, years of accumulated ability lost (YAAL), weights the num-
ber of deaths by the age at which they occur, on the assumption—contrary to that
made in YPLL—that the potential contribution of the decedent is greater with greater
age and experience; YAAL may be regarded as the inverse of YPLL (11 ).
YPLL measures the burden of mortality among the relatively young. As a rate (gen-
erally calculated per population aged <65 years), YPLL could be compared by cause
(e.g., injury, AIDS, and cancer) or etiologic agent (e.g., cigarette smoking, alcohol con-
sumption, and automobiles), among populations (e.g., by sex, race/ethnicity, and
state), and over time. Although YPLL rates may be age-adjusted, adjustment may
mask differences in the public health burden of mortality among youth, which YPLL
measures.
YPLL can be interpreted in at least two ways. First, as indicated by its name, YPLL
may be regarded as the sum of years of life lost by persons who died before age
65 years; thus, for example, a person who died at age 24 years lost 41 years of life,
assuming he or she would have lived to be only 65. Second, assuming that young
persons have greater life expectancy than older persons and that death at young ages
is therefore a greater loss than death at older ages, YPLL can be interpreted as a meas-
ure of mortality in which death at young ages is numerically weighted more heavily
than death at older ages. For example, the death of a 5-year-old has a weight of 60 (i.e.,
65 minus 5 years), 12 times the weight of 5 for a 60-year-old who dies (i.e., 65 minus
60 years).
The measure of YPLL reported in the MMWR  has been modified in several ways
over the course of its publication. Until 1986, deaths among infants (aged <1 year)
were excluded from YPLL calculations in the MMWR  because it was believed that
they would “be weighted heavily and would therefore contribute a disproportionately
large share of potential years of life lost” (12 ). In 1986, deaths during the first year of
life were added to the calculation, and infant mortality was no longer reported sepa-
rately in Table V (13 ). This change resulted in the addition of congenital anomalies,
prematurity, and SIDS as the fifth, sixth, and seventh causes of YPLL, respectively.
Also beginning in 1986, YPLL tables and analyses were published annually rather than
more frequently. In 1990 and 1992, annual MMWR  reports on YPLL included compari-
son of YPLL with an upper age cutoff of 85 years in addition to the standard cutoff of
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65 years (14,15 ). Initially, the nine leading causes of YPLL were reported; in the last
years of publication, 13 leading causes were reported. While all-cause YPLL has de-
clined slightly since the mid-1980s, this overall decline has been offset by an 11-fold
increase in the proportion of YPLL associated with AIDS, first reported for 1984. In
1993, YPLL estimates based on provisional mortality data were not compared directly
with estimates based on final data because of cause-specific differences in the delay
of reporting provisional data (16 ). In 1986, a widely cited MMWR  supplement, Pre-
mature Mortality in the United States: Public Health Issues in the Use of Years of Po-
tential Life Lost, was published to review alternative methods for the estimation of
potential life lost (8 ).
The limitations of YPLL measures may constrain, in part, their usefulness. First,
although YPLL has been thought to measure premature, preventable, and unneces-
sary morbidity and mortality, this assumption has not been evaluated and depends on
the current state and deployment of knowledge and prevention strategies. Second,
many YPLL measures ignore a large proportion of deaths in the population, including,
for example, all deaths among persons aged ≥65 years. In 1994, 73% of deaths in the
United States occurred among persons aged ≥65 years, and 24% occurred among per-
sons aged ≥85 years (17 ). Many measures neglect the potential for premature, pre-
ventable, and unnecessary morbidity and mortality among persons in these age
groups.
An annual report on changes in YPLL was last published in MMWR  in 1993 (16 ),
although YPLL statistics have been routinely published in CDC’s annual compen-
dium Health, United States (18 ), and CDC programs continue to report condition- and
etiology-specific YPLL in MMWR. CDC is reviewing its policy on how best to routinely
disseminate age-related mortality information to achieve public health objectives. In
addition to concerns about age-related value assumptions, there is growing interest in
incorporating into summary health measures assessments of the “quality” of years
lived or lost, the morbidity and disability associated with given causes of death before
death, and self-perceived health status. These measures are intended to be used for
surveillance and to provide a common denominator for cost-utility analysis. In addi-
tion, the importance of notions of premature, preventable, and unnecessary morbidity
and mortality should be related to effective clinical and public health practice.
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Public Health Focus:
Effectiveness of Disease and Injury Prevention
Effectiveness of Disease and Injury PreventionMMWR 1992;41:265–6 (April 24, 1992)
Public health practice is based on scientifically sound strategies for improving the
quality of life and reducing morbidity and premature mortality. To maximize the health
benefits of available resources, public health decision-makers require information on
the effectiveness, as well as the economic and social impact, of disease and injury
prevention strategies (1 ). This report introduces a monthly series of articles to be pub-
lished in MMWR  (weekly) that highlight prevention effectiveness.
The development of prevention technology begins with researchers in the basic
public health and biomedical sciences identifying potentially effective technologies
that can be used to reduce unnecessary morbidity and premature mortality. Applied
research under carefully controlled conditions may then determine whether such
techniques are efficacious (e.g., the effect of smoking cessation on lung cancer). As
these techniques are applied at the community level, their impact and cost can be
assessed first in demonstration settings and then in routine community settings, and
improvements in techniques can then be incorporated into prevention strategies.
Important considerations in the assessment of disease and injury prevention
strategies (i.e., the scientific method for evaluating the effectiveness of prevention
strategies) include
• identification of efficacious and effective strategies to reduce morbidity and pre-
mature mortality and improve the quality of life;
• characterization of the social, legal, and ethical impact of these strategies;
• estimation of the economic impact of prevention strategies;
• determination of optimal methods for implementing those strategies; and
• evaluation of the health impact of prevention programs.
Each report in the monthly series will highlight the knowledge base regarding a
specific prevention strategy and will address related considerations, including effi-
cacy, effectiveness, safety, and economic factors. Topics have been selected based on
their inclusion in the national health objectives for the year 2000 (2 ), CDC and other
public health program efforts, and the availability of data. In particular, the reports will
present specific examples of disease and injury prevention strategies and illustrate
approaches to evaluating the effectiveness of such strategies.
Reported by: Office of Program Planning and Evaluation, Office of the Director; Office of the
Director, Epidemiology Program Office, CDC.
Editorial Note: Public health officials and policy-makers at all levels require a scientific
framework for assessing the effectiveness of disease and injury prevention as a basis
for establishing priorities, selecting prevention strategies, and allocating resources.
The success of prevention activities can be defined by whether they delay or avert
morbidity and mortality. However, the ability to evaluate objectively many prevention
techniques with randomized controlled trials is often limited by fiscal, ethical, or other
constraints. The MMWR Recommendations and Reports  issue, “A Framework for
Assessing the Effectiveness of Disease and Injury Prevention” (1 ), focuses on the
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challenges of assessment that arise as a consequence of these constraints. Reports in
the MMWR  (weekly) series will describe examples of how prevention effectiveness
can be assessed.
Because public health programs sometimes may begin to implement preventive
measures before appropriate assessments are completed, gaps may exist in knowl-
edge of the efficacy, effectiveness, safety, or economic impact of specific prevention
strategies. The series of reports in MMWR  (weekly) will characterize many of these
gaps and describe how they have been addressed. In addition, the reports in this
series are intended to 1) provide decision-makers with information about the potential
impact of these interventions on the health of their communities; 2) suggest
approaches suitable for adaptation to public health practice; and 3) encourage further
examination of these topics and stimulate additional systematic efforts by public
health professionals to assess and enhance the effectiveness of public health
programs.
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Editorial Note—1997
Steven M Teutsch, MD, MPH, Office of the Director, Division of Prevention Research and Analytic
Methods (proposed), Epidemiology Program Office, CDC.
Since the initiation of the series of articles (1–7 ) and publication of the MMWR
Recommendations and Reports  (8 ) on prevention effectiveness, the concepts have
been institutionalized as a public health science at CDC and many other organizations
in the public health community. Public health programs traditionally have been ac-
countable for their effectiveness and have had to exist within resource constraints.
Choices among competing priorities and intervention strategies have been and will
continue to be made regardless of the information available. Prevention effectiveness
integrates the best available information into the value of those choices.
The prevention-effectiveness initiative has helped to catalyze the integration of the
principles of evidence-based medicine (9 ) into public health. A central feature of this
approach is the focus on health outcomes. By examining the links between interven-
tions, intermediate impacts, and health outcomes, synthetic analyses can be devel-
oped as tools to assist in selecting the best intervention strategies. These tools assist
in clarifying the objectives, the strategies available to achieve those objectives, the
logic of the causal pathways, and the evidence that supports the links in those path-
ways. In addition to facilitating understanding of problems and potential solutions,
these tools provide a basis for developing practice guidelines (10 ) and, in the future,
adapting those guidelines to communities with differing demographics, risk profiles,
and health concerns (11 ).
Public health uses clinical interventions as well as behavioral, environmental, and
social approaches. Many of the prevention-effectiveness methods that have been
applied in the clinical arena (e.g., decision analyses and economic evaluations as
applied to technology assessments, outcomes research, and health services research)
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needed to be adapted to public health. Recommendations for comparable methods
for decision modeling and analysis and economic evaluation in public health are now
available (12,13 ). These standards for analysis assure policymakers that studies con-
ducted in accordance with these principles are reliable and comparable.
The need to spend limited health-care resources more efficiently is generally ac-
cepted. Managed-care and public health partners now routinely explore the broadest
range of community-based intervention strategies to improve the health of the popu-
lations they serve. The tools of prevention effectiveness provide decision-makers with
critical information necessary for improving decision-making to weigh along with eth-
ics, feasibility, and the distribution of costs and benefits to different populations. For
example, policy discussions on the fortification of food with folic acid to reduce neural
tube defects used economic evaluations to compare the costs, benefits, and hazards
associated with fortifying foods with different levels of folic acid, with diet supplemen-
tation, or with no intervention (14 ).
Since 1992, CDC has increased substantially its capability in prevention effective-
ness through courses, postdoctoral fellowships, routine use of economic evaluations
(cost-effectiveness and cost-benefit and cost-utility analyses), and the development of
comparable methodologies (11 ). For example, a recent study of the cost-effectiveness
of antibiotics for the treatment of chlamydia cervicitis (15 ) led to a negotiated public
health price for a single-dose formulation of azithromycin suitable for administration
in clinics. Prevention effectiveness has become a core science for public health,
but additional efforts are required to clarify understanding of how prevention-
effectiveness studies can be better used by decision-makers. Methods for measuring
outcomes (such as quality-adjusted life-years and benefits estimation for cost-benefit
analyses) and resource allocation need to be refined. Finally, improved, more com-
plete, and comparable information on cost-effectiveness needs to be available to
users.
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28 DISEASE AND INJURY SURVEILLANCE
Addition of Prevalence of Cigarette Smoking
as a Nationally Notifiable Condition — June 1996
MMWR 1996;45:537 (June 28, 1996)
On June 6, 1996, by a unanimous vote, the Council of State and Territorial Epidemi-
ologists (CSTE) added prevalence of cigarette smoking to the list of conditions desig-
nated as reportable by states to CDC. The addition of prevalence of cigarette smoking
marks the first time a behavior, rather than a disease or illness, has been considered
nationally reportable.
Goals of smoking prevalence surveillance identified by CSTE include monitoring
trends in tobacco use, guiding allocation of tobacco-use prevention resources, and
evaluating public health interventions to reduce smoking. Given these goals, CSTE
selected population sampling as the appropriate surveillance methodology and desig-
nated the Behavioral Risk Factor Surveillance System (BRFSS) as the preferred data
source. CSTE and CDC are developing the format to regularly present this information
in national disease reporting statistics. The addition of cigarette smoking prevalence
brings to 56 the number of diseases and conditions designated by CSTE as reportable
by states to CDC. 
Reported by: Council of State and Territorial Epidemiologists. Office on Smoking and Health,
National Center for Chronic Disease Prevention and Health Promotion; Div of Surveillance and
Epidemiology, Epidemiology Program Office, CDC.
Editorial Note: National notifiable disease surveillance has been critical to the success-
ful campaign against infectious diseases throughout this century. By agreement
among states, CSTE, in partnership with CDC, determines the list of conditions report-
able to CDC. The addition of prevalence of cigarette smoking to this list is a historic
step in the evolution of the public health surveillance in the United States.
Although most conditions reportable by states to CDC have been acute infectious
diseases, and surveillance for such diseases remains a public health priority, the addi-
tion of prevalence of cigarette smoking reflects shifts in morbidity and mortality pat-
terns in the United States and therefore the need to expand the range of nationally
reportable conditions. Traditionally, infectious disease reporting has relied on a single
methodology—mandated reporting of all cases. The decision by CSTE to designate
BRFSS as the recommended data source for reporting of this condition marks a tran-
sition to a more flexible system in which surveillance methods are determined by sur-
veillance goals. Most importantly, this action underscores the role of tobacco use as
the leading preventable cause of death in the United States and the need to conduct
national public health surveillance for both conventional disease outcomes and for
underlying causes (e.g., smoking and other risky behaviors) amenable to public health
intervention (1 ).
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Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:172 (May 24, 1963)
Smallpox weden — Stockholm was declared a smallpox infected area on May 16. A seaman
who returned from Indonesia in late March is the apparent source of an outbreak
which has now spread through two generations of transmission and has resulted in
one fatality. Preliminary information on cases to date, received from the Ministry of
Health, Sweden, and forwarded by Dr. Reimert T. Ravenholt, Epidemiologic Consult-
ant, Division of Foreign Quarantine, U.S. Public Health Service, Paris, is given below:
The outbreak was recognized on May 13 when the diagnosis of smallpox was first
suspected in Case #7. The disease was sufficiently mild in Cases 1, 4, 5 and 12 that
medical assistance was not sought. The only fatality to date occurred in Case #2 who
apparently suffered an acute hemorrhagic form of the disease, diagnosed as smallpox
in retrospect.
This outbreak is of unique interest in that it represents one of the few epidemics in
Western nations in recent years not evidencing a predominant spread among hospital
contacts. Recent immunization programs among hospital personnel presumably have
altered the pattern of hospital spread observed in other recent outbreaks. The mild-
ness of the disease in several of the earlier cases, resulting in the failure of these pa-
tients to seek medical care and hospitalization, has contributed to the pattern of
community transmission.
The outbreak emphasizes the sinister role of mild or vaccine-modified cases of
smallpox in initiating and propagating outbreaks of severe disease. Since the outbreak
was discovered during the second generation of indigenous cases, it is possible that
Americans recently in Stockholm have been unknowingly exposed to the disease, and
cases of suspicious febrile illness in such individuals should receive the utmost scru-
tiny by clinicians and public health authorities.
Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:174–6 (May 31, 1963)
Four additional cases of smallpox have been identified in Stockholm with onsets of
illness since May 18. All four presumably acquired their disease as a result of hospital
contact.
The outbreak (See MMWR, Vol. 12, page 172) now totals 16 cases, with three gen-
erations of transmission following the importation of smallpox by a seaman who pre-
sumably acquired his disease in transit through Southeast Asia. Information on cases
to date received from Dr. Bo Zetterberg, Chief, Epidemiology Division, State Bacteriol-
ogy Laboratory, Stockholm, is summarized in the table below [See table, page 32].
The pattern of spread of the illness is presented diagrammatically in the accompa-
nying figure [See figure, page 33].
The first case to be identified occurred in an unvaccinated 19-year-old bricklayer
(Case 7) who had onset of fever, vomiting, and backache on May 5. He was hospital-
ized three days later and subsequently developed an extensive maculo-papular rash
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which became pustular by May 12. Smallpox was suspected and confirmed the fol-
lowing day by the laboratory.
Immediate epidemiologic investigation revealed that an aunt of the bricklayer
(Case 2) had developed on April 18 an acute febrile illness, manifest by hemorrhagic
skin lesions, and had died shortly after admission to the hospital on April 23. Ten other
cases of smallpox were identified May 14–16.
The original source of the outbreak was a 24-year-old seaman who after two weeks
residence in Australia left Darwin on March 22 on BOAC Flight #709. In-transit stops of
not more than 50 minutes each were made in Djakarta, Singapore, Rangoon, Calcutta,
Karachi, Teheran, and Damascus en route to Zurich. At Zurich, the seaman deplaned
and the following day boarded Swissair Flight #250, reaching Stockholm March 24. He
apparently acquired his disease as a result of in-transit exposure either at a terminal
or on the plane. On April 6, 15 days after the flight, he developed a moderate fever and
mild rash and remained in the home of his grandmother (Case 3) throughout his ill-
ness. Cases 2, 3, 4, and 5 all had contact with him in the grandmother’s home during
the course of his illness. On April 21, the grandmother fell ill, subsequently exposing
three women (Cases 8–10) who visited the home to provide nursing care to the elderly
woman prior to her hospitalization on May 27. She was originally diagnosed as having
chickenpox and recovered uneventfully. Another resident of the building (Case 11)
who lived two stories above the grandmother, developed smallpox but denied ac-
quaintance or contact with the grandmother.
Case 2, the first fatality, apparently acquired the illness from the seaman during a
visit to the grandmother’s apartment and subsequently transmitted it to her husband






1 24 M April 6 Southeast
Asia
1959 Modified illness
2 58 F April 18 Case #1 Childhood Died April 23
3 80 F April 21 Case #1 Childhood
4 24 F April 25 Case #1 1943 Modified illness
5 20 F Not known Case #1 1950 No rash (Lab diagnosis)
6 53 M May 3 Case #2 1920 Husband of Case #1
7 19 M May 5 Case #2 Never Died May 28
8 50 F May 5 Case #3 Childhood Home Nurse of Case #3
9 55 F May 5 Case #3 1916 Home Nurse of Case #3
10 67 F May 6 or 9 Case #3 1918
11 72 F May 8 Case #3 1915 No known direct contact
12 22 M May 11 Case #4 1961 Laboratory diagnosis only
13 61 M May 18 Case #3 or 6 1949** Hospital acquired
14 11⁄2 F May 19 ? Case #6 Never** Hospital acquired
15 72 F May 24 Case #9 Childhood Hospital acquired–
Died May 27
16 75 F ? May 24 Case #9 Childhood Hospital acquired
 *First identified case.
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(Case 6) and her nephew (Case 7) the first identified case. Case 12 who had only fever
and serologic evidence of infection, acquired his disease presumably from his fiancee,
Case 4.
The appearance of cases among hospital contacts is more consistent with the pre-
viously observed patterns of imported smallpox in Western countries. Case 13 is a
gardener at the Infectious Disease Hospital where Cases 3 and 6 were admitted as
presumptive chickenpox on April 27 and May 7, respectively. He is thought to have
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DIAGRAMMATIC REPRESENTATION OF THE OUTBREAK
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handled laundry from these patients prior to the first suspicion of smallpox on May 12.
He was initially employed by the hospital only two months previous and had not yet
been vaccinated in the hospital’s annual revaccination program.
Case 14 was a patient admitted to the Infectious Disease Hospital with whooping
cough on April 30. She was located in the same hospital vicinity as Case 6, although
there was no connection between the rooms housing these patients. Cases 15 and 16
were patients on the same hospital ward to which Case 9 was admitted on May 9.
Case 9 was originally thought to have a toxic drug eruption prior to her diagnosis of
smallpox on May 15.
With the exception of Case 12 who had an exceptionally mild illness, it is apparent
that spread of the disease to date has been primarily among individuals vaccinated at
times far distant in the past. Of the three fatalities to date, one occurred in a person
never vaccinated and the other two in persons vaccinated more than 50 years prior to
exposure. The absence of additional spread to hospital personnel is probably related
to efforts in Sweden to emphasize revaccination of hospital personnel at frequent in-
tervals. Notably, the last four cases have occurred in persons already identified and
isolated by virtue of being known contacts.
Some 8,000 persons living in neighborhoods of the earlier cases have been vacci-
nated. In addition, vaccination has been provided for other residents of Stockholm on
request and to date some 300,000 persons have availed themselves of this protection.
Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:183,188 (June 7, 1963)
Three additional cases, two hospital acquired, were identified last week bringing to
19 the total number of smallpox cases comprising the current outbreak, according to
information made available by Dr. Bo Zetterberg, Chief, Epidemiology Division, State
Bacteriology Laboratory, Stockholm.
Two of the three cases are actually part of the second generation of transmission
(See MMWR Vol. 12, pg. 174), having now been identified retrospectively by serologic
means. Neither patient developed a rash. Both were nurses in the Stockholm Infec-
tious Disease Hospital in close contact with the smallpox cases admitted there. The
first, a 44-year-old female, cared for Case No. 3 from April 27 to May 7 daily, including
bathing and local treatment of the lesions. On May 9, the nurse developed fever and
headache, as well as nausea and low back pain. Except for May 13 and 14, she contin-
ued to work throughout her illness until isolated on May 18. She was found to have a
very high hemagglutination inhibition antibody titer suggesting recent infection. Her
last vaccination prior to onset of illness was in 1962. She was also in daily contact with
Cases 6 and 14, and directly or indirectly may have transmitted the disease to Case 14.
The second nurse, a 22-year-old female, also employed in the Stockholm Infectious
Disease Hospital, had daily contact with Case No. 2 during the period April 27–May 7.
On May 11, she experienced onset of headache, fever, and sore throat and was absent
from work May 11 through May 13. No rash developed. A high HAI titer verified the
diagnosis of smallpox. She had previously been vaccinated in 1950 but at the time of
exposure had not yet been revaccinated under the hospital’s annual revaccination pro-
gram.
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The final additional case is that of a 47-year-old man who had onset of illness
May 21 while already isolated as a contact. He is the father of Case 7, the first identi-
fied case. He had never been vaccinated until 7 days before onset of illness.
The total number of hospital-acquired cases now stands at 6, one-third of the sec-
ondary indigenous cases. The evidence supports close contact as the primary requi-
site for spread both in the hospital and in the community. The disease has spread
among persons vaccinated more than 7 years prior to the time of their exposure with
2 notable exceptions, both patients with mild disease without rash. The table below
presents data on the vaccination status of the 18 indigenous cases [See table below].
Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:191,196 (June 14, 1963)
Two additional cases of smallpox were identified in Stockholm last week bringing
to 21 the total number of cases in the current outbreak. Unique circumstances involv-
ing these two persons, neither of whom were under surveillance as contacts at the
time of their detection, indicates that the outbreak may perhaps be expected to con-
tinue.
Information made available by Dr. Bo Zetterberg, Chief, Epidemiology Division,
State Bacteriology Laboratory, Stockholm, indicates that on June 6 an 85-year-old
woman, who lives with her daughter, went to a hospital out-patient department for
routine follow-up of a chronic medical problem. The daughter called in advance in-
forming clinic personnel that the elderly woman had developed a rash. On arrival at
the out-patient clinic, the mother spent some time in the general waiting room and
was then referred to the dermatology clinic, and again spent some time in the derma-
tology waiting room. When seen by physicians, a clinical diagnosis of smallpox was
made. In all, she had spent some four hours at the hospital and presumably exposed
some 450 persons in the two crowded waiting rooms. It was noted that on May 28 she
had developed a low-grade fever with dizziness, followed by the appearance of rash
on June 2.
She and her 54-year-old daughter share an apartment in a boarding house for
women housing some 100 occupants. The daughter works as a mortician and on
April 26 had prepared the body of smallpox Case 2 of the outbreak for cremation. She
had been placed under surveillance as a contact and 16 days after her exposure to the
dead woman, having had no symptoms or signs of illness, she was released from





Rash No Rash Deaths
 7 yrs. or less 2 – 2 –
 8–14 yrs. 3 1 2 –
15–24 yrs. 2 2 – –
25–50 yrs. 4 3 1 –
More than 50 years 4 4 – 2
Never 3 3 – 1
 Totals 18 13 5 3
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quarantine. She denied any evidence of illness since being released from surveillance.
The total elapsed time from her contact with the body of Case 2 and the onset of
disease in her mother was 32 days, consistent with two incubation periods of small-
pox. Except for the daughter’s exposure, no epidemiologic evidence could be found
linking the mother with a source of smallpox. Neither the mother nor daughter had
been vaccinated since childhood. The daughter demonstrated a high HAI titer on
June 6, suggesting a recent infection, and in the absence of an alternative explanation,
it may be presumed that the daughter developed a sub-clinical infection and transmit-
ted virus to her mother. Two very unusual aspects of smallpox transmission seem
apparent. The daughter, unvaccinated since childhood and exposed to hemorrhagic
smallpox, developed an infection so mild as to produce no symptoms, yet developed
serologic evidence of infection. Despite the presumed absence of any rash or systemic
manifestations of disease, she was apparently able to transmit the illness to her
mother.
The inadvertent exposure of the mother during her eruptive stage to some 450 per-
sons at the hospital, as well as possible contacts in the boarding house, establishes an
additional large group of contacts in which cases may yet occur.
An epidemic curve for the outbreak to date is presented showing the chronologic
relationship of the generations of transmission [See Figure below]. Using the median
date in the span of onset dates for each generation, it is apparent that the median
incubation periods for all generations are strikingly similar.
Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:220 (July 5, 1963)
No new cases have been reported during the past week. The total number of con-
firmed cases remains at 23, including four deaths. The fourth death reported involved
an unvaccinated 47-year-old male who died on June 15, 25 days after onset of illness.
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He was the father of case 7, also a fatality (See MMWR, Vol. 12, No. 21, pp. 174 and
183).
Smallpox — Stockholm, Sweden, 1963
MMWR 1963;12:236 (July 19, 1963)
Two additional cases of smallpox were reported from Stockholm on July 11 and
July 12, respectively. One of these, an 89-year-old female patient in a mental hospital,
had onset of rash and fever on July 7, 15 days after onset of illness in Case 23, a
73-year-old woman also hospitalized at this institution.
The total number of confirmed cases that has occurred during the outbreak is 25,
including four deaths.
Editorial Note—1996
Donald R Hopkins, MD, MPH, Carter Center/Global 2000, Atlanta, and former Deputy Director,
CDC. J Donald Millar, MD, DTPH (London), President, Don Millar & Associates, Inc., Atlanta, and
former Director, National Institute for Occupational Safety and Health, Center for Environmental
Health, Bureau of State Services, and Smallpox Eradication Program, CDC.
Reading this MMWR  account of the outbreak of imported smallpox in Sweden dur-
ing April–July 1963 is as haunting now as it was frightening then. At the time, there
was justifiable concern about possible spread of infection from Sweden to the United
States, and when residents of Stockholm were offered vaccination during the out-
break, “some 300,000 persons...availed themselves of this protection.”
Sweden was the first major country to eliminate indigenous smallpox, a distinction
it achieved in 1895 (1 ). This outbreak was the first appearance of imported smallpox
there since 1932, except for a single case in 1945 (2 ). Infecting 25 persons over six
indigenous generations of transmission, this was one of the larger such outbreaks in
Europe (which had two other imported outbreaks in 1963, four in 1962, and 10 in 1961,
for example) after 1958 (3 ). Despite Sweden’s active vaccination efforts among hospi-
tal personnel, eight of the indigenous cases were acquired by hospital staff or pa-
tients; most of the remainder were infected by face-to-face contact in the homes of
case-patients. However, the versatile virus apparently also spread in this one outbreak
from a corpse, from laundry of another case-patient, and by remote airborne expo-
sure, and its clinical presentation ranged from six cases (among persons with old vac-
cinations) who did not develop a rash at all to at least one hemorrhagic case.
Several aspects of the outbreak in Sweden differed dramatically from smallpox
outbreaks in Great Britain the previous winter following importations from Pakistan. In
particular, this outbreak was not recognized until seven cases already had occurred;
ambulatory cases with “mild” disease were important in early transmission; the over-
all case-fatality rate was substantially lower (15% in Sweden versus 40% in Great Brit-
ain). At the time, these differences were attributed to vaccine-modification of
smallpox associated with the ameliorating influence of partial immunity from distant
prior vaccinations. In retrospect, they may reflect infection with a strain of smallpox
virus from Indonesia where smallpox historically seemed to be less lethal than on the
Indo-Pakistan subcontinent.
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In the outbreak in Sweden, hospital transmission of smallpox was not prominent in
the early generations of disease as it was in most other European outbreaks associ-
ated with importation. However, once patients began to be admitted to the hospital,
the hospital became the focus of transmission. In addition, transmission also was as-
sociated with contact with fatal cases; indeed, handling smallpox corpses and attend-
ing funerals of smallpox victims resulted in outbreaks in Africa and other
smallpox-endemic areas during the global smallpox eradication campaign (4 ).
Dr. Ronald R. Roberto, an officer in CDC’s Epidemic Intelligence Service Program
during 1962–1964, went to Stockholm as an international observer during this out-
break. In addition to his role in rapidly communicating emerging information to CDC,
he formed relationships with Swedish colleagues—including epidemiologists H. B.
Lundbeck and B. O. Ringertz and virologist J. A. Espmark—who made important con-
tributions to the subsequent development of smallpox eradication activities of CDC
and the World Health Organization.
This outbreak also highlights how interconnected the world was already in 1963,
and it illustrates vividly the potential danger posed to all other humans as long as
smallpox existed anywhere on the planet. Even discounting the unknown, apparently
chance encounter by which the index patient in this outbreak came to be infected, the
capricious nature of many of the subsequent encounters that resulted in indigenous
cases in Sweden is breathtaking. The painful lesson was not lost on Sweden, which
contributed almost $16 million to the global Smallpox Eradication Program, beginning
in 1967, making it the second largest donor after the United States (3 ). Sweden’s gen-
erosity was especially important during the final battles against smallpox in India,
Bangladesh, and Somalia.
Finally, it is fitting that CDC marks the 50th Anniversary of its own founding by
commemorating the 200 years since Edward Jenner discovered vaccination in May
1796 and the 30 years since the Nineteenth World Health Assembly resolved in May
1966 to eradicate smallpox over the next 10 years. The CDC effort in helping 20 West
and Central African countries to eradicate smallpox early in the global campaign with
support provided by the U.S. Agency for International Development and by the Public
Health Service remains one of its finest and most beneficial achievements.
The glorious legacy of the global Smallpox Eradication Program lives today in the
campaigns to eradicate dracunculiasis and poliomyelitis. Others too will follow.
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Smallpox Surveillance — Worldwide
Smallpox Surveillance MMWR 1978;27:8 (January 6, 1978)
A total of 3,234 cases of smallpox have been reported from Eastern Africa to the
World Health Organization (WHO) in the period January 1–December 6, 1977. Since
October 16, 1975 — more than 2 years ago — when a case occurred in Bangladesh,
smallpox has been detected only in Ethiopia, Kenya, and Somalia, 3 countries which
together with Djibouti are linked by the Ogaden Desert to form one epidemiologic
unit.
To date, the last known case of smallpox occurred in Somalia on October 26 in the
Merca District. The source of this case was a known outbreak in the nearby district of
Kurtuware. All 211 contacts were traced, revaccinated, and kept under surveillance.
There have been no secondary cases. As of December 6, there were 6 pending out-
breaks* in Somalia — the one in Merca and 5 in Bardere.
During October and November surveillance in Somalia has been severely ham-
pered by heavy rains that have made it difficult or impossible to travel by vehicle.
Since work has had to be continued on foot, there have been some delays in reporting
and incomplete search coverage in certain areas. To combat this, personnel have been
concentrated in those areas considered to be at highest risk of having undetected foci
or where information is most limited. Currently there are 1,670 national staff and
24 WHO epidemiologists involved in the program. Increased mobility with restoration
of complete active searches will be necessary to ensure that all foci have been
detected. Accordingly, intensified activities are planned during the dry season, Janu-
ary through April 1978.
The last known case of smallpox in Ethiopia occurred on August 9, 1976, in El Kere
Region. In Kenya, the last case was on February 5, 1977, in the Mandera District.
Reported by the World Health Organization in the Weekly Epidemiological Record 52:389-391,
1977
Smallpox Surveillance — Worldwide
Smallpox Surveillance — WorldwideMMWR 1978;27:133 (May 5, 1978)
As of April 14, 1978, no cases of smallpox have been reported to the World Health
Organization (WHO) from anywhere in the world since the last case had onset of rash
on October 26, 1977, in Merka town, Somalia. However, a total of 2 years of effective
surveillance must elapse before this last endemic area can be confirmed to be
smallpox-free.
Worldwide, since January 1, 1976, smallpox cases have been detected only in cer-
tain areas of Ethiopia, Kenya, and Somalia (Figure 1). One year and 9 months has
elapsed since cases were detected in Ethiopia; 1 year and 1 month has elapsed since
*An outbreak is defined as one or more cases; a pending outbreak is one in which 6 weeks has
not elapsed since the onset of rash of the last case.
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5 cases were detected in Kenya after an importation from Somalia; and 6 months has
passed since the last case was found in Somalia.
With the apparent interruption of transmission of the disease on a global basis,
smallpox activities are being directed toward promptly certifying and providing
authoritative endorsement of this historic event. In January 1978 the Executive Board
of WHO endorsed the recommendations of a consultant group on worldwide certifica-
tion of smallpox eradication which met in October 1977. Recognizing that this certifi-
cation is based on verifying that 2 years has elapsed with no case of smallpox being
detected by a surveillance system which would have detected any case had it oc-
curred, the recommendations called for the establishment of a Global Commission.
This independent group of experts is to monitor and review the following steps to be
undertaken in 1978 and 1979: (1) certification by international commissions in the
15 countries not yet visited by commissions; (2) special documentation or visits to be
required for 16 countries; (3) the request for statements from other countries declaring
their smallpox-free status.
If no more cases of smallpox are detected, the countries of Somalia, Ethiopia, Dji-
bouti, Kenya, Yemen, and Democratic Yemen will be eligible for certification in Octo-
FIGURE 1. Eastern Africa: The world’s last known smallpox foci by area and dates
of last cases, as of April 14, 1978
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ber 1979. These will be the last of the 15 countries to be certified by an international
commission, and priority attention is being given to surveillance in these areas.
Reported by the World Health Organization in the Weekly Epidemiological Record 53:97-99, 108,
1978.
Editorial Note—1997
William F Foege, MD, Rollins School of Public Health, Emory University, and former Director,
CDC. Walter R Dowdle, PhD, Director of Programs, Task Force on Child Survival and Develop-
ment, and former Deputy Director, CDC.
Some things need be done only once in the entire history of the world. The devel-
opment of smallpox vaccine and the eradication of smallpox disease are on the list.
Perspective is elusive, even when one contemplates 20 years without a single case of
smallpox in the world. Part of the reason is that we all begin our reading “in the mid-
dle of the book.” Although the full story that went before can never be known,
smallpox eradication became possible, and then inevitable, when Edward Jenner, us-
ing his clinical powers of observation over a 25-year period during the 18th century,
became convinced that an infection with cowpox could protect against smallpox. He
then took the next step, inducing immunity by transferring cowpox from the hand of
Sarah Nelmes to the arm of James Phipps—creating a tool that would change the
health of entire populations (1 ).
In a real sense, the history of modern public health started on that day, May 14,
1796. Word spread quickly, despite communication barriers. By 1806, Jefferson was
able to visualize the last case of the disease when he wrote to Jenner, “future genera-
tions will know by history only that this loathsome disease has existed” (1 ).
It is a sad commentary that it took 170 years to finally organize to accomplish Jef-
ferson’s vision. But when it happened, it brought out the best in science and public
health. The resolution at the World Health Assembly in 1965 was unanimous and led
to excellent cooperation between the United States and the Soviet Union, even in the
midst of Cold War politics. The value of WHO, which represented the health needs of
every person in the world, was demonstrated. Workers and resources from around the
world were organized for use in the areas of greatest need. The public health situation,
rather than political concerns, dictated how the program was to be executed. The
United States can be proud of its role in this exciting program, contributing hundreds
of workers and millions of dollars for the eradication of a disease that no longer in-
volved our nation.
Twenty years have passed since the last naturally acquired case of smallpox oc-
curred, as reported in the January 6 and May 5, 1978, issues of MMWR. Smallpox has
not re-emerged from an unrecognized human or animal reservoir, from a variolator’s
store of infected scabs, or infected cadaver, either unearthed or thawed. There contin-
ues to be no evidence to support the theory of a “niche” for human pathogens that,
when vacated, will be filled by another. Although speculation increased when
monkeypox was recognized as causing human disease, fears decreased when
monkeypox was shown to have a low secondary attack rate among unvaccinated hu-
mans (2 ). In addition, monkeypox virus, probably arising from a squirrel reservoir, is
not ancestral to smallpox virus based on genomic studies (3 ).
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The issue of monkeypox again emerged with outbreaks in 1996 (4 ) and 1997 (5 ) in
the eastern Democratic Republic of the Congo with speculation about the need for
smallpox vaccine to provide cross-protection for the populations at highest risks.
Such recommendations must be considered carefully because of the adverse risks of
the vaccine, particularly in persons who may be immunocompromised by human
immunodeficiency virus infection (5 ). A better understanding of the current
epidemiology/epizoology of monkeypox is needed. 
Smallpox has been eradicated, but the etiologic agent is not extinct. The virus con-
tinues to exist in freezers in secure facilities at one institution in the United States and
another in the Russian Federation. During the past 10 years, various individuals and
three WHO committees have recommended destruction of virus stocks on the
grounds that the world needs to be assured that smallpox will never again be a threat
to humankind. In opposition to virus destruction are equally strong views that labora-
tory stocks serve as a counterbalance to terrorism and a source of unknown future
benefits to humankind. In May 1996, the World Health Assembly recommended, sub-
ject to further review, that all stocks be destroyed in June 1999.
The legacy of the smallpox program, beyond eradication, has been enduring and
includes the Expanded Program on Immunization (with its remarkable reductions of
measles and other vaccine-preventable illnesses), the impending eradication of
Guinea worm disease and poliomyelitis, and improved global disease surveillance
and public health logistics systems. The growing interest in eradication as a global
health strategy led to the creation of the International Task Force for Disease Eradica-
tion, which reviewed >80 potential candidate diseases and concluded in 1993 that six
were eradicable (6 ). The science of infectious diseases eradication was the subject of
a multidisciplinary Dahlem Workshop in Berlin in March 1997. As a follow-up to the
Dahlem Workshop, a conference is scheduled in Atlanta in early 1998 on Global Dis-
ease Elimination/Eradication as Public Health Strategies; this conference will explore
the potential synergistic relations between disease elimination/eradication and pri-
mary health-care programs throughout the world.
The health benefits of smallpox eradication have been enormous and the economic
benefits satisfying. Because of smallpox eradication, the United States saves more
each year than its annual dues to WHO. For the first time, social justice in public health
has been achieved, with everyone benefiting from a body of scientific knowledge and
experience. The benefits will continue to be enjoyed by every person who will ever be
born. “Future generations will know by history only” that world cooperation reached
an unprecedented level in the 20th century, making this bequest possible.
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Nosocomial Bacteremias Associated with
Intravenous Fluid Therapy — USA
Nosocomial BacteremiasMMWR 1971;20 (Special Supplement) (March 6, 1971)
Between October 1970 and March 1, 1971, eight United States Hospitals in seven
states experienced 150 bacteremias caused by Enterobacter cloacae  or Gram-
negative organisms of the Erwinia group. There were nine deaths; all were associated
with intravenous (IV) fluid therapy. The Enterobacter bacteremias in all hospitals were
substantially increased as compared to previous time periods. Four hospitals which
isolated and identified Erwinia had not previously encountered infections with these
organisms. In-depth epidemiologic investigations were performed in three of the hos-
pitals (Figure 1).
All eight hospitals utilize fluids and systems manufactured by Abbott Laboratories,
which produces approximately 45 percent of all IV fluids sold within the United States.
In approximately 30 cases, the same organisms were isolated from blood cultures and
contaminated in-use IV fluids. In hospital B (see arrow, Figure 1) no further cases were
observed after discontinuance of Abbott products.
Figure 1
IV-ASSOCIATED SEPTICEMIAS, BY WEEK OF ONSET, 1970-1971
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Enterobacter cloacae  is occasionally encountered as an agent of bacteremia in
American hospitals. However, unless fully speciated, this organism will not be identi-
fied. Erwinia, most well known as a plant pathogen, has only very rarely been isolated
from human infection (1). Erwinia may be confused with members of the Klebsiella-
Enterobacter group, and a rather detailed series of biochemical tests, with special
emphasis on decarboxylase reactions, are needed to reliably differentiate the organ-
isms.
These septicemias were constantly characterized by intermittent high fever, al-
though shock was infrequent. Young individuals or other patients without predispos-
ing host factors were frequently afflicted. The great majority of cases simultaneously
manifested extensive phlebitis at the site of infusion which occurred even when poly-
ethylene catheters had been in place for only brief periods, and also occurred where
only scalp vein needles were used. Discontinuance of IV therapy has resulted in dra-
matic clinical improvement; if such therapy is continued, however, antimicrobials
have frequently been without apparent effect on the course of the infection.
Studies of IV systems by CDC have shown a minimum of 6 percent prevalence of
contamination within the tubing or bottles after the system has been in use. A signifi-
cantly greater risk of contamination was noted in all systems where administration
apparatus remained unchanged for greater than 48 hours. The studies also revealed
that routine once-daily complete change of all IV administration apparatus, especially
at the time of replacement of infusion devices (polyethylene catheters, needles, etc.)
can greatly decrease the hazard of extrinsic contamination by preventing introduced
organisms from propagating to dangerous levels.
Bacterial contamination of the outer surface of the insert discs (synthetic cap liner)
of unopened Abbott bottles has recently been demonstrated by CDC, which ranges
from 0 to 52 percent among sampled lots. Bacillis species, S. epidermidis, Pseudo-
monas maltophillia  and yeasts have been most frequently isolated, however, E. cloa-
cae  or Erwinia species have been isolated from 12 of 212 caps tested. Between April
and September 1970, Abbott Laboratories partially converted to a new type of cap
liner.
Direct sampling of fluids from intact non-manipulated bottles by CDC has been
negative, but transfer of organisms from contaminated caps to the fluid has been ef-
fected approximately 25 percent of the time by sequentially striking the cap several
times, unscrewing and replacing it, and then hanging the bottle inverted for 24 to
48 hours. Transfer of organisms from contaminated caps to the fluid of bottles, where
the cap has not been manipulated, has not been demonstrated, but is currently under
further investigation. Once inoculated into commercial dextrose containing solutions,
organisms of the Klebsiella-enterobacter group are capable of proliferating at room
temperature, whereas other tested members of the Enterobacteriacae or Staphylo-
cocci either fail to grow or die.
(Reported by the Food and Drug Administration and the Center for Disease Control.)
Reference:
1. von Graevenitz A: Erwinia species isolates. Ann NY Acad Sci 174(2):436-443, 1970.
Editorial Comment:
The following press release was issued March 13, 1971:
The Commissioner of Food and Drugs, Dr. Charles C. Edwards, and the Director of
the Center for Disease Control, Dr. David J. Sencer, today announced that special pre-
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cautions must be taken in hospitals, nursing homes, and other health care facilities to
reduce the risk of septicemia from the use of Abbott Laboratories intravenous (IV)
infusion products. While contamination resulting in septicemia can occur in the use of
infusion products from any manufacturer, recent Abbott production appears to pre-
sent a unique problem. These products will be replaced as rapidly as possible by Ab-
bott, however, these solutions are essential for patient care and cannot be withdrawn
before replacement is in hand.
A rising incidence of septicemia caused by organisms rarely associated with septi-
cemia has been found in connection with the use of intravenous fluids in eight hospi-
tals surveyed by the CDC. All eight were users of the Abbott infusion system. CDC has
been closely examining the fluids, the infusion apparatus, and clinical reports of sep-
ticemia. The plastic liners in some Abbott bottle caps have been found contaminated
by the implicated organisms. A tentative conclusion is that the organisms can enter
the fluid from the plastic cap liners when the caps are opened and replaced while the
bottle is held for later use. There is no evidence that the closure system allows or
contributes to contamination before it is opened. It has been shown that when the cap
has been removed and replaced that migration of bacterial organism from the cap
lining may occur.
The bottles of fluid known to be involved have been manufactured from February
1970 and they bear codes beginning with 842 through 855.
Teams of experts from CDC, FDA, and Abbott Labs are reviewing all aspects of the
problem. This review will be completed within a few days and it is expected that a
resolution will be developed rapidly.
Meanwhile, with cooperation of the American Hospital Association, hospitals and
other users of these solutions are being advised of special procedures to reduce the
contamination hazard to a minimum. These procedures include: opening the contain-
ers at the point of use only; not replacing the cap; and using the contents of the con-
tainers immediately upon opening. Hospitals also are being advised to change IV
apparatus at least every 24 hours. The CDC studies have demonstrated that any brand
of IV apparatus is more likely to cause infection if left in place longer.
CDC and FDA conclude that the joint actions being taken are reasonable and neces-
sary in the interest of patient care and to prevent a disruption in the availability of
these essential drugs.
On the basis of the studies conducted thus far, several additional specific measures
which might minimize the risk of contamination from Abbott products are recom-
mended:
1. At the first suspicion of clinical septicemia or fever which might be associated
with contaminated intravenous fluid, all existent IV apparatus should be re-
moved and microbiologically sampled; if continued IV therapy is necessary, it
should be reinitiated with entirely new equipment and solutions.
2. Bottle caps should not be struck or otherwise traumatized to effect removal. If a
cap is not easily removed, the bottle should be discarded.
3. A cap should never be replaced after the bottle has been opened.
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Editorial Note—1997
Frank S Rhame, MD, Abbott Northwestern Hospital, Minneapolis; Dennis G Maki, MD, Professor
of Medicine, University of Wisconsin, Madison; former EIS officers in the Hospital Infections Sec-
tion, Bacterial Diseases Branch, CDC, John V Bennett, MD, former Director, Division of Bacterial
Diseases, CDC; and William R Jarvis, MD, Acting Director, Hospital Infections Program, National
Center for Infectious Diseases, CDC.
In December 1970, CDC’s Hospital Infections Section, Bacterial Diseases Branch,
first received reports of episodes of nosocomial Enterobacter  sp. bloodstream infec-
tion (BSI). There was early concern about an association with receipt of intravenous
(IV) fluids because the patients had no primary infections or cultures yielding Entero-
bacter. Initially, it was hypothesized that this was caused by the vulnerability of IV
solution bottle screw-cap closures to extrinsic contamination. By January 1971, sev-
eral hospitals across the United States reported patients with BSIs caused by E.
cloacae  and an organism then uncharacterized as a human pathogen, E. agglomer-
ans. Furthermore, many of the episodes occurred in patients more healthy than those
who ordinarily were at risk for nosocomial BSIs, and all of the hospitals used IV fluids
manufactured by one company, Abbott Laboratories, Inc. On-site epidemiologic inves-
tigations were initiated at two hospitals by Epidemic Intelligence Service (EIS) officers
from CDC’s Hospital Infection Section. The investigations could not relate the IV-
associated BSIs at these hospitals to a particular additive or to any IV system compo-
nent and could not identify any defect in IV system management leading to extrinsic
contamination.
In general, contamination outbreaks involve a single organism; in these investiga-
tions, two bacterial species were involved. Nevertheless, the finding of these same
two unusual organisms causing BSIs at multiple hospitals decreased the likelihood of
extrinsic contamination and raised the possibility of a common source. By February
1971, epidemic organisms were found in the caps of IV solution bottles. Opened and
unopened bottles of IV solution were obtained, and cultures of these IV fluid bottles
were initiated at CDC. In vitro studies documented that simple, commonly performed
manipulations, such as unscrewing the cap, adding a medication, replacing the cap,
and inverting the bottle for mixing would transfer the contaminating organisms from
the cap to the fluid. After the warning published in MMWR  on March 6, 1971, CDC and
Food and Drug Administration (FDA) teams conducted investigations at both of the
Abbott manufacturing plants (1 ). Ultimately, CDC isolated the epidemic strains di-
rectly from the solutions in 13 (0.7%) of 1825 1-liter bottles (2 ).
By March 1971, E. cloacae  and E. agglomerans  BSIs had been reported from eight
hospitals across the United States. Approximately 20 persons at CDC were involved in
assembling data from these hospitals, culturing IV bottles and working with Abbott
and FDA on the appropriate response to the situation. The bases for action were the
occurrence of unexpected primary nosocomial BSIs in multiple hospitals exclusively
among patients receiving Abbott IV solutions, the recovery of epidemic organism
from bottle caps and several hanging IV bottles, and the termination of an outbreak in
a hospital after changing from Abbott IV fluids. Meetings in Washington, D.C., led to
the decision to issue the joint press release on March 13 by Charles Edwards, M.D.,
Commissioner of Food and Drugs, and David Sencer, M.D., Director of CDC. The need
for an MMWR  special supplement, without precedent for this publication, arose be-
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cause the MMWR  dated March 13 had been finalized by Wednesday, March 11. The
decision to issue the press release was not made until Thursday and the data under-
lying it could not have been added to the MMWR  dated March 13.
The March 13 governmental action was not a total recall of all Abbott IV fluids be-
cause it was not clear that there was sufficient substitute IV solution from alternate
manufacturers to meet the nation’s needs. To reduce the risk for BSI, instructions on
proper IV bottle manipulation were issued to minimize transfer of organisms from the
cap to the fluid. On March 22, FDA issued a recall of all Abbott IV fluids when it became
clear that the scope of the epidemic was larger than initially recognized, that some
hospitals continued to have episodes of BSI despite implementation of the March 13
recommendations, and that sufficient substitute IV fluids were available (3 ). By March
31, a total of 405 patients with BSI had been reported, of whom none had had onset
after the March 22 recall (1 ). The full epidemiologic analysis published in 1976 (4 ) was
delayed in part because of medicolegal considerations, and underscored the excep-
tional magnitude of the outbreak: estimates of the magnitude ranged from 2000 to
8000 episodes of BSI caused by these contaminated IV fluids. Approximately 10% of
the case-patients in the studied hospitals died while bacteremic or soon thereafter.
The cause of this outbreak was ultimately attributed to unexpected consequences
of a new cap design for IV solution bottles (1 ). After the March 13 warning, it was
learned that the company had been phasing in a new cap type since approximately
March 1970, although substantial production did not occur until about November
1970. The old cap liner incorporated a natural red rubber disc between the metal cap
and a thin Gilsonite wafer that was pressed against the bottle orifice by the natural
rubber. Fortuitously, the rubber had antibacterial properties against E. agglomerans
and E. cloacae, two organisms unusual among bacteria in their ability to proliferate in
acidic, nitrogen-poor, dextrose-containing fluids (5 ). In vitro studies showed that
these organisms were drawn up into the cap as cooling occurred after autoclaving but
were not destroyed by the new elastomer lined cap. Manufacturing plant environ-
mental cultures documented that these organisms were abundant in the manufactur-
ing plant environment because of spillage of glucose-containing solution that favored
their growth. It is uncertain whether the organisms may have been drawn into the
fluid itself during cooling or whether it was impossible to remove the caps without
transferring organism to the fluid. Furthermore, the United States Pharmacopeia
(USP) sampling procedures did not require identification of contaminating organisms,
and the required two-step sampling scheme was too insensitive—missing 98% of lots
contaminated at a 1% rate. Identification of recovered organisms would probably have
revealed the problem earlier.
Surveillance of nosocomial infections had begun at CDC in 1965 when the Hospital
Infection Section initiated the Comprehensive Hospital Infections Program (CHIP)
study in six community hospitals. CHIP produced high-quality data on infection rates
in hospitalized patients and was used to develop nosocomial infection surveillance
methods applicable to U.S. community hospitals. In May 1969, CDC initiated the
National Nosocomial Infections Surveillance (NNIS) system, a substantially larger
program that accepted data from up to 80 hospitals nationwide. These efforts helped
establish nosocomial infection surveillance programs in U.S. hospitals. Without such
programs, the detection of this outbreak would have been more difficult, and the out-
break likely would have resulted in additional deaths. While several hospitals recog-
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nized the phenomenon independently because of clustering of BSIs and/or by the in-
volvement of the unusual organisms, most involved hospitals had small numbers of
infected patients and recognized their involvement only in retrospect (6 ).
This outbreak required a compilation of national prospective data to detect, inves-
tigate, and terminate. The epidemiologic expertise and laboratory resources required
to carry out multiple onsite investigations and in vitro microbiologic studies in a
timely fashion were only available at CDC, a national public health institution. During
February–April 1971, approximately 3000 cultures of large volume parenteral fluids
were performed by CDC laboratory personnel—the extraordinarily large number of
cultures resulted in a national shortage of brain heart infusion broth. The necessary
and synergistic interaction between epidemiologists and microbiologists in solving
the outbreak is still recognized by the prestigious Mackel Award, offered annually to
EIS officers in honor of the competence and dedication of the late Donald C. Mackel,
who directed the laboratory studies. This outbreak also resulted in development of
more sensitive and restrictive USP requirements for monitoring contamination of
large volume parenterals by manufacturers and the development of the first guide-
lines by CDC on the prevention of nosocomial infection (7,8 ). These guidelines were
the precursors to the current Hospital Infections Program Nosocomial Infection Pre-
vention Guidelines.
One consequence of this outbreak was the media attention and litigation incurred
by some of the involved hospitals. Ironically, it was the active surveillance for noso-
comial infections at these hospitals and the quality of their infection-control programs
that facilitated recognition of this outbreak. Headlines about BSIs in hospitalized
patients were not mitigated by the hospitals’ ultimate medicolegal exoneration.
The manufacturer incurred considerable economic consequence from this outbreak,
even though this outbreak occurred before the era of cooperation between plaintiff’s
attorneys in product liability suits. The trials were conducted in 1976, and most of the
epidemiologic evidence was not admitted. Judgments turned on whether an individ-
ual lot could be demonstrated to be contaminated and whether the patient could be
proven to have received fluid from that lot. Since lot numbers were not often re-
corded, few plaintiffs prevailed.
One of the special features of the CDC in response to this crisis was the compres-
sion of hierarchy, including the open information channels throughout CDC. For ex-
ample, during the most intense period of the investigation, the CDC Director was in
frequent direct conversation with front-line EIS officers. In negotiating sessions with
FDA in Washington, data presentations were made by EIS officers.
This large nationwide outbreak of nosocomial BSIs traced to intrinsic contamin-
ation of IV solutions led to widespread changes at industry, hospital, state, and federal
levels. Expansion of nosocomial infection surveillance and control programs oc-
curred at the hospital and federal level. There was enhancement of FDA and CDC sur-
veillance for outbreaks attributable to potentially contaminated products, expansion
of training programs for infection-control professionals and hospital epidemiologists,
development of guidelines for the prevention of nosocomial infection, strengthening
of CDC core epidemiologic and laboratory capacity to respond to nationwide out-
breaks, and strengthening of FDA and USP requirements for monitoring potential
product contamination. Since the institution of these measures, no large nationwide
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outbreak of BSIs traced to intrinsically contaminated IV solutions has occurred in the
United States.
References
1. Mackel DC, Maki DG, Anderson Rl, Rhame FS, Bennett JV. Nationwide epidemic of septicemia
caused by contaminated intravenous products. III. Mechanisms of intrinsic contamination.
J Clin Microbiol 1975;2:486–97.
2. CDC. Follow-up on septicemia associated with contaminated intravenous fluid from Abbott
Laboratories. MMWR 1971;20:110.
3. CDC. Follow-up on septicemias associated with contaminated Abbott intravenous fluids—
United States. MMWR 1971;20:91–2.
4. Maki DG, Rhame FS, Mackel DC, Bennett JV. Nationwide epidemic of septicemia caused by
contaminated intravenous solutions. I. Epidemiologic and clinical features. Am J Med 1976;60:
471–32.
5. Maki DG, Martin WT. Nationwide epidemic of septicemia caused by contaminated infusion
products. IV. Growth of microbial pathogens in fluids for intravenous infusions. J Infect Dis
1975;131:267–72.
6. Goldmann DA, Dixon RE, Fulkerson CC, Maki DG, Martin SM, Bennett JV. The role of nationwide
nosocomial infection surveillance in detecting epidemic bacteremia due to contaminated
intravenous fluids. Am J Epidemiol 1978;108:207–13.
7. Maki DG, Goldmann DA, Rhame FS. Infection control in intravenous therapy. Ann Intern Med
1973;79:867–87.
8. Goldmann DA, Maki DG, Rhame FS, Kaiser AB, Tenney JH, Bennett JV. Guidelines for infection
control in intravenous therapy. Ann Intern Med 1973;79:848–50.
Original report published with new editorial note in MMWR 1997;46:1227–33 (December 26,
1997).
Nosocomial Bacteremias 51
Respiratory Infection — Pennsylvania
Legionnaires Disease MMWR 1976;25:244 (August 5, 1976)
A total of 152 persons associated with a state American Legion convention in Phila-
delphia July 21–24 have been hospitalized with respiratory infections. Onsets of
illness were in the period July 22–August 3; the majority occurred from July 25 to
July 31. Twenty-two of these patients have died. The deaths, reported over the past
week, were primarily due to pneumonia.
Although information about the disease and its epidemiology is incomplete, it ap-
pears to be characterized by the acute onset of fever, chills, headache, and malaise,
followed by a dry cough and myalgia. Some of the most seriously ill developed high
fever and died in shock with extensive pneumonia. No etiologic agent has yet been
incriminated. There is no information available concerning other Legionnaires who
may be ill with less severe symptoms.
The patients, among several thousand attending the convention, stayed in at least
3 or 4 hotels while in Philadelphia. There is no evidence of increase in respiratory
disease in Philadelphia residents, nor has there been any confirmed secondary spread
to family members or other contacts. There have been several reports of similar
disease in non-conventioneers who were in Philadelphia at the same time as the
convention.
Reported by RG Sharrar, MD, City of Philadelphia Dept of Public Health; WE Parkin, DVM, Acting
State Epidemiologist, Pennsylvania State Dept of Health; the Bur of Epidemiology and the Bur
of Laboratories, CDC.
Follow-up on Respiratory Illness — Philadelphia
Legionnaires Disease MMWR 1977;26:9–11 (January 18, 1977)
Last summer an outbreak of severe respiratory illness occurred in Pennsylvania
chiefly among those who had attended a state American Legion convention in Phila-
delphia July 21–24, 1976 (MMWR 25 [30,33,34]). An estimated 180 cases including
29 deaths occurred (MMWR 25 [38]). An organism has now been isolated in yolk sacs
of embryonated hens’ eggs that appears to be the etiologic agent. For the purpose of
this report the yolk sac isolate is being called a bacterium on the basis of its size and
morphology.
The bacterium was first isolated from the lung tissues of 1 fatal case of Philadelphia
respiratory disease and 1 fatal case of Broad Street pneumonia (see below) by inocu-
lation of guinea pigs intraperitoneally. After a 1- to 2-day incubation period the guinea
pigs developed a febrile illness that was characterized in most animals by watery eyes
and prostration. Spleen suspensions of febrile guinea pigs were inoculated into yolk
sacs of embryonated eggs from antibiotic-free chicken flocks. The embryos died after
4–6 days, and Gimenez-stained smears of the yolk sacs were found by microscopic
examination to contain many bacilli. The bacilli were gram-negative and moderately
pleomorphic. Surviving guinea pigs were shown by indirect immunofluorescence to
have developed antibody to the yolk sac isolates. Because most bacteria when inocu-
lated into the yolk sac kill the eggs in 1–2 days, an unusual rickettsia was suspected.
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The organism is bigger than a rickettsia, however, and the convalescent guinea pig
sera failed to react in the complement fixation test with standard rickettsial antigens
prepared from Coxiella burnetii, Rickettsia rickettsii, R. prowazekii, and R. typhi. Culti-
vation on sheep blood agar and Trypticase Soy Agar has been attempted at each yolk
sac passage. Frequently, no growth has been observed, but yolk sacs infected with
1 isolate have sometimes given many minute colonies after 2–3 days’ incubation. The
slowness of growth has delayed bacteriological identification.
Evidence for the etiologic role of the yolk sac isolate in the epidemic has been ob-
tained by indirect fluorescent antibody stains carried out by methods that are the
same as those in regular use in the diagnosis of rickettsial diseases, except that the
microdrops fixed to the slide were prepared from yolk sacs infected with isolate 1 and
isolate 2 of the Philadelphia agent. The results in Tables 1 and 2 were obtained with
sera from 33 patients who were selected because they were Legionnaire delegates
who were hospitalized, survived, and had radiologic evidence of pneumonia and fe-
vers of at least 102 F; they thus represented the most typical survivors.
Table 1 shows some representative results. The sera with high titers gave bright
staining at low dilutions which gradually decreased with increasing dilution. The
brightness of staining and height of the titers are similar to that observed in other
infectious diseases, for example, Rocky Mountain spotted fever. Patients 1, 2, and
3 had distinct increases in antibody titers, and 4 had only a 4-fold increase. The first
specimen from patient 5 was already at a titer of 128, and there was no further in-
crease between the eighth and twenty-ninth day of illness.
Table 2 summarizes the results with sera of the 33 Legionnaire patients tested to
date; 29 gave results that suggest they were infected with the organism. Seroconver-
sions were seen in 25 patients and antibody rises of more than 4-fold in 19. The maxi-
mum titers observed were 128 or greater in 26 out of 29 patients. The titers were
usually low in the first week of illness, but they rose rapidly in the second and third
weeks. The fact that 3 patients had no serologic response is not surprising since the
cases were defined on a clinical and epidemiological basis. The staining of isolates
1 and 2 has been very similar with these sera and with the other sera reported below.
Thus the 2 yolk-sac isolates are antigenically very similar if not identical.
Cases of Broad Street pneumonia represent disease clinically similar to Philadel-
phia respiratory disease that occurred in persons who did not attend the Convention,
were within 1 block of Hotel A between July 1–August 18, but said they did not go into
Hotel A during the epidemic period. Sera from 4 of the 38 such patients have been
tested. Two have shown serologic conversions from titers of 16 or less to 512 or
greater. Two had unchanging titers of 32 or less.
As controls for the fluorescent antibody tests, sera were tested from 40 patients
unrelated to the outbreak whose specimens had been submitted for rickettsial diagno-
sis (Table 3). The rickettsial complement fixation tests had failed to demonstrate rick-
ettsial antibody. The sera were first screened at a dilution of 1:32 and those with
staining at this dilution were retested at dilutions of 1:16 through 1:512. Most of the
titers observed with the yolk sac isolate were low. Two specimens had titers of 64, that
is, they overlapped with the lowest titers observed in Legionnaire patients in Table 2.
The staining at low dilutions with these sera was only 1+ bright; however, in all the
seropositive Legionnaire patients in Table 2 and in the 2 Broad Street pneumonia pa-
tients who converted, fluorescence was 3–4+ bright in low dilutions.
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TABLE 1. Results with indirect fluorescent antibody stains of the agent cultivated in





Disease 16a 32 64 128 256 512 Titer
Interpre-
tationb
1 S1  1 1+/1+c ±/± 0/0 0/0 0/0 0/0 16/16d
S2 22 3+/3+ 3+/3+ 2+/3+ 1+/2+ ±/1+ 0/0 128/256 C
2 S1  4 ±/± 0/0 0/0 0/0 0/0 0/0 <16/<16
S2 11 2+/3+ 2+/2+ 1+/2+ 1+/1+ ±/± 0/0 128/128
S3 25 3+/3+ 2+/2+ 2+/2+ 1+/1+ ±/1+ ±/± 128/256 C
3 S1 24 ±/± ±/± 0/0 0/0 0/0 0/0 <16/<16
S2 34 3+/3+ 3+/3+ 2+/3+ 2+/3+ 1+/2+ 1+/1+ >512/>512 C
4 S2 12 3+/3+ 2+/2+ 1+/1+ ±/± 0/0 0/0 64/64
S3 33 3+/3+ 2+/2+ 1+/2+ 1+/1+ ±/1+ 0/0 128/256 C
5 S1  8 2+/2+ 2+/2+ 1+/1+ 1+/1+ ±/± 0/0 128/128
S3 29 3+/3+ 3+/3+ 2+/3+ 2+/± ±/0 0/0 128/64 P
6 S1  5 0/0 0/0 0/0 0/0 0/0 0/0 <16/<16
S3 29 0/0 0/0 0/0 0/0 0/0 0/0 <16/<16 N
a
The reciprocal of the dilution is shown in this and other tables.
bC = seroconversion or increase in titer of at least 4-fold with 1 or both antigens. P = classified
as positive because the titer was high but showed little change. N = classified as negative
because all specimens had low titers.
c Brightness of staining: 0 = no staining, ± = questionable staining, 1+ = barely detectable but
definite staining, 2+ and 3+ = increasing brightness.  The 2 numbers refer to staining of the
bacteria in yolk sacs infected with the first 2 isolates.
dHighest dilution with definite staining with either antigen.
TABLE 2. Results with indirect fluorescent antibody stains of the agent cultivated in
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 256  6
 128  6
  64  3
Negatives  <64  4
Total patients tested 33
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In the outbreak, illness in conventioneers was associated with time spent in Hotel
A. The incidence was directly related to time spent in the lobby. Sera were available
from some hotel employees of 2 categories: those who worked in the lobby and those
who worked in locations removed from the lobby (Table 4). Also shown in the table are
the results with sera from a group of Pennsylvania Legionnaires who did not attend
the convention. One positive titer in a hotel employee was seen, a cashier checker,
who had a titer of 256. The titers with the other employees and the Legionnaires who
did not attend the convention were within the range of the 40 non-epidemic sera re-
ported in Table 3.
In 1966 an outbreak of acute pneumonia occurred at a large psychiatric hospital in
the District of Columbia. There were 94 cases and 16 deaths. Acute and convalescent
sera were available from 14 patients; they were also tested against the antigens from
Isolate 1 and 2. Thirteen had distinct rises in titer of 8-fold or more, and 12 had titers of
128 or more. The brightness of staining and titers were the same as those seen with
the Legionnaire patients.
The intensity of public interest in the Philadelphia epidemic makes it necessary to
provide a factual account of these findings now. The etiology of the outbreak has been
unknown. The present findings provide very strong evidence that the 2 epidemics
were caused by the bacterium isolated in yolk sacs and that nearly all the cases had
the same cause. The bacterium can be identified now by the characteristic disease it
produces in guinea pigs, the characteristic death pattern in eggs, the at best dysgonic
growth on the bacterial media tried, and by the fluorescent antibody staining results.
Other, more complex explanations are possible. For example, the bacterium might be
thought of as a secondary invader associated with a virus, but extensive virological
searches have failed to reveal a virus and the serologic responses for the bacterium
have been present in a very high percentage of the cases. There has not been time to
TABLE 3. Results with sera from control patients clinically suspected to have Rickettsia
infections
Titer
  Number of
Persons
 64  2
 32  6




TABLE 4. Serologic results with other persons who did not meet clinical criteria for a
case of Philadelphia respiratory diseasea
Titers
<16 16 32 64 128 256 Total
Hotel employee, lobby 1 2 3
Hotel employee, non-lobby 6 4 2 1 13
Legionnaire, not at convention 3 5 1 2 11
a
In all these sera the staining, even at low dilutions, was not more than 1+ (barely detectable).
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identify the organism taxonomically. The source of the organism in the outbreak is not
known, but the search should now be greatly facilitated.
Reported by the Leprosy and Rickettsia Br, Virology Div, Bur of Laboratories, CDC.
Follow-up Survey Data: In December 1976, selected survivors of Philadelphia respi-
ratory disease and matched controls were interviewed concerning smoking habits,
liquor and snack food preference, and knowledge of homemade liquor. The 56 pa-
tients selected for interview represented all hospitalized male survivors who had been
delegates to the American Legion convention and were known to have developed an
illness characterized by temperature of 102 F or higher and pneumonia proved by
X-ray. The 56 controls were male delegates matched by age who had indicated on
earlier survey that they had not been ill since the convention. The interviews were
completed with 52 case-control pairs. Cigarette smoking habits at the time of the con-
vention were the only significant associations with illness. The relative risk of illness
among cigarette smokers was 3.4 compared to non-smokers (X
2
(1) = 5.5, p< .05,
McNemar) (Table 5). Cases also smoked more cigarettes and were more likely to have
smoked sample cigarettes available at the convention. A previous survey showed no
single cigarette brand common among cases. Pipe or cigar smoking was not associ-
ated with illness.
Reported by RG Sharrar, MD, City of Philadelphia Dept of Public Health; E Streiff, RN, MPH,
Allegheny County Dept of Health; WE Parkin, DVM, Acting State Epidemiologist, Pennsylvania
State Dept of Health; Bur of Epidemiology and Bur of Laboratories, CDC.
Editorial Note—1997
David J Sencer, MD, former Director, CDC; Joseph E McDade, PhD, Associate Director for Labo-
ratory Science, National Center for Infectious Diseases, CDC.
A bacterial etiology was not initially evident during the field investigation phase of
the Legionnaires disease outbreak. Chest radiographs of case-patients revealed an in-
terstitial pneumonia, which at that time was considered indicative of a viral infection.
Because the Legionnaires disease bacterium is refractory to most stains, no bacteria
could be visualized when sections of lung tissues from deceased patients were
stained by commonly used methods, such as the Brown-Brenn technique. Addition-
ally, no species of bacteria was reproducibly isolated from autopsy materials or
clinical specimens because the special nutritional requirements of the Legionnaires
disease bacterium precluded its growth on conventional culture media. The bacterium
was, however, isolated in guinea pigs and in the yolk sacs of embryonated hens’ eggs
TABLE 5. History of cigarette smoking at the American Legion Convention,




Smoker 14  5 19
Non-smoker 17 16 33
Total 31 21 52
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and was visualized by Gimenez stain during one of several efforts to isolate Q fever
rickettsiae (Coxiella burnetii ) from specimens of lung tissue collected at autopsy. It
subsequently was cultivated on enriched Mueller-Hinton agar using heavily infected
yolk sacs as inoculum. The unique nutritional requirements of the bacterium were
identified in separate studies, and a new culture medium was developed that now
allows routine isolation of the Legionnaires disease bacterium from clinical specimens
(1 ).
Determination of the phenotypic and genotypic properties of the Philadelphia iso-
late indicated that it was a novel species (Legionella pneumophila) (2 ). The genus
Legionella  now comprises approximately 40 named species and subspecies that are
associated with water. Approximately half of the species have been implicated in hu-
man disease; L. pneumophila  serotype 1, the prototype strain that was isolated fol-
lowing the Philadelphia outbreak, is responsible for most infections.
The epidemic of pneumonia that followed the American Legion convention in
August 1976 was one of the most publicized epidemics in which CDC had participated.
Daily newspaper reports contained “body counts,” rumors of biological and chemical
warfare, and accusations of cover-up by CDC. Reports by CDC in the MMWR, however,
were limited to short back-page accounts, reporting that the epidemic had occurred
and was under investigation.
On Friday, January 14, 1977, the director of CDC’s Laboratory Division, Charles
Shepard, M.D., and microbiologist Joseph E. McDade, Ph.D., went to the office of the
CDC Director, David J. Sencer, M.D. After a few hesitant moments, they informed him
that they had isolated the agent that had caused the outbreak. Dr. Shepard wanted to
take the weekend to redo the isolation in a laboratory where they had not been work-
ing to rule out any possibility of contamination.
Although Dr. Shepard did not want to release the information until it was
published in the peer-reviewed scientific literature, Dr. Sencer wanted to fulfill
CDC’s responsibility to immediately release the information to state and local health
departments because the outbreak had been in the national news for months and this
information could prevent other cases. A solution was found: MMWR  is a scientific
publication, and CDC published and printed MMWR. CDC could print a special edition
on the following Tuesday, January 18, 1977 (normal publication was on Thursdays).
Once it was in print at 1 p.m., it could be given to the news media with an embargo
until 3 p.m.
Tuesday morning, as the presses were beginning to run 180,000 copies,
Dr. Shepard reported that he had retrieved serum specimens from the serum bank of
two earlier unsolved outbreaks of pneumonia, and they were positive for the identical
organism. The presses were stopped, and the changes were made.
At 1 p.m., a conference call was scheduled from CDC to the state health officers, the
Surgeon General, the National Institutes of Health, and other public health officials
participating in the investigation. CDC employees who had worked in any way on Le-
gionnaires disease—from dishwashers in the laboratory to the chiefs of epidemiology
and the laboratory—were invited to this conference call. Following that call, CDC con-
ducted a press conference, in which Drs. Shepard and McDade presented the findings
and distributed the MMWR. This is the only occasion on which an extra issue of the
MMWR  (weekly) has been published.
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Legionnaires disease is only one of many new diseases, syndromes, or etiologic
agents that have been identified during the past 2 decades (3 ), and CDC has re-
sponded to these new challenges. Other noteworthy examples include Lyme disease,
human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS),
toxic-shock syndrome, human ehrlichiosis, hantavirus pulmonary syndrome, hepa-
titis C virus, and Escherichia coli  O157. In some instances (for example, HIV/AIDS),
both the disease and its etiologic agent previously were unknown to medical science.
In others, the disease already existed but was unrecognized. Legionnaires disease
apparently occurred sporadically as early as the 1940s. Retrospective analysis of a
“rickettsia-like agent,” which was isolated from a pneumonia patient in 1947, revealed
that this agent was identical to L. pneumophila  (4 ). However, at the time of its isola-
tion, the source of the bacterium was erroneously attributed to the guinea pigs that
were used in the isolation procedure. Since the 1940s, other technologic changes, in-
cluding the introduction of air-conditioning cooling towers, have facilitated the
potential for exposure through dissemination of infectious aerosols of Legionella  in
contaminated water (5 ). This realization has lead to changes in routine maintenance
procedures for many aerosol-producing devices such as cooling towers, spas, and
respiratory therapy equipment. The development of prevention strategies is an on-
going process involving medical professionals, engineers, and chemical disinfectant
manufacturers.
Identification of new etiologic agents undoubtedly will continue. For example, of
the approximately 4 million cases of pneumonia that occur in the United States each
year, the etiologic agent remains unidentified in up to 50% of cases even when an
etiology is actively sought (6 ). Similarly, no etiologic agent is found in 60% of reported
foodborne disease outbreaks, most of which are studied using routine diagnostic
methods, nor in 32% of diarrheal outbreaks on cruise ships, despite intensive investi-
gation (7,8 ). However, in contrast to the Legionnaires disease investigation, during
which the etiologic agent was identified serendipitously, new molecular techniques
allow for a more systematic search for infectious etiologies. In particular, the extreme
sensitivity of representational difference analysis and consensus sequence-based
polymerase chain reaction technology should allow the identification of many etio-
logic agents that previously have been refractory to culture (9 ).
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Poliomyelitis — United States, Canada
Poliomyelitis MMWR 1979;28:229–30 (May 25, 1979)
As of May 22, an additional case of polio caused by type 1 poliovirus has been
reported in Pennsylvania, bringing to 4 the total number of such cases this year. Two
other states have reported suspected cases. Three of the confirmed and both sus-
pected cases are in Amish residents (1,2 ). In addition, Ontario, Canada, has confirmed
a case of paralytic poliomyelitis (type 1 virus) in an Amish woman.
United States: The Pennsylvania Department of Health’s most recent report is of a
case of non-paralytic polio (aseptic meningitis) in a 36-year-old, non-Amish woman
whose vaccination history is unclear. The woman became ill on April 30. She was
hospitalized with apparent aseptic meningitis on May 8. The State Laboratory con-
firmed a poliovirus type 1 isolate from her stool on May 14. The patient is from Mifflin
County, where 2 cases of paralytic polio were recently identified in an Amish commu-
nity (2 ). Although this woman’s husband has had regular contact with Amish farmers
in the county, the patient, herself, has had no direct contact with this community. She
is the first non-Amish ill person identified in 1979 with confirmed poliovirus type 1.
In addition, Iowa and Wisconsin are each currently evaluating a case of acute para-
lytic illness in a previously unvaccinated Amish person. These 2 patients became ill on
April 30 and May 5, respectively. In Wisconsin at least 8 of 20 stool specimens from the
patient’s unvaccinated family members showed early growth of probable enterovirus.
Canada: Ontario has reported a case of paralytic poliomyeltis in a previously
unvaccinated, 25-year-old Amish woman, hospitalized on May 13 with right lower ex-
tremity weakness. Her brother was hospitalized the same day with a similar acute
paralytic disorder. Poliovirus type 1 has been confirmed from stool specimens of the
woman and from her asymptomatic mother and sister. The female patient had at-
tended an Amish wedding in the United States on April 5; Amish persons from various
areas, including Pennsylvania, attended the wedding.
Reported by S Acres, MD, Dept of National Health and Welfare, Ottawa; J Joshua, MD, Ontario
Ministry of Health, Toronto; R Gens, MD, WE Parkin, DVM, DrPH, State Epidemiologist, Penn-
sylvania Dept of Health; LA Wintermeyer, MD, State Epidemiologist, Iowa State Dept of Health;
JP Davis, MD, State Epidemiologist, Wisconsin State Dept of Health and Social Services; Bur
of State Services, Viral Diseases Div, Bur of Epidemiology, CDC.
Editorial Note: There have now been 5 confirmed and 3 suspected cases of type 1
polio reported in the United States and Canada in 1979. These cases, from geographi-
cally distinct areas, are further evidence of the spread of the type 1—presumably
wild-type—poliovirus. The virus appears to have spread from 1 unvaccinated Amish
group to another, with transmission enhanced by the extensive travel and large social
gatherings characteristic of this population. It is unlikely that the wild poliovirus will
spread significantly among the general population, even to areas adjacent to Amish
groups, because routine immunization practices have led to a high level of community
protection.
Because dissemination of poliovirus is occurring among unvaccinated Amish
populations, and because of the possibility for increased (often inapparent) transmis-
sion throughout the upcoming summer months, CDC considers the entire American
Amish population at risk of infection and recommends vaccination of all unvaccinated
Amish persons (including adults) with a full series of trivalent oral poliovirus vaccine
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(TOPV). TOPV is also recommended for unimmunized persons who are in daily con-
tact with an unvaccinated community from which a wild-type poliovirus is isolated.
Immunization levels of children in areas near Amish communities should be reviewed
to assure that routine immunizations are up-to-date.
CDC has notified all 21 states known to have Amish residents of the new cases and
of current recommendations. These states include Delaware, Florida, Georgia, Illinois,
Indiana, Iowa, Kansas, Kentucky, Maryland, Michigan, Minnesota, Missouri, Montana,
New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Virginia, and Wis-
consin. Particularly in these states, physicians should include polio in the differential
diagnosis of aseptic meningitis and acute paralytic disease.
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Follow-Up on Poliomyelitis — United States, Canada, Netherlands
Poliomyelitis MMWR 1979;28:345–6 (July 27, 1979)
No new cases of epidemic-associated poliomyelitis have been reported to CDC dur-
ing the past month. Two cases previously reported as suspected have now been con-
firmed, bringing the 1979 total of confirmed cases in the United States and Canada to
17. Fourteen of these cases (all paralytic) occurred in unvaccinated Amish persons;
2 (both nonparalytic) were in unvaccinated non-Amish persons, who lived in or near
an Amish area; and 1 case (paralytic) occurred in an Amish infant, who received oral
poliovirus vaccine 5 days before becoming ill. In the latter case, the patient had labo-
ratory evidence of recent infection with both type 1 and type 2 poliovirus; the other
16 cases were clearly due to a wild (type 1) poliovirus. These 17 cases have been re-
ported from 4 different states (Pennsylvania, 8 cases; Iowa, 3; Wisconsin, 3; Missouri,
1) and Canada (2). Immunization campaigns for the Amish are continuing; at least half
of the nation’s Amish have now received 1 or more doses of oral poliovirus vaccine.
Antigenic marker tests, consisting of (a) the van Wezel Method, using cross-
absorbed rabbit antisera against vaccine and nonvaccine (wild) poliovirus strains and
(b) the modified Wecker method, using guinea pig antisera against vaccine strains,
have been performed on the poliovirus type 1 strains isolated from 5 U.S. cases and
from a household contact of a sixth case. All isolates were nonvaccine-like in their
antigenic characteristics.
The type 1 poliovirus isolated from the first 1979 poliomyelitis patient (an Amish
female from Pennsylvania) shows a resemblance to a wild type 1 strain isolated in Ku-
wait in 1977 (1 ). Type 1 strains from cases occurring in the 1978 epidemic in the Neth-
erlands and Canada also showed a resemblance to the Kuwait poliovirus strain (1 ).
Epidemiologic information also links last year’s poliomyelitis epidemic in the Neth-
erlands and Canada with this year’s outbreak in the United States and Canada. During
the 1978 outbreak, members of the affected religious group traveled from the Nether-
lands to Canada, where cases subsequently appeared. An Amish family from an On-
tario town 15 miles from the affected area moved in late summer 1978 to the
Pennsylvania town where the first U.S. Amish case subsequently occurred, in January
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1979. There were also other, less well-defined contacts between Amish persons in
Ontario and Pennsylvania.
Reported by Dr. A. van Wezel and Dr. van Zermarel, Rijks Institute voor der Volksgezondheit,
the Netherlands; S Acres, MD, Dept of National Health and Welfare, Ottawa; State Epidemiolo-
gists from Iowa, Missouri, Pennsylvania, and Wisconsin; Virology Div, Bur of Laboratories, and
Viral Diseases Div, Bur of Epidemiology, CDC.
Editorial Note: Both laboratory and epidemiologic information have suggested a link
between the poliovirus type 1 strain from the 1979 outbreak in the United States and
Canada with the type 1 strain responsible for last year’s outbreak in the Netherlands
and Canada. The onset of illness in the last case occurring in Canada in 1978 was in
August, more than 4 months before the onset of illness in the first 1979 case, which
occurred in Pennsylvana. Nearly 3 months elapsed before the next 1979 cases oc-
curred, and these were also in Pennsylvania. These data suggest that the wild
poliovirus circulated inapparently through several generations without causing para-
lytic disease. The absence of new cases of paralytic poliomyelitis reflects, in part, the
success of the multi-state immunization campaigns for the Amish; the possibility of
new cases remains, because the wild type 1 poliovirus may continue to be excreted by
some infected persons throughout the summer months. However, the risk of addi-
tional cases is diminishing as more of the susceptible Amish persons receive vaccine.
Reference
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Editorial Note—1997
Alan R Hinman, MD, MPH, Senior Consultant for Public Health Programs, Task Force for Child
Survival and Development, and former Director, Immunization Division, Center for Prevention
Services, CDC.
MMWR  should never again publish an article describing a contemporaneous out-
break of polio in the United States. Although it was not known at the time the 1979
MMWR  articles were published, these articles describe the last outbreak of polio in
the United States. The 1979 outbreak occurred in unvaccinated Amish persons living
in Iowa, Missouri, Pennsylvania, and Wisconsin. Overall, 15 cases of illness caused by
wild poliovirus type 1 occurred among U.S. citizens: all 10 paralytic cases occurred
among unvaccinated Amish persons; three cases of transient paralysis occurred
among unvaccinated Amish persons; and two nonparalytic cases occurred among un-
vaccinated members of the Mennonite church who were in frequent contact with
Amish persons. Epidemiologic and virologic evidence indicated this outbreak resulted
from importation of poliovirus from the Netherlands through Canada (Ontario), where
outbreaks had occurred during 1978 in members of religious groups with objections
to vaccination. Intensive studies in an outbreak-affected area where there were exten-
sive contacts between Amish and non-Amish persons indicated that existing
immunity levels provided an effective barrier to extensive circulation of poliovirus in
the general community.
Investigation and control of the outbreak involved exceptional cooperation be-
tween local and state officials in the 21 states with Amish populations and CDC. As
highlighted in the May 25, 1979, MMWR  article, CDC considered the entire U.S. Amish
population to be at risk for polio and recommended vaccination of all Amish persons,
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including adults. Epidemiologic aspects of the investigation were coordinated by CDC
Epidemic Intelligence Service officers Marjorie Pollack, M.D., and Melinda Moore,
M.D., under the supervision of Larry Schonberger, M.D., of CDC’s Division of Viral Dis-
eases (which then was responsible for polio surveillance). The programmatic efforts
to reach and vaccinate Amish populations were coordinated through the Division of
Immunization and state immunization programs, and used the efforts of many CDC
public health advisors. Vaccination efforts involved extensive contacts with Amish
groups in the 21 states and ultimately resulted in vaccination of approximately one
half of Amish persons in the United States.
Another notable feature of this outbreak was the very close collaboration between
epidemiologists and the laboratory. Using oligonucleotide mapping (the newest tool
available at the time), CDC laboratory scientists Milford Hatch, Ph.D., and Olen Kew,
Ph.D., were able to show that the virus responsible for illness in the United States was
identical to the virus that had caused outbreaks in the Netherlands and Ontario, Can-
ada. Subsequent development of more sophisticated techniques such as genomic se-
quencing further confirmed the link. This was one of the first instances of use of
“molecular epidemiology” at CDC and heralded a collaboration between epidemiolo-
gists and laboratorians that has been a hallmark of the global polio-eradication pro-
gram.
The 1979 outbreak demonstrated both the tremendous progress to date in achiev-
ing protection of the U.S. population but also the fact that polio could find a way to
reach the remaining pockets of susceptible persons in the country. In addition, the
outbreak made clear the necessity of taking a global approach to polio.
During the first half of the 20th century, paralytic polio was a major cause of ill-
ness and public concern in the United States; reported cases increased annually and
peaked at approximately 20,000 reported cases in 1952. The introduction of
inactivated poliovirus vaccine (IPV) in 1955 and the subsequent introduction of oral
poliovirus vaccine (OPV) in 1961 had a dramatic impact on the occurrence of disease,
with the numbers of reported cases and outbreaks progressively decreasing to very
low levels by 1970.
Throughout the 1970s, there was continued evidence of possible circulation of wild
poliovirus in the United States. During the decade, 17 cases of polio were imported
from other countries and for 30 cases of paralytic polio, no foreign source could be
determined (endemic cases). Since the reports in 1979, no endemic cases have been
reported in the United States, although imported cases (on average less than one per
year, predominantly from Mexico) continued to occur throughout the 1980s.
In 1985, the Health Ministers of the Americas adopted a goal of regional eradication
of polio from the Western Hemisphere by 1990. The subsequent implementation of
polio-eradication strategies (focusing on routine vaccination with OPV, mass vaccina-
tion of all children aged 0–4 years through annual National Immunization Days [NIDs],
effective surveillance, and response to cases) resulted in a dramatic reduction in im-
portations of polio. The last case of paralysis caused by indigenously acquired wild
poliovirus in the Americas had onset in August 1991, and in 1994, the hemisphere was
certified free of polio by an independent commission.
Other industrialized countries have had experiences similar to those of the United
States. Most western European countries have been free of epidemic or endemic polio
for many years, although limited outbreaks occurred in Finland in 1984–1985 and in
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the Netherlands in 1992–1993. Asia and Africa have been the areas most affected by
polio in recent years.
In 1988, the World Health Assembly adopted a goal of global eradication of polio by
2000, and eradication efforts began throughout the world, largely using the strategies
developed in the Americas. Under World Health Organization (WHO) leadership, a re-
markable partnership of public and private organizations has been formed. Chief
among these has been Rotary International, United Nations Children’s Fund (UNICEF),
and CDC. Additional financial support has been provided by the governments of Aus-
tralia, Canada, Denmark, Italy, Japan, Norway, Sweden, the United Kingdom, and the
United States. In the private sector, most notable has been the extraordinary commit-
ment of Rotary International, which is donating approximately $400 million to support
the effort and is providing essential financial and physical support from local Rotari-
ans, including volunteers for social mobilization, vaccination posts, and advocacy
efforts. A global laboratory network has been developed by WHO to support the eradi-
cation effort.
Unprecedented public health efforts by many countries where polio is endemic
have characterized the polio-eradication effort. In several countries (including Af-
ghanistan, El Salvador, and Sudan), civil wars have been temporarily suspended to
allow vaccination of children in both government- and rebel-controlled areas. Seven-
teen nations in the Middle East, the Caucasus, and Central Asia have cooperated in
coordinating NIDs (Operation MECACAR). Probably the most spectacular accomplish-
ment has been the administration of OPV to more than 257 million children aged
<5 years in a single week in 1996 as a result of simultaneous efforts in Bhutan, China,
India, Myanmar, Nepal, Pakistan, Thailand, and Vietnam.
The reported incidence of polio in India has declined dramatically. China, with ap-
proximately one fourth of the world’s population, has not detected indigenous wild
poliovirus since 1994. The only indigenous transmission of polio in 1997 in WHO’s
Western Pacific Region occurred in the area of the Mekong delta. In the face of finan-
cial and societal crises, 31 countries in Africa have conducted NIDs, and those that
have not done so already are in the planning phases.
The remaining challenges in the fight against polio are 1) resources to fully imple-
ment eradication strategies (a shortfall of approximately $50 million per year in donor
support still remains); 2) maintenance of the political will to see the program through
to ultimate success; and 3) development of surveillance systems in many countries to
assure that circulation of poliovirus (or its absence) can be detected.
The United States has much to be proud of in the fight against polio. The U.S. Con-
gress has supported global polio-eradication efforts through both the Agency for
International Development and CDC. In addition, the United States is, and will con-
tinue to be, one of the major beneficiaries of polio eradication. The polio-free status
the United States has enjoyed since 1979 comes at a cost, both personal and financial.
Each year in the United States, there are five to 10 cases of vaccine-associated polio,
a personal and societal tragedy; this number should be reduced substantially as a
result of the recently adopted sequential IPV-OPV schedule. An estimated $230 million
also is spent each year to maintain the high levels of polio vaccine coverage. Once
polio is eradicated from the planet, polio vaccination can be discontinued, and the
respective resources can be devoted to other important global health problems. In
1987, the objective of eradication was underscored: “Global eradication of poliomye-
Poliomyelitis 65
litis is inevitable; the only question is whether we will accomplish it or pass on the
needed action to our successors. We believe we should act now to leave the legacy of
a poliomyelitis-free world for our children” (1 ). It now seems clear that this commit-
ment will be fulfilled.
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Toxic-Shock Syndrome — United States
Toxic-Shock Syndrome MMWR 1980;29:229–30 (May 23, 1980)
Cases of a newly recognized illness known as toxic-shock syndrome (1 ) have re-
cently been reported to CDC by state health departments in Wisconsin, Minnesota,
Illinois, Utah, and Idaho. Physicians in 8 other states have reported individual cases to
CDC or to investigators at the University of Colorado, Denver.
Toxic-shock syndrome typically begins suddenly with high fever, vomiting, and
profuse watery diarrhea, sometimes accompanied by sore throat, headache, and my-
algias. The disease progresses to hypotensive shock within 48 hours, and the patient
develops a diffuse, macular, erythematous rash with non-purulent conjunctivitis.
Urine output is often decreased, and patients may be disoriented or combative. The
adult respiratory distress syndrome or cardiac dysfunction may also be seen.
Laboratory studies reveal elevated blood urea nitrogen, serum creatinine, bilirubin,
and creatine phosphokinase levels, and white blood cell counts with marked left shifts.
Platelet counts are low in the first week of illness but are usually high in the second
week.
Patients require large volumes of fluid to maintain perfusion and usually require
intensive care. In the recovery phase, there is desquamation of at least the palms,
soles, or digits and often of other skin areas as well.
Since October 1, 1979, 55 cases have been reported to CDC. Fifty-two of these (95%)
have been in women. The mean age is 24.8 years, with a range of 13-52 years. Seven
deaths have occurred, for a case-fatality ratio of 13%.
Of 40 patients in whom a menstrual history was obtained, 38 (95%) had onset of ill-
ness with the 5-day period following onset of menses. Two others had onset of illness
10 days after onset of menses. Moreover, 13 patients have had recurrence of symp-
toms with a subsequent menstrual period.
In 33 of 45 (73%) patients cultured, Staphylococcus aureus  was isolated from
the throat, cervix, vagina, or rectum. Four of 15 patients (27%) tested for Herpesvirus
hominis  had serologic or cultural evidence of herpes infection. No evidence for
leptospirosis, Rocky Mountain spotted fever, viral exanthematous diseases, or strep-
tococcal scarlet fever has been found in those patients in whom it has been looked for.
Reported by: PJ Chesney, MD, RW Chesney, MD, W Purdy, MD, Dept of Pediatrics, University
of Wisconsin; D Nelson, T McPherson, P Wand, A Helstad, Wisconsin State Laboratory of
Hygiene; JP Davis, MD, State Epidemiologist, Wisconsin Dept of Health and Social Services;
C Shrock, MD, B Campion, MD, K Crossley, MD, R Derro, MD, R Dinter, MD, W Keane, MD,
G Lund, MD, R Opheim, MD, C Simonelli, MD, R Tofte, MD, F Walder, MD, D Williams, MD,
Minnesota Dept of Health; S Sokalski, MD, Christ Community Hospital, Oak Lawn, Illinois;
J Phair, MD, Northwestern University Medical Center; AG Barbour, MD, CB Smith, MD, Dept of
Internal Medicine, University of Utah; RE Johns, Jr, MD, State Epidemiologist, Utah Dept of
Health; MH Tanner, MD, Riverview Hospital, Idaho Falls; JK Todd, MD, Children’s Hospital,
Denver, Colorado; Field Services Div and Special Pathogens Br, Bacterial Diseases Div, Bur of
Epidemiology, CDC.
Editorial Note: Toxic-shock syndrome is a serious disease of unknown etiology. It
affects primarily young women of child-bearing age who have been previously
healthy, and it has a case-fatality ratio for reported cases of 10%-15%. This ratio is
probably high because severe cases are easier to recognize. In Wisconsin, where sur-
veillance has been very active, the case-fatality ratio has been 3.2%. The incidence of
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the disease is not known but is apparently low. The increasing number of reported
cases over the past 6 months is probably due to increasing recognition. In support of
this theory, a review of medical charts in Wisconsin for the past 2 years revealed
6 cases fitting the case description that had not previously been recognized as toxic-
shock syndrome.
The syndrome resembles Kawasaki disease (mucocutaneous lymph node syn-
drome) in several respects, namely fever, rash with subsequent desquamation, and
cardiac involvement. However, shock, which is prominent in toxic-shock syndrome,
is not usually seen in Kawasaki disease. The character of the rash is also different in
the 2 diseases: it is a maculopapular one in Kawasaki disease but a non-papular,
diffuse erythroderma in toxic-shock syndrome. Azotemia and thrombocytopenia
are rarely seen in Kawasaki disease and are common in toxic-shock syndrome.
Kawasaki disease classically occurs in children less than 5 years of age; some recently
reported cases of “adult Kawasaki disease” (2,3 ) may actually be cases of toxic-shock
syndrome.
Toxic-shock syndrome was first recognized in 7 children aged 8-17 years, 3 of
whom were boys (1 ). In 5 of the 7, S. aureus  was isolated from the nasopharynx,
vagina, or localized abscess. At that time it was hypothesized that the syndrome was
caused by a toxin elaborated by the staphylococci. Although S. aureus  was isolated
from vaginal cultures in two-thirds of patients in the current report, no control study
has been done to show that this prevalence is unusually high. The isolation of Herpes-
virus  in a small number of cases probably reflects stress-related recurrence of infec-
tion and not an etiologic role for the virus. CDC, in cooperation with a number of
investigators, is setting up a nationwide case-control study to try to define the
epidemiologic features and the cause of this disease.
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Editorial Note—1997
Arthur L Reingold, MD, University of California, Berkeley. Gene W Matthews, JD, Legal Advisor
to CDC. Claire V Broome, MD, Deputy Director, CDC.
Although case reports of “Staphylococcal scarlet fever” had been published in the
medical literature as far back as the 1920s, a 1978 report describing seven cases of
what was named toxic-shock syndrome (TSS) heralded the apparent emergence of
TSS in late 1979 and early 1980 (1 ). The report about TSS in the May 23, 1980, MMWR
and the veritable landslide of studies of TSS that followed demonstrate the speed and
effectiveness with which astute clinicians—together with public health officials, epide-
miologists, and laboratory scientists—can respond to an “emerging” infectious
disease threat. Did TSS truly “emerge” at that time, or did the intensive case-finding
efforts of clinicians and epidemiologists in states such as Wisconsin and Minnesota
simply make it appear to “emerge”? The limited data available from retrospective
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chart-review studies that were designed to identify TSS cases, whether previously di-
agnosed or not, clearly demonstrated that the number of cases of TSS in women of
reproductive age increased beginning in the late 1970s (2–4 ). Cases of TSS in men
also occurred during that time but at a low and stable rate. Thus, what “emerged”
during late 1979–early 1980 was not all TSS, but TSS in reproductive-aged women,
particularly menstruating women, as reflected in the dramatic data presented in the
MMWR  report—of the 55 reported cases, 95% occurred among women, and 95% of
the cases among women for whom information was available had onset of their ill-
ness within the 5-day period following onset of menses.
The startling proportion of TSS cases identified during 1979–1980 among women
who had onset during menstruation led investigators to focus on understanding the
risk factors for development of menstrual TSS, rather than TSS in general. The wave
of rapidly completed case-control studies of menstrual TSS that followed clearly dem-
onstrated that use of various brands and styles of tampons was by far the most impor-
tant risk factor for TSS during menstruation (5–8 ). Although the relative importance of
absorbency, chemical composition, and other tampon-related factors in determining
the risk for menstrual TSS has remained difficult to determine, the most plausible
explanation for the “emergence” of menstrual TSS in the late 1970s was the manufac-
ture and widespread use of more absorbent tampons made of a variety of materials
not previously used in tampons. There is no evidence to suggest that changes in
Staphylococcus aureus, the source of the toxin that causes TSS, were responsible for
the emergence of menstrual TSS.
The week after the MMWR  report appeared in May 1980, Dr. William Foege, the
director of CDC at the time, testified before the Senate Subcommittee on Health re-
garding “toxic dumps.” Given the widespread news media attention the MMWR  re-
port had received and a perceived connection between toxic dumps and toxic-shock
syndrome, Dr. Foege also was asked about TSS at that hearing, and he optimistically
promised “an answer” by the end of 1980. Although much more was learned about
TSS during the years that followed (e.g., the biologically important properties of TSS
toxin-I, the toxin responsible for most cases of TSS, particularly menstrual cases), in
retrospect Dr. Foege was correct. From the public health point of view, before the end
of 1980, enough was known about menstrual TSS based primarily on observational
epidemiologic studies to promulgate recommendations (9,10 ) that led to a substantial
reduction in the risk for menstrual TSS.
Perhaps less well known in the public health community is the important legal
precedent that emerged from the civil litigation surrounding menstrual TSS. Faced
with a large number of lawsuits filed by women with menstrual TSS, one of the tam-
pon manufacturers filed suit to compel CDC to release the names and other personal
identifiers of all women who had participated in the CDC case-control studies of men-
strual TSS. Because the results of these studies (and hence the “collective evidence”
of the study participants) were being introduced as evidence by women in their law-
suits against the manufacturer, the manufacturer argued that it had a fundamental
legal right to know who these women were and even cross-examine them. Although
the manufacturer had been given copies of all the data tapes and all the raw data
forms from the studies (with identifiers removed) so its experts could reanalyze the
results, the manufacturer also argued that it needed to re-interview the study partici-
pants several years after the case-control studies had been conducted to assess the
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extent to which bias had been introduced at the time of the original interviews (11 ).
The federal appeals court decided that the manufacturer could not have access to the
personal identifiers of the study participants. The court ruled that in furtherance of its
mission to protect the public health, CDC must be able to “conduct probing scientific
and social research supported by a population willing to submit to indepth question-
ing.” The court further ruled that “disclosure of the names and addresses of … re-
search participants could seriously damage this voluntary reporting” and that “even
without an express guarantee of confidentiality there is still an expectation, not unjus-
tified, that when highly personal and potentially embarrassing information is given for
the sake of medical research, it will remain private” (12 ). Thus, the series of events
that unfolded following the publication of the MMWR  report not only led to an expe-
ditious public health response to the emergence of menstrual TSS but to enhanced
legal protection at the federal level of the public health research process.
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Reye Syndrome — Ohio, Michigan
Reye Syndrome MMWR 1980;29:532,537–9 (November 7, 1980)
In addition to a previously reported study from Arizona (1 ), CDC has received re-
ports of studies conducted in Ohio and Michigan which suggest a relationship be-
tween Reye syndrome and salicylates (i.e., aspirin) taken during an associated
antecedent illness.
Between December 1978 and March 1980, a prospective case-control study of Reye
syndrome was conducted by the Ohio State Department of Health. This study in-
volved 6 pediatric centers in the state and examined the possible relationship between
Reye syndrome and medications taken during the antecedent illness. One hundred
fifty-nine cases were identified in this study; slightly more than half were relatively
mild, developing only stage I encephalopathy (difficult to arouse, lethargic, sleepy). A
large percentage of these patients were identified during an outbreak of influenza A
(H1N1) that occurred in December 1978-March 1979 and an outbreak of influenza B
that occurred in December 1979-March 1980, or had varicella as an antecedent illness.
Reye syndrome patients and controls, selected from the same school classroom or
neighborhood and matched for age, sex, race, and the occurrence of a similar ante-
cedent illness (respiratory, varicella, or gastrointestinal) within 1 week of that which
occurred in the case, were interviewed concerning medications taken between the
time of onset of the antecedent illness and either admission to the hospital for Reye
syndrome (for cases) or recovery from the illness (for controls). For each Reye syn-
drome case, the date of onset of vomiting, which is usually associated with the onset
of Reye syndrome, was recorded. The frequency of usage of only 2 medications was
found to be significantly different statistically in cases and controls. Salicylates, in-
cluding those contained in various compounds, were the only medications which
were taken significantly more frequently in cases (95/98, 97%) than controls (114/160,
71%) (p<.001). All of the Reye syndrome cases with a history of salicylate ingestion
took salicylates during their antecedent illness and prior to the onset of the pre-
encephalopathic vomiting associated with this syndrome. Multiple logistic analysis
using a model that included histories of salicylate ingestion, fever, headache, and sore
throat has demonstrated that although a history of fever was significantly greater in
cases than controls, this difference did not account for the even stronger association
of cases with a history of salicylate ingestion. Using this model, the estimated relative
risk of Reye syndrome for patients taking salicylates was 11.3 (95% confidence limits
2.7-47.5). Histories of headache and sore throats were not significantly different in
cases and controls. Medications containing acetaminophen were taken by only 16%
(16/98) of cases compared to 32% (51/160) of controls (p<0.01). Although analysis has
not yet been completed concerning the dose of salicylates ingested by the patients
with Reye syndrome, the majority had a history of taking no more than normally rec-
ommended. The medication history was usually obtained from parents within 7-
10 days (for cases) and 10-20 days (for controls) after the onset of antecedent illness.
The recently reported study from Michigan involved 25 patients with Reye syn-
drome and 44 controls selected in a manner similar to that of the Ohio study, matched
for the same criteria, and interviewed 4 to 83 days (mean 6.5 weeks) after their acute
illness. When cases and controls were retrospectively matched for fever (±1o F), aspi-
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rin was taken significantly more often in cases (14/14, 100%) than controls (14/21, 67%,
p<0.02), and acetaminophen-containing compounds were taken significantly less
often in cases (0/14), than in controls (6/21, 29%, p<.05).
Reported by TJ Halpin, MD, State Epidemiologist, F Holtzhauer, Ohio State Dept of Health; Dept
of Epidemiology, University of Michigan School of Public Health; N Hayner, MD, State Epide-
miologist, Michigan Dept of Public Health; Field Services Div, Viral Diseases Div, Bur of
Epidemiology, CDC.
Editorial Note: Although the epidemiologic association between Reye syndrome and
antecedent viral illnesses is well established, the etiology of this rare disease remains
unclear. Several previous reports have suggested the possibility that medications
taken during the antecedent illness of patients with Reye syndrome may play a role in
the development of this disease, and aspirin is 1 medication which has been men-
tioned frequently (2-4 ).
The Ohio and Michigan studies reported here and the previously reported smaller
study from Arizona (involving 7 cases and 16 controls) are the only controlled studies
of the relationship between Reye syndrome and medications taken during the ante-
cedent illness reported since this disease was first described. All 3 of these studies
involved in-home interviews focusing specifically on medication histories of Reye syn-
drome patients and controls.
A number of potential problems are encountered when conducting and analyzing
such studies. These include 1) difficulties in obtaining comparable and accurate medi-
cation histories in patients following a significant event (Reye syndrome) when com-
pared to controls who have had a relatively minor illness, and the difficulty of accurate
recall of events several weeks later, 2) the possibility that cases had a more severe
antecedent illness and/or a pre-encephalopathic illness that included severe vomiting
and headaches—both of which may have predisposed them to take more medications
than controls—and 3) the presumed need to select cases and controls with the same
viral infections, including influenza B, influenza A (H1N1), and varicella, since Reye
syndrome is thought to be more strongly associated with these infections.
It is possible that parents of patients with Reye syndrome were more likely than
parents of controls to recall events immediately preceding their child’s major illness
and hospitalization, including medications taken by their child during this period. Re-
call of medication histories for Reye syndrome patients may also have been more
accurate and complete than the recall for controls because parents of cases were fre-
quently interviewed earlier after their child’s acute illness than were parents of con-
trols. However, the fact that only aspirin or salicylate-containing compounds were
found to have been taken significantly more frequently during the antecedent illness
in cases than controls in these studies suggests that the association between
Reye syndrome and salicylates may indeed be real. Furthermore, the fact that
acetaminophen-containing compounds were taken by significantly fewer cases than
controls in both studies, which might be expected if Reye syndrome patients were
more likely to use salicylates than acetaminophen for fever or other symptoms, sug-
gests that the recall of parents of cases was not greater than the recall of parents of
controls for these medications.
Another possible reason for differences in medication histories in cases and con-
trols is that Reye syndrome patients may have a more severe or prolonged antecedent
illness and/or may subsequently develop a pre-encephalopathic illness, associated
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with severe vomiting, for which they might receive additional medications. Because
elevated temperatures are 1 major reason for taking salicylates, both of these studies
have attempted to compare the effects of differing histories of fever among cases and
controls. In the Michigan study, even when cases and controls were matched for de-
gree of fever, the difference in salicylate usage remained significant. Analyses com-
pleted in the Ohio study have demonstrated that a history of fever, as well as
headaches and sore throats—symptoms which might also cause cases to take more
salicylates than controls—did not account for the observed differences in salicylate
ingestion. Additional analyses in Ohio of aspirin ingestion histories of Reye syndrome
patients for the specific period between onset of prodromal illness and onset of vom-
iting demonstrated that all of 95 patients who received salicylates received some dur-
ing their antecedent illness—before the onset of pre-encephalopathic vomiting. The
possible confounding effects of other symptoms and combinations of symptoms are
being further examined in the Ohio study.
Reye syndrome is rare and associated frequently with certain viruses. Thus, com-
parison of medication histories in cases and controls who had the same viral infection
may be important. In both of these studies, controls were selected from the same
school and had a prodromal illness within 1 week of that of the cases. It is probable
that many cases and controls were matched for infection because a large percentage
of the cases occurred during outbreaks of influenza, and varicella patients were
matched with other children who had varicella. Further analysis of the salicylate asso-
ciation by specific type of infection should be possible in the Ohio study.
In 1976 the Food and Drug Administration advised that, when treating children who
develop vomiting associated with a viral illness, caution should be exercised in using
acetaminophen, salicylates, and antiemetics because of the suspicion that these
drugs, in combination with a viral illness (a possible cause of vomiting in children)
might contribute to the development of Reye syndrome (5 ). The results of these stud-
ies suggest that during certain viral illnesses the use of salicylates—even before the
onset of vomiting—may be a factor in the pathogenesis of Reye syndrome. In view of
these data, parents should be advised to use caution when administering salicylates
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Editorial Note—1997
Eugene S Hurwitz, MD, Day Care Activities Coordinator, and Lawrence B Schonberger, MD, MPH,
Assistant Director for Public Health, Division of Viral and Rickettsial Diseases, National Center for
Infectious Diseases, CDC.
Reye syndrome (RS) was first described in Australia (1 ) and in the United States in
1963 (2 ). During the 1960s and 1970s, RS outbreaks in the United States became in-
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creasingly recognized in association with outbreaks of influenza and following chick-
enpox. National surveillance for RS, first conducted during the 1973–74 nationwide
epidemic of influenza B, resulted in the recognition of regional as well as nationwide
outbreaks of RS. Although children of all ages were affected, incidence peaked among
children aged 5–15 years. During the initial years of national surveillance, 236–555
cases were reported each year; the largest number occurred in association with out-
breaks of influenza B and influenza A(H1N1). Population-based studies suggested that
the average annual incidence among children aged <18 years was approximately one
case per 100,000 persons. Case-fatality rates reported through national surveillance
were initially as high as 40% and between 20% and 35% during the late 1970s to mid-
1980s.
Although anecdotal reports during the 1970s had suggested the possibility of an
association between RS and aspirin, the series of studies reported in 1980—the first
from Arizona (involving seven cases and 16 controls) followed by larger studies con-
ducted in Michigan and Ohio—were the first case-control studies to examine this is-
sue. However, the possibility that a commonly used medication such as aspirin, which
had been prescribed for several decades for febrile illnesses by those taking care of
pediatric patients, might be associated with a severe and frequently fatal illness was
not readily accepted by many in the medical community. As a reflection of the contro-
versial nature of this matter, the initial Editorial Note published in the November 7,
1980, issue of MMWR  outlined several of the most important potential limitations of
these studies and the considerations that had led CDC to conclude that the studies
were strongly suggestive of an association between aspirin use and increased risk for
RS. In an effort to fulfill CDC’s public health responsibility, the Editorial Note advised
parents to “use caution when administering salicylates to treat children with viral ill-
nesses, particularly chickenpox and influenza-like illnesses.”
In October 1982, after CDC received a report of a fourth case-control study con-
ducted in Michigan during the 1980–81 influenza season demonstrating a similar as-
sociation, CDC convened a working group of expert consultants to review all four
studies. The working group, which included pediatricians and epidemiologists as well
as representatives of the Food and Drug Administration (FDA) and the American
Academy of Pediatrics (AAP), reviewed the studies that had been completed and the
many concerns expressed by those in the medical community, including consultants
and representatives of the pharmaceutical industry. The working group supported
CDC’s original recommendation and stated that “until the nature of the association
between salicylates and RS is clarified, the use of salicylates should be avoided, when
possible, for children with varicella infections and during presumed influenza out-
breaks” (3 ).
Soon after CDC made these recommendations, FDA conducted an independent
audit and analysis of the data from the Ohio and Michigan studies. FDA then convened
a scientific workshop to review the data, including analyses completed by FDA. Ex-
perts from the academic community, the pharmaceutical industry, and consumer or-
ganizations attended the meeting and had opportunities to present their independent
analyses and concerns and to express their opinions regarding the studies. After an
intensive review of all the concerns, the scientific working group concluded that the
new analysis supported earlier evidence of the association between use of aspirin and
increased risk for RS. As a result of this review process, in June 1982, the Surgeon
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General issued a recommendation advising “against the use of salicylate and
salicylate-containing medications for children with influenza and chickenpox” (4 ).
Despite the numerous reviews by expert panels and intense scrutiny of the first
four studies, many continued to express concerns about these studies, including in-
dustry representatives, the Office of Management and Budget (5 ), and the executive
committee of the AAP, which issued a statement calling for further investigation.
These concerns focused on the nature of the case-control studies and the many poten-
tial epidemiologic issues in such studies, including potential biases of selection and
reporting as well as possible confounding (5 ). As a result of the concerns expressed
by many groups, in December 1982, the Assistant Secretary of Health appointed a
Public Health Service Task Force, comprised of representatives from CDC, FDA, and
the National Institutes of Health, to assist in planning and conducting additional re-
search on this issue. A decision about warning labels on packages of certain medica-
tions for children was deferred pending the results of this research (5 ).
The Public Health Service Task Force designed a new epidemiologic study to ad-
dress the concerns that had been raised about the first four studies. A committee was
convened by the Institute of Medicine to serve as an advisory board to review the
protocol, monitor the study’s progress, and review the analysis and results. Between
February and May 1984, a pilot study, designed to test the methods for the main study
of the relation between medication use and risk for RS, was undertaken. The pilot
study, which involved 14 states and 33 pediatric tertiary-care centers, demonstrated a
high odds ratio (16.1; lower 95% confidence limit=4.6) associated with the ingestion of
aspirin during an antecedent respiratory or chickenpox illness and the development of
Reye syndrome, consistent with the risks observed in previous studies. Evaluation of
the epidemiologic issues raised concerning previous studies did not indicate that any
of these issues could explain the observed association. Although in 1983 there had
been no agreed-upon plans to publish the pilot study, the study was subsequently
published in October 1985 (6 ) at the recommendation of the Institute of Medicine
committee. In March 1986, FDA ruled that all over-the-counter aspirin and aspirin-
containing products were required to be labeled with a warning about RS.*
Following completion of the pilot study, the main study of RS and medications was
conducted during January 1985–May 1986. Although 70 pediatric tertiary-care centers
throughout the United States participated in this study, including many that had pre-
viously reported the largest number of cases through CDC’s national surveillance,
only 33 cases of RS that met the study criteria were identified during the 17-month
study period, which included two influenza seasons. However, the number of cases
enrolled was fewer than had been expected based on prior experience and than had
been specified by the original protocol (at least 100 cases), and the decision was made
to discontinue the study because of the small number of cases identified, which re-
flected the declining incidence of RS that had been observed nationally during the
preceding several years. In addition, in this study, as in the earlier studies, a high odds
ratio was observed that could not be explained by any of the epidemiologic issues that
the study had sought to address (7 ).
Although several years were required to address all the concerns about the initial
studies, assessment of temporal trends in RS in the United States indicate that a dra-
*51 FR 8180–8182
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matic decline in the incidence of this disease began to occur in the early 1980s soon
after the initial and subsequent MMWR  reports of these studies. This decline ap-
peared to coincide with a decline in aspirin use among children that occurred as a
result of the publicity surrounding these studies (8–10 ). The initial studies conducted
during the early 1980s suggested that aspirin was administered to up to 70% of chil-
dren with febrile respiratory illnesses. The national intervention involving the removal
of a risk factor, aspirin use among children, was associated with a marked reduction in
the incidence of this disease, providing the most convincing corroborating evidence
for the association first reported in the case-control studies.
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Pneumocystis  Pneumonia — Los Angeles
Pneumonia MMWR 1981;30:250–2 (June 5, 1981)
In the period October 1980–May 1981, 5 young men, all active homosexuals, were
treated for biopsy-confirmed Pneumocystis carinii  pneumonia at 3 different hospitals
in Los Angeles, California. Two of the patients died. All 5 patients had laboratory-
confirmed previous or current cytomegalovirus (CMV) infection and candidal mucosal
infection. Case reports of these patients follow.
Patient 1: A previously healthy 33-year-old man developed P. carinii  pneumonia
and oral mucosal candidiasis in March 1981 after a 2-month history of fever associ-
ated with elevated liver enzymes, leukopenia, and CMV viruria. The serum
complement-fixation CMV titer in October 1980 was 256; in May 1981 it was 32.* The
patient’s condition deteriorated despite courses of treatment with trimethoprim-
sulfamethoxazole (TMP/SMX), pentamidine, and acyclovir. He died May 3, and post-
mortem examination showed residual P. carinii  and CMV pneumonia, but no evidence
of neoplasia.
Patient 2: A previously healthy 30-year-old man developed P. carinii  pneumonia in
April 1981 after 5-month history of fever each day and of elevated liver-function tests,
CMV viruria, and documented seroconversion to CMV, i.e., an acute-phase titer of
16 and a convalescent-phase titer of 28* in anticomplement immunofluorescence
tests. Other features of his illness included leukopenia and mucosal candidiasis. His
pneumonia responded to a course of intravenous TMP/SMX, but, as of the latest re-
ports, he continues to have a fever each day.
Patient 3: A 30-year-old man was well until January 1981 when he developed
esophageal and oral candidiasis that responded to Amphotericin B treatment. He was
hospitalized in February 1981 for P. carinii  pneumonia that responded to oral
TMP/SMX. His esophageal candidiasis recurred after the pneumonia was diagnosed,
and he was again given Amphotericin B. The CMV complement-fixation titer in March
1981 was 8. Material from an esophageal biopsy was positive for CMV.
Patient 4: A 29-year-old man developed P. carinii  pneumonia in February 1981. He
had had Hodgkins disease 3 years earlier, but had been successfully treated with ra-
diation therapy alone. He did not improve after being given intravenous TMP/SMX
and corticosteroids and died in March. Postmortem examination showed no evidence
of Hodgkins disease, but P. carinii  and CMV were found in lung tissue.
Patient 5: A previously healthy 36-year-old man with a clinically diagnosed CMV
infection in September 1980 was seen in April 1981 because of a 4-month history of
fever, dyspnea, and cough. On admission he was found to have P. carinii  pneumonia,
oral candidiasis, and CMV retinitis. A complement-fixation CMV titer in April 1981 was
128. The patient has been treated with 2 short courses of TMP/SMX that have been
limited because of a sulfa-induced neutropenia. He is being treated for candidiasis
with topical nystatin.
The diagnosis of Pneumocystis  pneumonia was confirmed for all 5 patients ante-
mortem by closed or open lung biopsy. The patients did not know each other and had
no known common contacts or knowledge of sexual partners who had had similar
illnesses. The 5 did not have comparable histories of sexually transmitted disease.
*Paired specimens not run in parallel.
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Four had serologic evidence of past hepatitis B infection but had no evidence of cur-
rent hepatitis B surface antigen. Two of the 5 reported having frequent homosexual
contacts with various partners. All 5 reported using inhalant drugs, and 1 reported
parenteral drug abuse. Three patients had profoundly depressed in vitro  proliferative
responses to mitogens and antigens. Lymphocyte studies were not performed on the
other 2 patients.
Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD Weisman, DO,
Div of Clinical Immunology-Allergy, Dept of Medicine, UCLA School of Medicine; I Pozalski, MD,
Cedars-Mt. Sinai Hospital, Los Angeles; Field Services Div, Epidemiology Program Office, CDC.
Editorial Note: Pneumocystis  pneumonia in the United States is almost exclusively
limited to severely immunosuppressed patients (1 ). The occurrence of pneumo-
cystosis in these 5 previously healthy individuals without a clinically apparent
underlying immunodeficiency is unusual. The fact that these patients were all homo-
sexuals suggests an association between some aspect of a homosexual lifestyle or
disease acquired through sexual contact and Pneumocystis  pneumonia in this popu-
lation. All 5 patients described in this report had laboratory-confirmed CMV disease or
virus shedding within 5 months of the diagnosis of Pneumocystis  pneumonia. CMV
infection has been shown to induce transient abnormalities of in vitro  cellular-
immune function in otherwise healthy human hosts (2,3 ). Although all 3 patients
tested had abnormal cellular-immune function, no definitive conclusion regarding the
role of CMV infection in these 5 cases can be reached because of the lack of published
data on cellular-immune function in healthy homosexual males with and without CMV
anti-body. In 1 report, 7 (3.6%) of 194 patients with pneumocystosis also had CMV
infection; 40 (21%) of the same group had at least 1 other major concurrent infection
(1 ). A high prevalence of CMV infections among homosexual males was recently re-
ported: 179 (94%) of 190 males reported to be exclusively homosexual had serum
antibody to CMV, and 14 (7.4%) had CMV viruria; rates for 101 controls of similar age
who were reported to be exclusively heterosexual were 54% for seropositivity and
zero for viruria (4 ). In another study of 64 males, 4 (6.3%) had positive tests for CMV
in semen, but none had CMV recovered from urine. Two of the 4 reported recent ho-
mosexual contacts. These findings suggest not only that virus shedding may be more
readily detected in seminal fluid than in urine, but also that seminal fluid may be an
important vehicle of CMV transmission (5 ).
All the above observations suggest the possibility of a cellular-immune dysfunction
related to a common exposure that predisposes individuals to opportunistic infections
such as pneumocystosis and candidiasis. Although the role of CMV infection in the
pathogenesis of pneumocystosis remains unknown, the possibility of P. carinii  infec-
tion must be carefully considered in a differential diagnosis for previously healthy
homosexual males with dyspnea and pneumonia.
References
1. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii  pneumonia
in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med
1974;80:83–93.
2. Rinaldo CR, Jr, Black PH, Hirsch MS. Interaction of cytomegalovirus with leukocytes from pa-
tients with mononucleosis due to cytomegalovirus. J Infect Dis 1977;136:667–78.
3. Rinaldo CR, Jr, Carney WP, Richter BS, Black PH, Hirsch MS. Mechanisms of immunosuppres-
sion in cytomegaloviral mononucleosis. J Infect Dis 1980;141:488–95.
78 INFECTIOUS DISEASES
4. Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of cytomegalovirus infection
in homosexual men. J Infect Dis 1981;143:188–92.
5. Lang DJ, Kummer JF. Cytomegalovirus in semen: observations in selected populations. J Infect
Dis 1975;132:472–3.
Editorial Note—1996
James W Curran, MD, Dean, Rollins School of Public Health of Emory University (Atlanta); Coor-
dinator of the 1981 Task Force on Kaposi’s Sarcoma and Opportunistic Infections; and former
Director of the Office of HIV/AIDS, CDC.
The June 4, 1981, report of five cases of Pneumocystis carinii pneumonia (PCP) in
homosexual men in Los Angeles was the first published report about acquired immu-
nodeficiency syndrome (AIDS). This report in MMWR  alerted the medical and public
health communities 4 months before the first peer-reviewed article was published (1 ).
The timeliness of this report can be credited to the public health sensitivity of the
astute reporting physicians and the diligence of CDC staff. Dr. Gottlieb and his col-
leagues at the University of California at Los Angeles School of Medicine and Cedars-
Mt. Sinai Hospital worked closely with the CDC Epidemic Intelligence Service Officer
assigned to the Los Angeles Department of Health Services to summarize the data and
draft this brief report. When news of these cases reached CDC, scientists in the Para-
sitic Diseases Division of CDC’s Center for Infectious Diseases already were concerned
about other unusual cases of PCP. That division housed the Parasitic Diseases Drug
Service and requests for pentamidine isethionate to treat PCP in other similar patients
in New York had been called to the attention of these scientists by the CDC employee
who administered the distribution of this drug (which was not yet licensed and was
available in the United States only from CDC).
In July 1981, following the report of these cases of PCP and cases of other rare
life-threatening opportunistic infections and cancers (2 ), CDC formed a Task Force on
Kaposi’s Sarcoma and Opportunistic Infections. A key first task facing CDC was to de-
velop a case definition for this condition and to conduct surveillance. The CDC case
definition was adopted quickly worldwide. Results from active surveillance conducted
in the United States rapidly established that the syndrome was new, and the number
of cases was increasing rapidly (3 ). By the end of 1982, the distribution pattern of
cases strongly suggested that AIDS was caused by an agent transmitted through sex-
ual contact between men (4,5 ) and between men and women (6,7 ) and transmitted
through blood among injecting-drug users and among recipients of blood or blood
products (8–10 ). Cases also were identified among infants born to women with AIDS
or at risk for AIDS (11 ), and the epidemic extended beyond the life-threatening re-
ported cases to include persistent unexplained lymphadenopathy (12 ).
To prevent transmission of AIDS, in 1983 the Public Health Service used epidemio-
logic information about the condition to recommend that sexual contact be avoided
with persons known or suspected to have AIDS and that persons at increased risk for
AIDS refrain from donating plasma or blood (10,13 ). In addition, work was intensified
toward developing safer blood products for persons with hemophilia. These recom-
mendations were developed and published only 21 months after the first cases were
reported and well before the first published reports identifying what is now termed
HIV as the etiologic agent of AIDS (14,15 ). Isolation of HIV enabled development of
assays to diagnose infections; characterization of the natural history of HIV; further
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protection of the blood supply; development of specific antiviral therapies; and expan-
sion of surveillance criteria to include other conditions indicative of severe HIV dis-
ease. Research and prevention programs for HIV have contributed greatly to scientific
and programmatic approaches to other public health problems.
During 1981–1996, approximately 350 reports related to AIDS were published in
MMWR, an average of two per month since June 1981. Throughout the HIV epidemic,
timely publication of reports about AIDS and related topics in MMWR  have continued
to play a crucial role in alerting health professionals and the public.
In 1996, HIV transmission occurs worldwide and has an impact in all countries
(16 ). In the United States, prevention efforts have been successful at reducing HIV
transmission. For example, blood-donor deferral and blood screening have virtually
eliminated HIV transmission through blood and blood products, and adoption of less
risky behaviors has greatly reduced sexual transmission between men; most recently,
therapeutic advances have reduced transmission from mother to newborn (17 ). How-
ever, in the United States, AIDS has been diagnosed in 548,000 persons, and 343,000
have died. HIV infection has become the leading cause of death for persons aged 25–
44 years, and an estimated 650,000–950,000 persons are living with HIV infection.
Throughout the world, HIV continues to spread rapidly, especially in impoverished
populations in Africa, Asia, and South and Central America. The emergence of the HIV
pandemic demonstrates the vulnerability of the world’s populations to previously un-
known infectious diseases.
The first 15 years in the recorded history of AIDS have included remarkable scien-
tific successes and countless examples of individual courage and accomplishment.
Although these accomplishments provide hope for the future, further efforts are
needed to halt the steady spread of HIV throughout the world.
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Isolation of E. coli  O157:H7 from Sporadic Cases
of Hemorrhagic Colitis — United States
MMWR 1982;31:580,585 (November 5, 1982)
Since the beginning of August 1982, stool isolates of Escherichia coli  serotype
O157:H7 have been identified at CDC from specimens obtained from four patients in
two states. Three of four patients had an unusual bloody diarrheal illness; each illness
began suddenly with severe crampy abdominal pain followed within 24 hours by wa-
tery diarrhea, which subsequently became markedly bloody. One patient underwent a
laparotomy to rule out appendicitis. All patients recovered within 7 days without com-
plications or specific therapy. In one instance, E. coli  O157:H7 was isolated from the
stool of a patient’s spouse. This fourth patient had abdominal cramps and non-bloody
diarrhea. Since early August, 25 additional sporadic cases of this unusual illness have
been reported to CDC, but appropriately collected stool specimens were available in
only two of these. E. coli  O157:H7 was not isolated from either specimen. The four
patients with sporadic cases in which E. coli  was isolated from stools and 24 of the
remaining 25 patients with sporadic cases had eaten hamburgers from a variety of
sources (including homes and/or local or national-chain restaurants) within the week
before they became ill.
Examination of stool samples from sporadic cases of this recently recognized diar-
rheal illness, currently designated “hemorrhagic colitis,” began at CDC after E. coli
O157:H7 was isolated from patients in two separate outbreaks of this illness earlier
this year in Oregon and Michigan. Illness was associated with eating hamburgers at
restaurants of one national chain.
Hemorrhagic colitis appears to be a distinct clinical entity, characterized by severe
crampy abdominal pain, grossly bloody diarrhea, little or no fever, a characteristic
barium-enema finding of marked edema involving the cecum, ascending and/or trans-
verse colon, and the absence of usual pathogens in stool.
Reported by RR Uyeyama, MD, Good Samaritan Hospital, San Jose, SB Werner, MD, S Chin,
MD, State Epidemiologist, California Dept of Health Svcs; SF Pearce, MD, CL Kollip, MD, Port-
land Adventist Medical Center, Portland, LP Williams, DVM, JA Googins, MD, State
Epidemiologist, Oregon State Health Div; Enteric Diseases Br, Div of Bacterial Diseases, Center
for Infectious Diseases, CDC.
Editorial Note: The diagnoses of hemorrhagic colitis are based on the typical clinical
presentation and isolation of E. coli  O157:H7 from the stool specimens. Early stool
collection (within 4 days after onset of illness and before any antibiotic exposure) is
crucial for detecting the E. coli, so physicians encountering typical cases need to en-
sure that stool samples are obtained and a portion held frozen (preferably at –70 C
[–94 F] or on dry ice) while their laboratories perform routine examinations for Salmo-
nella, Shigella, Campylobacter, Yersinia, and parasites. If these test results are
negative, arrangements can be made through the state epidemiologist and state labo-
ratory director to look for E. coli  O157:H7 in the frozen specimen. Those state
laboratories that do not have the antisera to identify E. coli  O157:H7 may wish to send
either the whole frozen stool or 10 picks (if possible) of E. coli  colonies to CDC. This
strain of E. coli  O157:H7 does not ferment sorbitol, and this biochemical property may
facilitate screening for this serotype. Further studies are under way at CDC to better
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characterize the epidemiology of hemorrhagic colitis, the reservoir of E. coli  O157:H7,
and serologic methods to confirm infection.
Epidemiologic investigation of the outbreaks showed that one source of E. coli
O157:H7 is hamburger. Other enteric diseases, such as salmonellosis, have been re-
ported following consumption of hamburger (1 ). Careful handling and adequate
cooking of raw meat products should minimize or eliminate the risk of contracting
infectious diseases from this source.
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Editorial Note—1997
Stephen M Ostroff, MD, Associate Director for Epidemiologic Science, National Center for Infec-
tious Diseases, CDC.
              A journey of a thousand miles must begin with a single step.
                                                                —Lao-Tzu, Chinese philosopher
This description of four persons with diarrheal illness attributable to E. coli
O157:H7 was among the earliest published references to this pathogen and the first
report of this problem to be published in MMWR. From this modest beginning, E. coli
O157:H7, the most commonly identified member of a group of organisms that is now
referred to as the Shiga toxin-producing E. coli  (STEC), has become one of the best-
known emerging pathogens and one that is considered prototypic for the current
paradigm of foodborne diseases in the United States (1 ). Over its 15-year history,
E. coli  O157:H7 has evolved as a major problem for primary-care practitioners, pedi-
atric nephrologists, infectious-disease physicians, public health authorities, and those
in the child-care setting and the food industry. In the process, the public health impera-
tive to address this problem has influenced the careers of many of CDC’s Epidemic
Intelligence Service officers. For example, during a 2-year training assignment to the
Washington State Department of Health, this author devoted a substantial amount of
time investigating outbreaks attributed to this organism and systematically interview-
ing the hundreds of persons in that state with sporadic cases of E. coli  O157:H7 infec-
tion (2 ).
As all successful public health practitioners and clinicians quickly learn, there is no
better way to develop a feel for a disease and its risk factors than by talking to patients
with the illness. In reading the MMWR  article of 1982, it is striking to discover how
many of the now classic features of E. coli  O157:H7 infection could be identified in
those four initial patients—these features are typical of hemorrhagic colitis, including
abdominal cramping and nonbloody diarrhea rapidly progressing to bloody diarrhea
in the absence of prominent fever. In addition, the report notes the occurrence of non-
bloody, culture-confirmed disease; the suggestion of person-to-person transmission
(which was subsequently confirmed); the great potential for misdiagnosis and inap-
propriate clinical procedures (in this case laparotomy); and spontaneous recovery
without specific therapy, obviating the need for antimicrobial agents (3 ). The report
also highlights another critical issue—the failure to collect appropriate specimens to
diagnose this and other enteric pathogens. Even today, with the increasingly high pro-
file of this disease, clinicians often fail to consider the diagnosis of E. coli  O157:H7 or
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to collect appropriate specimens, and laboratories often fail to use necessary screen-
ing techniques for its identification.
However, one element of this disease was not mentioned in the 1982 report. None
of the four patients developed hemolytic uremic syndrome (HUS) nor was it men-
tioned as a potential complicating factor. HUS is now recognized to occur in 5%–10%
of reported cases of E. coli  O157:H7; it occurs most commonly in patients with this
disease who are aged <5 years (3 ). Remarkably, the outbreaks in Oregon and Michi-
gan early in 1982, which led to the initial identification of E. coli  O157:H7, are among
the only ones recognized in which none of the case-patients developed HUS, probably
because few of the illnesses occurred in children (4 ). It was not until the following
year that the association between E. coli  O157:H7 and HUS was first reported (5,6 ).
However, two outbreaks of HUS had occurred earlier in North America before this
association was recognized, including one in 1980 outside of Toronto in association
with apple juice (7 ) and one in 1982 in Sacramento (8 ). The history of this problem
highlights the need for rapid reporting and thorough evaluation of clusters of un-
known etiology. These two outbreaks probably were due to infections with E. coli
O157:H7, because in North America, most cases of HUS—the most common cause of
acute renal failure of childhood—are associated with this infection (9 ). The combina-
tion of the severity of the clinical syndrome, the frequency of severe complications,
and the lack of specific therapeutic interventions account for the perception of E. coli 
O157:H7 as one of the most feared emerging pathogens.
The initial outbreaks of E. coli  O157:H7 were associated with two outlets of the
same fast-food chain, and illness was linked to undercooked hamburgers. The MMWR
report mentioned that most of the persons with sporadic hemorrhagic colitis had
eaten hamburgers from a variety of sources. Since this report, many other E. coli
O157:H7 outbreaks, including a large outbreak in 1993 in the Pacific Northwest (10 ),
have been linked to ground beef. Although cattle are known to be a major reservoir for
this pathogen, the ecology of the organism in animals is poorly understood.
However, accumulating experience has established a diversity of sources for E. coli
O157:H7, including apple juice and cider, raw vegetables such as lettuce, raw milk, and
processed foods such as salami (1 ). Some recent outbreaks have been related to low-
level contamination of widely dispersed products, which are more available as a result
of advances in the food production and distribution industry. In such instances, out-
breaks are marked by small numbers of cases occurring over wide geographic areas.
These outbreaks are difficult to detect and investigate. Expanded use of subtyping
methods, such as pulsed-field gel electrophoresis for seemingly sporadic cases of
E. coli O157:H7, will increase the likelihood of detecting diffuse outbreaks (11 ). Al-
though this will expand knowledge of this pathogen, investigation of such outbreaks
is likely to further strain health department resources.
Despite the substantial gains in knowledge about E. coli  O157:H7 since its recogni-
tion 15 years ago, many fundamental questions and concerns remain. For example,
the reasons for the original emergence of this pathogen and for its geographic spread
are not known. In recent years, the organism has become a global health problem; in
1996 alone, major outbreaks were reported in Germany and Scotland, and the largest
recognized outbreak, affecting approximately 5000 persons, occurred in Japan (12 ).
How frequent is this infection? In a recent study of 10 hospitals from all U.S. regions,
E. coli  O157:H7 was the second or third most commonly isolated bacterial enteric
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pathogen in four hospitals, and its overall isolation rate was more than one third of
that for Shigella  sp. (13 ). However, despite its frequency and the availability of inex-
pensive commercial tests for screening and identification, by the end of 1994 only
approximately 50% of U.S. clinical laboratories were screening either all stools or
bloody stools for E. coli  O157:H7 (14 ). Because misdiagnosis can lead to unnecessary
therapies and procedures and because person-to-person spread is not uncommon,
stool specimens from all patients with a history of acute bloody diarrhea should be
cultured for this pathogen (13 ).
Other issues that need to be addressed include 1) determining the public health
importance in North America of other STEC—STEC have been recognized as the
cause of two outbreaks in the United States and appear to be more common than
E. coli  O157:H7 in other parts of the world, such as Argentina and Australia; 2) decid-
ing whether laboratory screening approaches in the United States should be changed
to identify other STEC; 3) determining why some persons develop HUS after STEC
infection and others do not, and whether there is any secondary prevention for this
complication; 4) identifying the best primary prevention strategy; and 5) estimating
the extent to which measures such as Hazard Analysis Control Critical Point work to
reduce the threat of E. coli  O157:H7 to the food supply, and what other measures
might be necessary. Efforts to address these and other questions are included in the
President’s Food Safety Initiative, which was issued in May 1997 (15 ). Such efforts are
critical to enhance understanding of E. coli  O157:H7, other known foodborne patho-
gens, and as yet undiscovered pathogens that will constitute the foodborne chal-
lenges of the future.
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Pentachlorophenol Poisoning in Newborn Infants —
St. Louis, Missouri, April–August 1967
Pentachlorophenol Poisoning MMWR 1967;16:334–51 (October 7, 1967)
From April to August 1967, nine cases of a clinically distinct illness characterized by
fever and profuse sweating occurred in a small nursery for newborns in St. Louis,
Missouri. Two of the cases were fatal. Early in the course of the outbreak the disease
was felt to be an intoxication, but the nature of the poison and the mode of exposure
of the patients remained obscure. Only after the ninth case developed was it discov-
ered that an antimildew agent, containing a high concentration of sodium pentachlo-
rophenate (the sodium salt of pentachlorophenol), was being used in the hospital
laundry. All of the clinical, epidemiological, and biochemical evidence indicated that
this outbreak resulted from pentachlorophenol poisoning. The only identified mode of
exposure was skin absorption of sodium pentachlorophenate residues on diapers and
other fabrics, resulting from the misuse of the antimildew agent in the final laundry
rinse.
The outstanding clinical feature of the illness was extreme diaphoresis. Attendants
consistently noticed that the infants’ clothing and brows were drenched with sweat.
Nevertheless, the neonates nursed avidly. As the disease progressed, fever rose as
high as 103 F, respiratory rates increased, and breathing became labored, though aus-
cultation of the lungs was normal and cyanosis was absent. Other common findings
included tachycardia, hepatomegaly, and irritability followed by lethargy. Anorexia,
vomiting, and diarrhea were notably absent. Stiffness of the neck, muscular fascicula-
tions, and convulsions were not observed. Skin rashes or evidences of inflammation
or irritation of the skin were not seen.
Laboratory tests frequently showed a progressive metabolic acidosis, proteinuria,
a rising blood urea nitrogen, and “pneumonia” or “bronchiolitis” on X-ray. Bacterial
and viral cultures of blood, cerebrospinal fluid, nose, throat and stool revealed no
pathogens. Autopsy findings of the two fatal cases showed fatty metamorphosis of
the liver in both cases and fatty vacuolar changes in the renal tubules of one case.
All except one of the seriously ill infants, a fatal case, were transferred to other
hospitals for treatment. After the first fatal case occurred, the attending physicians
suspected a toxic cause and therefore promptly performed exchange transfusions on
each of the seriously ill infants who were subsequently transferred for medical care.
This treatment yielded dramatic results. Within minutes to hours, the infants became
more responsive and had less respiratory distress. Fever and sweating disappeared,
as did metabolic acidosis. Renal function returned to normal during the next few days.
Except for the two fatal cases, recovery was apparently complete.
The first four cases developed between April 17 and 19 among a group of 25 infants
who were in the nursery during this interval. The first infant to become ill died. The
institution was closed on April 24 and thoroughly cleaned and disinfected before re-
opening on May 3. A second cluster of four cases occurred between May 10 and 15.
One of these also was fatal. The average age of these eight cases, at onset of illness,
was 8.9 days. Several additional suspect cases with fever and sweating were detected
among 13 infants who had been discharged from the hospital in apparent health be-
tween April 17 and May 15.
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From the time of the first recognition of the outbreak, an intensive and persistent
search was made for toxic substances in the environment of the infants. A solid-stick
evaporating deodorizer had been used without change in practice for 4 years. A com-
mercial exterminator had sprayed regularly with a carbamate insecticide monthly for
2 years within the hospital, but never in the nursery. The management of drugs and
the preparation of babies’ formulas revealed no deviations that were likely to permit
the introduction of a toxic substance to this many babies.  
For the preceding 10 months, a commercially available disinfectant containing a
mixture of synthetic phenolic derivatives had been repeatedly applied to surfaces that
came in contact with infants’ skin.
One-dimensional thin-layer chromatography of serum specimens obtained from
the first eight cases was performed. These tests revealed the presence of a phenolic
substance in all test specimens, which was similar to a phenolic ingredient of the dis-
infectant. This substance was thought to be the toxic chemical causing the disease.
The nursery was closed and recleaned. Use of the suspect disinfectant was aban-
doned, and all equipment that had been treated with it was discarded or rendered free
of phenolic residues by extensive cleaning with alcohol. New linens and diapers were
purchased and the nursery reopened July 11.
On August 29, an 8-day-old infant had the acute onset of an illness identical to the
previous eight infants. The infant received an exchange transfusion and promptly re-
covered. A follow-up survey of infants discharged from the hospital in July and Au-
gust revealed six additional infants who had the characteristic excessive sweating in a
milder form of the same syndrome.
The formerly suspect disinfectant was no longer in use. Reinvestigation of laundry
procedures disclosed a previously overlooked source of phenols. An antimildew
agent, containing 22.9 percent sodium pentachlorophenate and 4.0 percent trichloro-
carbanilide, was being used in the terminal rinse of all nursery linens and diapers,
despite a warning on the label that the compound “must not be used” in laundering
diapers.
This product had been in use in the laundry since March 1966. The recommended
quantity was one ounce of powder per laundering cycle, but it was ascertained that
the laundry was actually using 3 to 4 ounces.
Thin-layer chromatography of the serum and urine of the new case revealed an
abnormal substance with characteristics that were identical to those detected in the
previous infants’ sera. Further studies in two different laboratories with improved
methods of analysis have shown that the chemical in the urine and serum of the new
case was pentachlorophenol, and was clearly not one of the phenolic ingredients in
the previously suspected disinfectant. Additionally, pentachlorophenol was identified
in freshly laundered diapers obtained from the nursery. The quantity of pentachloro-
phenol varied from 1.5 to 5.7 mg. per diaper. Pentachlorophenol, when fed to rats, was
found to be highly toxic and was isolated from urine of surviving rats in concentra-
tions comparable to that found in the sick child. Unfortunately, no samples from the
earlier cases remained for these more sophisticated analyses.
Actions have been instituted to prevent further illnesses that might be caused by
the misuse of this product, or two other sodium pentachlorophenate-containing prod-
ucts that are recommended for similar purposes. The manufacturer has been directed
to trace all sales and shipments of these products during the past 18 months, and to
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remove such products from all hospitals and any establishment that is involved in
general laundry work. The company has voluntarily ceased sale of these three prod-
ucts.
(Reported by J. Earl Smith, M.D., Health Commissioner, Division of Health, Department of Health
and Hospitals, City of St. Louis, Missouri; L.E. Loveless, Ph.D., Chemist, Clinical Laboratories,
St. Louis, Missouri; E. A. Belden, M.D., Consultant, Communicable Disease Control, Local Health
Services Section, Division of Health, Missouri Department of Public Health and Welfare; the
Epidemiology and Pesticides Programs of the National Communicable Disease Center, Atlanta,
Georgia; the Toxicology Section, Occupational Health Program, National Center for Urban and
Industrial Health, Cincinnati, Ohio; and a team of EIS Officers.)
Editorial Note: The clinical, laboratory, epidemiological, and pathological findings, as
well as the prompt response to exchange transfusion, all indicate a toxic, rather than
an infectious, cause of this outbreak. The fever, sweating, and acidosis are consistent
with intoxication with certain phenolic derivatives, which are known to increase the
metabolic rate (1 ). The symptoms described here are remarkably similar to industrial
accidental poisonings resulting from overexposure to pentachlorophenol or its so-
dium salts (2,3 ). The exact manner in which the infants became poisoned cannot be
established, but the most reasonable explanation is absorption through the intact skin
as a result of repeated contact with diapers, blankets, and linens containing small, but
readily absorbable, quantities of sodium pentachlorophenate. The antimildew agent,
which is labelled not for use in laundering diapers or hospital linens, nevertheless,
was in use in this hospital. Pediatricians, hospital administrators, housekeepers, and
local health authorities should check commercial diaper services and hospital laun-
dries to ensure that this product is not in use.
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Editorial Note—1996
Michael A McGeehin, PhD, MSPH, Chief, Health Studies Branch, Division of Environmental Haz-
ards and Health Effects, National Center for Environmental Health, CDC.
This report, one of the first well-documented accounts of an investigation of a non-
infectious disease problem to be published in MMWR after responsibility for the
publication had been transferred to CDC, illustrates one of the most difficult chal-
lenges facing environmental epidemiologists—exposure assessment. Even in acute
situations such as that described in this report, the search for a toxic agent and the
route of exposure is difficult and time consuming. In investigations of chronic and
many environmentally related illnesses, exposures that may have occurred over an
extended period may be particularly difficult to characterize accurately; the paucity of
accurate exposure data has been termed the “Achilles heel” of environmental
epidemiology (1 ). 
As illustrated by this investigation in St. Louis in 1967, the use of innovative labora-
tory methodologies has been critical to improving the accuracy of exposure assess-
ments. For example, during this investigation, epidemiologists initially relied on the
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laboratory techniques of thin-layer chromotographic analysis of patient specimens to
identify a phenol as the probable etiologic agent; more advanced laboratory methods
were used to confirm the causative role of this agent and to further focus the investi-
gation. Since 1967, the close collaboration between epidemiologists and laboratory
scientists during environmental investigations has continued to strengthen, and the
development of biomarkers of exposure, disease, and susceptibility has been critical
in assisting public health scientists in exposure assessment (2 ). Environmental epide-
miologists in state and federal health agencies are addressing the difficulties of accu-
rately classifying exposure in other innovative ways. For example, computer mapping
techniques, such as Geographic Information Systems, have enabled investigators to
more accurately use environmental sampling data to represent individual exposure.
Finally, although the investigation in St. Louis was highly focused, the approach to this
outbreak underscored the public health benefits of basic “shoe leather epidemiology”
for solving problems regardless of their etiology.
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Human Lead Absorption — Texas
Human Lead Absorption MMWR 1973;22:405–7 (December 8, 1973)
In December 1971, the City-County Health Department in El Paso, Texas, discovered
that an ore smelter in El Paso was discharging large quantities of lead and other me-
tallic wastes into the air. Between 1969 and 1971, this smelter had released 1,116 tons
of lead, 560 tons of zinc, 12 tons of cadmium, and 1.2 tons of arsenic into the atmos-
phere through its stacks (Table 1).
Twenty-four hour air samples to determine the amounts of lead and other heavy
metals suspended in the atmosphere were collected throughout 1971 and again
between July 1972 and June 1973 by the local health department. Both series of tests
showed that mean concentrations of metallic wastes in the air were highest immedi-
ately downwind of the smelter and that levels decreased logarithmically with distance
from the smelter. The annual mean lead level immediately downwind of the smelter in
1971 was 92 µG/m3 and in 1972-73 was 43 µG/m3; the U.S. Environmental Protection
Agency’s proposed safe upper limit for airborne lead content is 2.0 µG/m3 of air (1). No
metallic emissions were found near any of 15 other industrial establishments studied
in El Paso.
Similarly, soil samples taken by the health department at selected sites within the
urban area between June and December 1972 showed the highest concentrations of
lead and other metals to be in surface soil from within 0.2 miles of the smelter
(Figure 1). Samples of drinking water, milk, and food obtained from homes in El Paso
between January and March 1972 by the health department were uniformly free of
lead.
Preliminary testing programs to evaluate the effect of the environmental contami-
nation on human blood lead levels were conducted in El Paso between January and
March 1972 by the local health department, the smelting company, and CDC. These
initial studies showed that 43% of persons in all age groups and 62% of children
through age 10 years living within 1 mile of the smelter had blood lead levels
≥40 µG%, a level considered to be evidence of undue lead absorption (2). There was a
lower prevalence among persons living at greater distances from the smelter. No
cases of overt lead poisoning were noted.
In August 1972, a random survey of the entire population living within 4.1 miles of
the smelter in south and west El Paso was conducted by the health department and
CDC. The area was divided along census tract lines into 3 strata, roughly concentric
Table 1
Particulate Waste Stack Emissions (in Tons [t]), by Year
El Paso Smelter, 1969–1971
Year
Total
Particulates Lead Cadmium Zinc Arsenic
1969  1,443t    292t   3.3t  139t  0.3t
1970 2,274   511  4.9 264 0.6
1971 1,282   313  3.8 157 0.3
Total  4,999t  1,116t  12.0t  560t  1.2t
Source: El Paso City-County Health Department
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about the smelter and each with a radius of 1.0-1.5 miles. In the small, innermost stra-
tum, all households were visited; in the 2 outer strata, approximately 2% of house-
holds were selected. Of 833 occupied households included in the survey, 672 (80.6%)
were reached for the interview. A venous blood sample for lead analysis by atomic
absorption spectrophotometry (AAS) was obtained from all persons up to age
20 years and from every other person above that age; samples of paint, soil, house-
hold dust, and pottery were also collected in each home for lead analysis by AAS. In
all age groups, the percentage of blood levels ≥40 µG% was found to be highest in
those persons living nearest the smelter (Figure 2), and the prevalence was highest in
the youngest individuals; migration rates among these persons were low. In area I,
5 (8.5%) of 59 persons 1-19 years of age with blood lead levels ≥40 µG% had moved
into the area in the 2 years preceding the survey. In areas II and III, the migration rate
for persons 1-19 years of age with blood levels ≥40 µG% was 8.2% (4 of 49); 1 person
in this group had moved from area I.
A total of 1,971 paint samples were collected for lead analysis. In area I, 9 (39.1%)
of 23 children 1-4 years had exposure to at least 1 paint sample with a lead content of
1.0% or more; the comparable figures for areas II and III were 11 (33.3%) of 33 and
17 (34.0%) of 50 children, respectively. These three rates were virtually identical (p>0.9
by Chi-square).
Analysis of over 4,000 soil and household dust samples indicated that the mean
content of lead in these specimens was significantly higher in area I than in areas II
Figure 1
LEAD SURFACE SOIL LEVELS
EL PASO, TEXAS, AND DONA ANA COUNTY, NEW MEXICO — 1972
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and III. Furthermore, persons 1-19 years with blood lead levels ≥40 µG% were found to
have been exposed to soil and dust samples with significantly higher (p<0.001) mean
lead contents (3,264 ppm for soil, 3,522 ppm for dust) than persons with blood lead
levels below 40 µG% (means: 1,032 ppm and 1,279 ppm).
Pottery vessels were used for food storage or preparation in 37 homes visited. After
1% hydrochloric acid incubation for 6 hours, 2 of 6 vessels from sector I, 6 of 19 from
sector II, and 4 of 12 from sector III had a lead content ≥100 G per ml in the eluate.
(Reported by Bernard F. Rosenblum, M.D., M.P.H., Director, El Paso City-County Health Depart-
ment; James M. Shoults, Acting Environmental Engineer, El Paso City-County Health
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nity and Environmental Management Activities, Bureau of State Services, CDC; the Field Serv-
ices Branch, Bureau of Epidemiology, the Toxicology Section, Clinical Chemistry, Hematology,
and Pathology Branch, Bureau of Laboratories, CDC; and a team of EIS Officers.)
Editorial Note: It may be estimated from this prevalence survey, using 1970 U.S. Cen-
sus data, that at least 2,700 persons 1-19 years of age in El Paso had blood lead levels
≥40 µG% at the time of the survey (Table 2). These results indicate that the problem of
undue lead absorption affects persons across all of south and west El Paso to a dis-
tance of at least 4 miles from the smelter. Lead emitted by the smelter and deposited
in soil and dust would appear to be the major source of the lead absorbed by humans;
the accumulation in the soil and dust of emitted lead is facilitated by several features
of the local environment, particularly the aridity, the sheltering effect of the high
mountains, and the frequent thermal inversions. Ingestion of lead-based paint may
account for a small fraction of cases of undue absorption (at most 1/3) in the youngest
children. Careful neurologic and psychologic studies of persons in El Paso with blood
lead levels ≥40 µG% have been conducted and are being compared with results of
similar studies in a matched group with lower lead levels. This story will make it pos-
sible to ascertain objectively whether any persons are suffering subtle but possibly
permanent neurologic or psychologic sequelae from prolonged lead absorption.
Control measures undertaken to date include partial reduction of smelter emission
and relocation to more distant public housing of approximately 500 persons who had
lived closely adjacent to the smelter property.
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Editorial Note—1997
Thomas Matte, MD, MPH, Medical Epidemiologist, Henry Falk, MD, Director, Division of Environ-
mental Hazards and Health Effects, National Center for Environmental Health, CDC.
When a team of Epidemic Intelligence Service officers from CDC, led by Dr. Philip
Landrigan, joined the local health department in El Paso, Texas, in March 1971 to in-
vestigate lead exposure associated with an ore smelter, the scientific understanding of
pediatric lead toxicity was about to enter a period of rapid progress. Many studies
Table 2
Estimated Numbers of Persons 1–19 Years With Blood
Lead Levels ≥40 µG%, by Distance from Shelter
El Paso, Texas — August 1972
Distance from
Smelter (Miles)
Sample Group Population 1–19 Years*
No. Tested
% With Blood




  0–1.0 259 43.2    723   312
1.1–2.4 246 11.0 12,316 1,355
2.5–4.1 253  9.5 11,486 1,091
Total 758 19.9 24,525 2,758
*1970 Census
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have since documented the public health threat posed by poorly controlled lead emis-
sions from lead smelters around the world (1 ). The range of lead exposure produced
in populations living near lead smelters has, in turn, facilitated studies of the mecha-
nisms and health consequences of pediatric lead exposure.
A major objective of the El Paso investigation was to determine whether high blood
lead levels (BLLs) in children were associated with smelter emissions or were ex-
plained by other lead sources also found in the community. A high level of lead emis-
sions in a residential area was not then assumed to be a public health threat, as it is
today. A 1972 National Academy of Sciences report on lead, while motivated by grow-
ing concern about widespread dispersal of lead in the environment, stated in its
preface: “lead attributable to emission and dispersion into the general ambient envi-
ronment has no known harmful effects” (2 ). In El Paso, the inverse gradient in air (3 ),
dust, and soil contamination as one moved away from the smelter, and the parallel
blood lead gradient (also found in a complementary investigation of lead exposure in
Juarez, Mexico [4 ]) supported the argument that soil and dust are important vehicles
of exposure. This finding foreshadowed subsequent research demonstrating the path-
way from lead in soil and dust to lead contamination of hands to lead in blood, pre-
sumably from normal hand-to-mouth behavior and ingestion of contaminated soil
and dust (5–7 ).
In 1975 and 1976, CDC investigators, led by Dr. Edward Baker, documented the po-
tential for exposure to leaded dust among children of workers at a secondary lead
smelter in Tennessee (8 ). Their findings and those of other investigations of “take-
home” lead exposure that followed brought about provisions in the 1978 Occupa-
tional Safety and Health Administration (OSHA) standard for occupational lead
exposure requiring hygienic measures in general industry to prevent lead workers
from carrying lead dust home on their skin, shoes, and clothing (9 ).
In the 1960s and 1970s, children living near smelters or in the households of
smelter workers were only a small part of a widespread national problem of “undue
lead absorption” (10 ). In urban areas, deteriorated lead paint in older housing made
the problem especially acute. In the same year as the El Paso survey, a door-to-door
survey of inner-city children in Rochester, New York, found a mean BLL of 44 µg/dL (5 ),
which was close to that measured near the El Paso smelter. 
Since the early 1970s, it also has become more clear that lead is a multimedia con-
taminant and that demonstrating the importance of a given source does not rule out
the contribution of other sources. For example, data from the Second National Health
and Nutrition Examination Survey (NHANES II) conducted from 1976 through 1980
indicated that the mean BLL among children aged <6 years residing in rural areas was
14 µg/dL (average levels were 3–6 µg/dL higher among children living in more urban-
ized areas) (11 ). During the same period, widespread population exposure to lead
emissions was reflected in average BLLs that declined in close parallel to the decreas-
ing consumption of leaded gasoline (12 ). Thus, children living near the El Paso
smelter, children in the homes of lead workers, and children in downtown Rochester
probably shared with children across the country a contribution to their BLLs from
lead in gasoline. Local sources, added to the higher background exposure prevalent at
the time, resulted in BLL distributions that are extremely high by today’s standards. 
Perhaps the most telling indication of how the scientific view of lead exposure has
changed since 1971 is that, in 1971 “undue lead absorption” referred only to BLLs
Human Lead Absorption 99
≥40 µg/dL. Numerous subsequent studies documented that BLLs much lower than
40 µg/dL, then considered acceptable, adversely impact the health of children without
causing overt symptoms. For example, investigators from CDC’s Bureau of Epidemiol-
ogy, again led by Dr. Landrigan, found an inverse relation between BLLs and nerve
conduction velocities among children exposed to emissions from a smelter near
Kellogg, Idaho (13 ). As the decade closed, Dr. Herbert Needleman’s landmark study
was published, demonstrating lower cognitive test scores and higher teachers’ ratings
of behavioral problems among children with higher tooth lead levels but no history of
clinically overt lead poisoning (14 ).
Epidemiologic studies identified subclinical effects of lead by comparing the health
of children with different levels of lead exposure. For most U.S. populations studied in
the 1970s, the least exposed children had BLLs well above the average in the U.S.
population today. Thus, health effects at lower levels could not be detected. As popu-
lation BLLs decreased through the 1980s, careful prospective studies found subtle ef-
fects of lead on learning and behavior at BLLs well below those of the least exposed
children in El Paso (15 ).
In addition to contributing to scientific knowledge about lead exposure and its
effects on health, findings from the El Paso survey and others precipitated measures
to reduce emissions at lead smelters. In 1977, a follow-up investigation by CDC and
the El Paso Health Department found that BLLs among children living nearest the
smelter had decreased by approximately 50% (16 ). More importantly, the El Paso sur-
vey was a prelude to a large body of continuously refined epidemiologic investiga-
tions that provided the impetus for actions to dramatically reduce population lead
exposure from lead in gasoline, soldered food cans, drinking water conduits, and
other sources in the United States. As a result, mean BLLs among children have de-
clined nationally by >80% overall and by similar amounts in population subgroups
defined by age, race, ethnicity, income levels, and urbanization (17,18 ). More recently,
international agreements to reduce the use of leaded gasoline may bring about signifi-
cant reductions in worldwide lead exposure. Ironically, the unfortunate epidemics of
lead toxicity near smelters in El Paso and elsewhere ultimately enabled more rapid
progress in understanding and controlling lead exposure than might otherwise have
been possible.
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Angiosarcoma of the Liver 
Among Polyvinyl Chloride Workers — Kentucky
Angiosarcoma MMWR 1974;23:49–50 (February 9, 1974)
Between September 1967 and December 1973, 4 cases of angiosarcoma of the liver
were diagnosed among men employed in the polyvinyl chloride polymerization sec-
tion of a B.F. Goodrich plant near Louisville, Kentucky. This section of the plant began
operations in 1938. It employs about 270 persons and produces polyvinyl chloride as
well as a variety of copolymers by polymerization of vinyl chloride monomer. All
4 men had worked continuously in the section for at least 14 years prior to onset of
illness (Table 1); all 4 had worked directly in various phases of the polymerization pro-
cess.
Case 1 presented in August 1967 with an epigastric mass and thrombocytopenia.
An exploratory laparotomy was performed in September 1967; liver biopsy revealed
angiosarcoma. Case 2 presented in January 1970 with gastrointestinal (GI) bleeding.
Recurrent bleeding in May 1970 led to an exploratory laparotomy at which time a di-
agnosis of angiosarcoma was made on liver biopsy. Case 3 presented in January 1964
with GI bleeding which recurred in May 1965 with signs of portal hypertension. A
portacaval shunt was performed, and liver biopsy yielded a diagnosis of cirrhosis.
Repeat biopsies in October 1970 and September 1972 confirmed this diagnosis.
Autopsy in March 1973 revealed angiosarcoma. Case 4 presented in July 1973 with
hepatosplenomegaly, weight loss, and jaundice. Two liver biopsies were interpreted
as showing severe cirrhosis. Autopsy in December 1973 revealed angiosarcoma.
In each case, pathologic material revealed the presence of extensive cirrhosis of a
non-alcoholic type in addition to angiosarcoma. In 2 cases, the diagnosis of angio-
sarcoma was made only at autopsy, cirrhosis having been diagnosed 7 years before in
Case 3 and 5 months before in Case 4. None of the patients gave histories of pro-
longed alcohol use or exposure to hepatotoxin outside their work place. In particular,
none had ever had exposure to thorium dioxide or to arsenic, two materials known
specifically to induce hepatic angiosarcoma in man (1,2 ).
Table 1
Cases of Angiosarcoma of the Liver















1 43    Aug. 1967    Sept. 1967   Jan. 7, 1968 17
2 36    Jan. 1970    May 1970   Sept. 27, 1971 14
3 41    Jan. 1964    Mar. 1973   Mar. 3, 1973 14
4 58    July 1973    Dec. 1973   Dec. 19, 1973 27
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(Reported by John Creech, M.D., Plant Physician, B.F. Goodrich Chemical Company, Louisville,
Kentucky; Maurice N. Johnson, M.D., Director of Environmental Health, B.F. Goodrich Chemical
Company, Akron, Ohio; Bradford Block, M.D., Medical Consultant, Kentucky Occupational Safety
and Health Administration, Kentucky State Department of Labor; National Institute for Occupa-
tional Safety and Health, and the Cancer and Birth Defects Division, Bureau of Epidemiology,
CDC.)
Editorial Note: Angiosarcoma of the liver is an exceedingly rare tumor. It is estimated
that only about 25 such cases occur each year in the United States. Four cases, there-
fore, among a small number of workers at a single plant is a most unusual event, and
one which raises the possibility of some work-related carcinogen, conceivably vinyl
chloride itself. Although no data are yet available concerning the occurrence of angio-
sarcoma among workers at other vinyl chloride plants in the United States, it seems
distinctly possible that the problem may be industry-wide. Epidemiologic studies have
started to determine the extent of the problem in the United States, with respect both
to angiosarcoma of the liver and to its possible relationship to post-toxic cirrhosis.
Published data concerning the potential hepato-toxicity and oncogenicity of vinyl
chloride are limited. Studies in Germany have suggested a link between hepatic dam-
age and occupational exposure to vinyl chloride (3 ), while Italian workers have sug-
gested that vinyl chloride may cause a wide variety of tumors in animals (4 ). The
chemical concentrations used in these latter experiments, however, far exceed levels
likely to be encountered in industrial environments. Efforts to confirm such observa-
tions and to measure effects at lower dose levels are now in progress.
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Editorial Note—1997
Philip J Landrigan, MD, MSc, Chairman, Department of Community Medicine, Mount Sinai
School of Medicine, New York, and former Director, Division of Surveillance, Hazard Evaluations,
and Field Studies, National Institute for Occupational Safety and Health, CDC.
Workers constitute the segment of the U.S. population most heavily exposed to
chemical toxins and physical agents. Because of their intense and prolonged expo-
sures compared with the general public’s, workers generally develop illnesses of toxic
etiology more frequently, more quickly after the introduction of new chemical com-
pounds, and in more severe forms.
Work-related diseases encompass a broad range of human illness (1 ). For exam-
ple, chronic bronchitis frequently occurs in coal miners; skin cancer in farmers; blad-
der cancer in dye workers exposed to aniline compounds; leukemia and lymphoma in
chemical workers exposed to benzene; kidney failure in lead workers; impaired repro-
ductive function in workers exposed to lead and certain pesticides; and chronic disor-
ders of the musculoskeletal system in workers who sustain repetitive trauma.
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The diagnosis of occupationally associated disease often is difficult (2 ). For most
diseases, a case of occupational origin is not clinically distinguishable from illness
resulting from other etiologies. Informed suspicion is therefore essential to recognize
occupational disease, and a careful history of occupational exposure is the critical
diagnostic instrument. In the initial diagnostic interview of each new patient, the phy-
sician must obtain at least a brief history of occupational exposures. Modification of
the concept of the sentinel health event (SHE) (3 ) has further assisted physicians in
establishing linkages between occupational exposures and disease (4 ).
A SHE has been defined as “an unnecessary disease, disability, or untimely death
whose occurrence signals a failure of prevention” (3 ). Examples in general medicine
include maternal deaths during childbirth, outbreaks of cholera, or a single case of
poliomyelitis. To extend the concept of the SHE to the workplace, a “sentinel health
event (occupational)” (SHE[O]) is analogously defined (4 ) as “an unnecessary dis-
ease, disability or untimely death which is occupationally related.” Recognition of a
SHE(O) requires clinical astuteness and attention to the exposure history. Typically,
the occurrence of a SHE(O) stimulates further investigation or research and may trig-
ger regulatory or other targeted preventive action.
This MMWR  report on angiosarcoma of the liver in vinyl chloride polymerization
workers represents a splendid description of a SHE(O). This report marked the first
recognition of the carcinogenicity to humans of vinyl chloride monomer (VCM), the
highly reactive gas to which workers were exposed in the B.F. Goodrich plant near
Louisville, Kentucky. The initial observation was made by John Creech, M.D., the plant
physician, and Maurice Johnson, M.D., the corporate medical director. These physi-
cians had evaluated three men with angiosarcoma of the liver during a 2-year period
(5 ). They realized, through careful history-taking, that all of the men with this rare
malignancy were employed in the same department of the plant.
Publication of this report and a related journal article (5 ) stimulated a series of
clinical investigations, epidemiologic studies, and toxicologic analyses. Henry Falk,
M.D., an Epidemic Intelligence Service (EIS) officer in the Cancer and Birth Defects
Division in CDC’s Bureau of Epidemiology, was assigned by his Division Director, Clark
W. Heath, Jr., M.D., to investigate this outbreak. Working with Richard Waxweiler,
Ph.D., of the National Institute for Occupational Safety and Health, Hans Popper, M.D.,
of the Mount Sinai School of Medicine, and Louis Thomas, M.D., of the National Can-
cer Institute, Dr. Falk confirmed the existence of the outbreak and also discovered a
premalignant lesion—idiopathic hepatic fibrosis—in additional members of the popu-
lation heavily exposed to vinyl chloride monomer (VCM) (6 ). This work stimulated a
major international conference that was convened at the New York Academy of Sci-
ences by Irving Selikoff, M.D. (7 ), at which the carcinogenicity of VCM was confirmed.
VCM is now universally considered to be a highly potent chemical carcinogen (7 ).
This recognition of the carcinogenicity of VCM also stimulated intense regulatory
activity (8 ). To prevent future cases of VCM-associated angiosarcoma, the Occupa-
tional Safety and Health Administration in 1974 proposed a 500-fold reduction in the
occupational exposure standard for VCM gas––from 500 parts per million (ppm) in air
to 1 ppm. The plastics-manufacturing industry immediately objected that such reduc-
tion was not possible and would drive the vinyl chloride polymerization industry over-
seas. An industry-sponsored study estimated that the costs to comply with the
proposed new standard would exceed $25 billion (8 ). Within the year, however, a ma-
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jor plastics manufacturer announced development of a novel closed-loop polymeriza-
tion process that greatly reduced atmospheric releases of VCM and almost completely
eliminated worker exposures. The manufacturer patented this system and sub-
sequently licensed it to other manufacturers at substantial profit. The VCM standard of
1 ppm remains in force today (9 ) and is readily achieved in the workplace. New cases
of hepatic angiosarcoma in vinyl chloride polymerization workers have been virtually
eliminated (10 ).
This episode, one of the earliest reports of an occupational disease outbreak pub-
lished in the MMWR, underscores the importance of informed clinical observation in
the recognition of work-related illness. Furthermore, the regulatory actions precipi-
tated by this report and the ensuing investigation of this episode illustrate that a safe
working environment and economic progress are not mutually exclusive. When well-
conceived protective standards are accepted with good will and ingenuity is used to
encourage compliance with those standards, then job safety, economic advances, and
a healthy environment can comfortably co-exist.
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IUD Safety: Report of a Nationwide Physician Survey
IUD Safety MMWR 1974;23:226,231 (June 29, 1974)
In an attempt to determine the morbidity and mortality associated with IUD use
nationwide, the Family Planning Evaluation Division, CDC, in conjunction with the
Committee on Maternal and Child Care of the American Medical Association (AMA)
and the American Osteopathic Association (AOA), began a physician survey in June
1973.
From their master files, AMA and AOA provided the names of 34,544 physicians in
the United States and Puerto Rico – virtually all physicians who had a primary, secon-
dary, or tertiary interest in obstetrics or gynecology, or a primary interest in family
practice, public health, or general preventive medicine. In the last week of June 1973,
CDC sent a questionnaire to all physicians on the list inquiring about women who had
been hospitalized or had died with possible complications related to the use of an IUD
in the preceding 6 months. Physicians were asked to check 1 or more of 8 diagnostic
categories for their patients such as complicated pregnancy, uterine perforation, and
hemorrhage. After a second mailing of the same questionnaire to physicians who had
not responded by August 1, a total of 16,994 responses (49.2%) were received
by January 2, 1974. Subsequently, a 1% probability sample was drawn from the
17,550 non-respondents; field officers were successful in obtaining information about
IUD complications from 173 of 176 practices by telephone and personal interviews.
Physicians responding by mail provided 3,502 net, unduplicated case reports
of women hospitalized in the first 6 months of 1973. After correction for the non-
respondent physicians, approximately 7,900 IUD-associated hospitalizations were es-
timated to have occurred in this period. Using an estimate by the Family Planning
Evaluation Division of approximately 3.2 million IUD wearers in early 1973, the calcu-
lated rate of IUD-related hospitalizations was 5 per 1,000 woman-years of IUD use.
While the small number of IUD-related deaths is insufficient to demonstrate an in-
creased mortality rate associated with any specific type of device, the overall rate of
IUD-related mortality appears to be low compared with the mortality rates associated
with pregnancy and other forms of contraception (1 ). Five fatalities were reported in
the 6-month study period by the 16,994 physicians who responded by mail and the
documenting details of each of these cases supported the suggestion that an IUD had
contributed to the death. Four of the 5 terminal illnesses involved severe infection; 2 of
these 4 infections involved a pregnancy. The devices used by these women were
2 Lippes Loops*, 2 Saf-T-Coils*, and 1 Dalkon Shield*. These 5 reports imply a mini-
mum IUD-related mortality rate of approximately 3 per million woman-years of use.
 *Inclusion of trade names does not imply endorsement by the Public Health Service or the
U.S. Department of Health, Education, and Welfare.
∗∗Odds Ratio  =  
( Dalkon ShieldAll Other IUDs )  pregnancy related 
( Dalkon ShieldAll Other IUDs )  not pregnancy related
**
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Of the 3,473 reports which included diagnoses, 2,932 also specified the type of IUD
involved. A relative excess of Dalkon Shield IUDs was observed among case reports
carrying the diagnosis of “complicated pregnancy” (Table 1). The crude odds ratio**
for all the cases in Table 1 is 2.1 (p<.001). Separate stratifications by the patient’s age,
race, and geographic region show a comparable elevation of the same odds ratio for
each group. When the case reports were stratified by the size of IUD, the odds ratio for
the 180 women with nulliparous-sized IUDs was not significantly different from
1.0, but was 2.0 and 2.2 for the parous (standard) and unknown sizes, respectively,
both statistically significant.
The 1% sample of non-respondent physicians who were interviewed in person or
by phone furnished 60 unduplicated case reports. The crude odds ratio for these
reports was 8.3 (p=.0049), establishing that a statistical association between the
Dalkon Shield and complicated pregnancies also existed in the experience of these
physicians.
Since the use prevalence of the various IUD types in early 1973 is unknown, it is
impossible to draw any firm conclusion about the morbidity rates associated with
each device. The magnitude of the odds ratio is influenced not only by the relatively
large number of Dalkon Shields involved in complicated pregnancies (numerator of
the odds ratio) but also by the relatively small number of Dalkon Shields involved in
complications in non-pregnant women (denominator of the odds ratio). If the Dalkon
Shield accounted for more than 41% (Table 1) of the IUDs in use early in 1973, then the
observed elevation in the odds ratio might be better explained by a relatively low rate
of hospitalizations for non-pregnant complications associated with this type of IUD.
Such a high use prevalence of the Dalkon Shield is very unlikely based on CDC’s
review of sales data furnished by the major IUD manufacturers. The relative excess of
women hospitalized with complicated pregnancies associated with the standard-sized
Dalkon Shield could possibly be explained by an elevated rate of pregnancy with this
device, by an increased rate of complications once a pregnancy is established, or by a
combination of these postulated factors.
(Reported by the Committee on Maternal and Child Care of the American Medical Association;
the American Osteopathic Association; and the Family Planning Evaluation Division, Bureau of
Epidemiology, CDC.)
Table 1
Association Between the Dalkon Shield and Complicated







Pregnancy Related   538 (53.9%)   461 (46.1%)   999 (100.0%)
Not Pregnancy Related   887 (35.9%) 1,587 (64.1%) 2,474 (100.0%)
Total 1,425 (41.0%) 2,048 (59.0%) 3,473 (100.0%)
*Table excludes 29 case reports with unknown diagnosis.
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Editorial Note—1997
Allan Rosenfield, MD, DeLamar Professor of Public Health and Obstetrics and Gynecology, and
Dean, Columbia School of Public Health. Herbert B Peterson, MD, Chief, Women’s Health and
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and Health Promotion, CDC. Carl W Tyler, Jr, MD, former Director, Family Planning Evaluation
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Since the mid-19th century when Ignaz Semmelweiss, Oliver Wendell Holmes, and
others showed that puerperal fever was both contagious and preventable, epidemiol-
ogy has been useful as an effective tool to assist in improving reproductive health.
CDC first applied epidemiology to family-planning evaluation and reproductive health
in the early 1960s when new female fertility-control measures had become available.
Oral contraceptives and plastic intrauterine contraceptive devices (IUDs) provided
promising new opportunities for family planning. CDC leaders, especially Alexander
D. Langmuir, M.D., Chief Epidemiologist, had both enthusiasm and concern about
these opportunities. Evidence for the effectiveness of the new methods of contracep-
tion was emerging, but potential adverse effects remained largely unevaluated. Of
specific concern to Langmuir was the possible relation between IUD use and pelvic
infection. Therefore, in 1964, CDC assigned Nicholas Wright, M.D., an officer in CDC’s
Epidemic Intelligence Service (EIS) program, to Grady Memorial Hospital, a public in-
stitution in Atlanta, Georgia, with a large ambulatory-care clinic and approximately
1000 beds, to investigate the safety of the IUD. Work by Wright and others determined
that women with IUDs had pelvic infections at a higher rate than expected but that
most of these women could be treated effectively and without serious complications.
A decade later, the MMWR  of June 29, 1974, raised questions about the safety of
the Dalkon Shield, an IUD marketed during 1970–1974. Both the AMA and the AOA
collaborated with CDC to conduct this survey of physicians in June 1973. Analysis of
the case reports supplied by the survey respondents showed an excess risk for com-
plicated pregnancies among Dalkon Shield users, compared with users of other IUDs
(1 ). In 1974, the manufacturer withdrew the device from the marketplace.
In 1975, CDC reported that Dalkon Shield users were more likely than users of other
IUDs to die from spontaneous abortions (2 ). Reports of mid-trimester septic abortions
associated with the Dalkon Shield hastened the passage of the Medical Device
Amendments of 1976, which gave the Food and Drug Administration (FDA) greater
control over medical devices. In 1983, CDC reported that Dalkon Shield users had a
greater risk for pelvic inflammatory disease than users of other types of IUDs and
non-IUD users (3 ). In that same year, CDC and FDA recommended that women still
using Dalkon Shield IUDs have them removed. The experience with the Dalkon Shield
has had a dramatic negative impact on the further use of IUDs in the United States and
has affected the pharmaceutical industry, physicians, and women who otherwise
might find the IUD an acceptable method of contraception (4,5 ).
IUDs, first used in Germany and Japan in the early 1900s, showed great promise
after their reintroduction in 1960 as biologically inert plastic devices (6 ). Thereafter, a
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large variety of devices were produced as manufacturers attempted to identify the
ideal device. The most important recent advance was the development of the medi-
cated devices, particularly the copper-bearing IUDs (7 ). The most commonly used IUD
in the United States today—the Copper T380A—has a low rate of side effects and is
perhaps the most effective IUD in use internationally, with a pregnancy rate of ≤1% per
year (8 ). In Europe, the levonorgestrel-releasing device also is associated with few
side effects, very low failure rates, and reduced menstrual blood flow because of intra-
uterine progestin effect (9 ). This device has not been introduced into the United
States. As a result, the only progesterone-releasing device available in the United
States requires change of the device annually and is rarely used in this country.
During the 1980s, the noncopper-bearing devices popular in the 1960s and 1970s
were withdrawn from the market for economic reasons (4 ). In 1986, manufacturers
also removed copper-bearing devices from the market—not because of new informa-
tion about risks, but because of the heavy financial burdens imposed on the manufac-
turers by issues related to liability (4 ). 
The major safety concern associated with the use of IUDs has been the risk for
developing pelvic inflammatory disease (10 ). Recent studies have suggested, how-
ever, that most cases of pelvic infection that occur with an IUD in place are attributable
to sexually transmitted diseases (STDs) (11,12 ) and that women at low risk for STDs
also are at low risk for pelvic infection while they are using an IUD. Further evidence
that the IUD is associated with low risk for pelvic infection is documented by a study
of infertility in which IUD users with one sexual partner were at no greater risk for
infertility than nonusers of the IUD (13 ). Most IUD-attributable infections appear to be
related to insertion of the device (12 ); some of these infections probably are prevent-
able with proper infection-control measures, and trials of the effectiveness of admin-
istering prophylactic antibiotics at the time of insertion are in progress.
The 1974 MMWR  and subsequent reports by CDC identified an increased risk for
infectious morbidity related to use of an IUD that is no longer marketed. Subsequent
epidemiologic studies of the safety of currently available devices indicate that women
at low risk for STDs are at low risk for pelvic infection with IUD use. 
In the United States, nearly 60% of pregnancies are unintended (14 ), and many
women wanting to prevent unintended pregnancy are appropriate candidates for IUD
use. Despite evidence that the long-term effectiveness of the Copper T380A device is
similar to that of tubal sterilization (15,16 ), <1% of women using contraceptives in
1995 were using this device (17 ). Among the small number of women using IUDs,
however, acceptance of this method is high: in 1992, for example, 96% of IUD users
viewed their method favorably, compared with 94% of oral contraceptive users,
93% of those who chose male or female sterilization, 76% of diaphragm users, and
74% of rhythm methods users (18 ). Women desiring long-term effective contracep-
tion and their clinicians should be aware that currently marketed IUDs are highly effec-
tive and acceptable and are associated with a low risk for complications in women at
low risk for STDs.
In addition to highlighting the commemoration of CDC’s 50th anniversary, reprint-
ing this 1974 MMWR  coincides with and highlights the 30th anniversary of
CDC’s Division of Reproductive Health. In 1967, the Family Planning Evaluation Activ-
ity (FPEA)—which authored the 1974 report—was established in CDC’s Bureau
of Epidemiology, becoming one of CDC’s earliest noninfectious disease program
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areas. The FPEA began with only four staff members; today, the staff consists of
160 members in what is now the Division of Reproductive Health, part of CDC’s
National Center for Chronic Disease Prevention and Health Promotion. In 1970, the
FPEA became the Family Planning Evaluation Division, and the division quickly
became a focus of excellence within CDC, helping to introduce and disseminate fur-
ther the concepts of analytic epidemiology eventually adapted by acute/infectious dis-
ease programs. From 1967 (when the division first assigned EIS officers to evaluate
family-planning programs in state health departments) to the present, the links be-
tween the division and the EIS have been crucial at CDC in helping to introduce CDC’s
methods of applied/field epidemiology to the challenges of reproductive health, both
nationally and internationally. The three decades of history of the division reflect the
creative and effective use of epidemiology for the promotion of reproductive health.
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Acute Childhood Leukemia — Columbus, Ohio
Childhood Cancer MMWR 1976;25:77–8 (March 19, 1976)
From August–October 1975, 8 cases of acute leukemia were diagnosed at Colum-
bus Children’s Hospital in Columbus, Ohio, in children living in that city. During any
consecutive 3-month period in 1972–1974, the greatest number of cases of acute leu-
kemia diagnosed at this hospital in Columbus children was 4 (Figure 1).
To evaluate this cluster of illness, all cases of acute leukemia diagnosed at Colum-
bus Children’s Hospital in 1972–1975 were reviewed with respect to age, race, sex,
type of leukemia, date of diagnosis, and residence in and outside of Columbus
(Table 1). The hospital provides care for most children with leukemia in Columbus and
for many such patients from surrounding areas. In the 3-year period 1972–1974, an
average of 5.3 cases of acute childhood leukemia were seen each year among Colum-
bus residents (the expected number is 6.1, based on age-specific rates from the Third
National Cancer Survey [1 ]). Over the 4-year period 1972–1975, 107 cases were seen,
28 among Columbus residents. Both Columbus and non-Columbus patients in 1975
were somewhat older and included relatively more females than in earlier years. Case

































































FIGURE 1. Acute Leukemia, Columbus Children’s Hospital, 1972–1975 — by Place of
Residence and Date of Diagnosis
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Twelve cases were diagnosed in Columbus residents in 1975, compared with a total
of 16 for all 3 preceding years. To assess the possibility of time-space clustering
among Columbus cases over the entire 4-year period a statistical analysis was per-
formed using the procedure devised by Knox (2 ). No statistically significant clustering
was found; 13 case-pairs were observed in which dates of diagnosis were less than
1 year apart and places of residence 1 mile or less apart, whereas 14.4 pairs were to be
expected on a random basis. Inspection of the 1975 case data showed no geographic
clustering and no obvious community or family interrelationships among cases. No
evidence of seasonal periodicity was found on statistical testing by month of diagno-
sis for pooled data from all 4 years.
Reported by I Ertel, MD, W Newton, MD, Children’s Hospital, Columbus, Ohio; TJ Halpin, MD,
MPH, State Epidemiologist, Ohio Department of Health; Field Services Div and Cancer and Birth
Defects Div, Bur of Epidemiology, CDC.
Editorial Note: The question of time-space clustering among cases of leukemia and
lymphoma has received considerable epidemiologic attention, particularly in connec-
tion with hypotheses regarding the possible viral etiology of cancer. While no
evidence has been found of statistically significant time-space clustering among adult
cases, several studies have suggested such a tendency among cases of childhood
acute leukemia (2–5 ). The significance of such observations remains unclear. In the
present investigation no evidence, statistical or otherwise, was found to suggest that
the recent case cluster in Columbus might be due to factors other than chance. Further
investigations of such clusters may be desirable, however, as a potential source of
clues regarding the etiology of childhood tumors.
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TABLE 1. Acute Leukemia, Columbus Children’s Hospital, 1972–1975 — By Age, Sex,







Total number of cases 16 57 12 22
Mean age at diagnosis    4.5    5.4    7.0    6.5
Sex:  Male 10 33  5 11
    Female  6 19  7 11
Race: White 13 55  9 21
    Black  3  2  0  1
    Other  0  0  1  0
    Unknown  0  0  2  0
Leukemic Cell Type:
 Myelocytic  3 11  3  4
 Monocytic  2  2  0  0
 Lymphocytic or Stem Cell 11 44  9 18
114 NONINFECTIOUS CONDITIONS
3. Till MM, Hardesty RM, Pike MC, et al: Childhood leukaemia in greater London: A search for
evidence of clustering. Br Med J 3:755–758, 1967
4. Gunz FW, Spears GFS: Distribution of acute leukaemia in time and space. Studies in New Zea-
land. Br Med J 4:604–608, 1968
5. Evatt BL, Chase GA, Heath CW, Jr: Time-space clustering among cases of acute leukemia in
two Georgia counties. Blood 41:265–272, 1973
Burkitt’s Lymphoma — Winchester, Virginia
MMWR 1976;25:173 (June 11, 1976)
Three cases of Burkitt’s lymphoma (BL) have occurred since 1971 in young boys
living in one residential section of Winchester, Virginia. Onset of illness in the first
2 cases (ages 9 and 15) occurred simultaneously in August 1971 (1 ); the third patient
(age 8) first became ill in July 1975.
The first 2 patients lived 2 houses apart and the third one-half mile away. None
of the 3 patients or their families was acquainted or shared common community
activities, although all 3 boys had attended the same grade school at different times.
All 3 patients were Caucasian.
Manifestations of disease were similar in all 3 cases. Initial symptoms in each case
involved persistent sore throat progressing to peritonsillar masses in the first 2 cases
and to cervical adenopathy in the third. Histologic diagnosis of BL was made on bi-
opsy of these masses and was confirmed on pathologic review at the National Cancer
Institute. Marrow aspiration was suggestive of leukemic transformation in the third
case, but not in the first 2. In each case there was clinical evidence of central nervous
system (CNS) tumor involvement. Despite intensive chemotherapy in all 3 cases, and
radiation therapy in 2, disease was unremitting and led to death 1, 4, and 7 months
after initial diagnosis. Autopsy findings in the first 2 cases showed widespread tumor
involving the CNS, as well as cervical and abdominal lymph nodes. In the third case,
autopsy showed residual tumor only at the original site of occurrence (the neck).
Serum antibody against Epstein Barr virus (EBV) was present at low titers in 2 cases.
Epidemiologic investigation revealed no clues to suggest a possible common etiol-
ogy for these cases beyond their closeness in time and place of occurrence. Although
the summers of 1971 and 1975 had somewhat greater rainfall than other years, no
evidence was found to link the cases to increased mosquito or other insect exposures.
No unusual local patterns of leukemia, lymphoma, or infectious mononucleosis inci-
dence were found, and no other persons with childhood cancer were identified as
having been in contact with the patients or being in their particular neighborhood.
Reported by N McWilliams, MD, Medical College of Virginia; W Hatfield, MD, Lord Fairfax Health
District; R Jackson, MD, State Epidemiologist, Virginia State Dept of Health; and Cancer and
Birth Defects Div and Field Services Div, Bur of Epidemiology, CDC.
Editorial Note: Burkitt’s lymphoma is extraordinarily rare outside certain parts of cen-
tral Africa and New Guinea where it constitutes the most common tumor of childhood
(2 ). Epidemiologic surveys of childhood cancer in the metropolitan areas of Atlanta,
Georgia, and Houston, Texas, suggest that the annual incidence of BL in the United
States is in the range of about 1 case per million children, or an expected incidence of
about 1 case every 200 years for a town the size of Winchester. In this context, the
occurrence of 3 cases over 5 years in one neighborhood is distinctly unusual.
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The etiologic significance of such case clustering is not clear. While early studies of
African BL suggested that time-space case clustering was a common feature of the
disease (3 ), more recent epidemiologic work has cast doubt on the idea (4 ). Current
evidence suggests that the etiology of African BL may be related to EBV infection in a
host whose immunologic state has been severely affected by constant and severe
malarial infections (5 ). The present cases, however, provide no obvious clinical or
epidemiologic clues regarding their particular etiology.
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Editorial Note—1997
Clark W Heath, Jr, MD, Vice President for Epidemiology and Surveillance Research, American
Cancer Society, Atlanta, and former Director, Division of Chronic Diseases, Center for Disease
Control. Glyn G Caldwell, MD, Clinical Coordinator, Indiana Medical Review Organization, Indian-
apolis, and former Chief, Cancer Branch, Bureau of Epidemiology, Center for Disease Control.
Public concern can quickly rise when persons perceive an excess of cancer in their
local community. Such situations are not infrequent. Each deserves prompt public
health attention to address community concerns and to explore possible etiologic
clues. However, it is difficult to know when field investigations are needed and how far
they should proceed. The problem is neither new nor unique to cancer because similar
concerns arise about other chronic or noninfectious diseases. Cases can cluster sim-
ply by chance, and random case distributions probably account for most community
case clusters. It is possible that certain clusters may have community-based causes,
possibly resulting from particular patterns of infectious disease occurrence or from
environmental exposures. Although methodologic problems greatly limit the explora-
tion of such possibilities, carefully designed field investigations in selected situations
should be considered (1,2 ).
Reports of such investigations about cancer clusters have appeared in MMWR. The
two reports reprinted in this issue illustrate the diversity of analytic approaches that
have been used, as well as the uncertainty of conclusions. Both of these investigations
involved collaborative efforts between CDC (the Chronic Diseases Division and
the Field Services Division) and local/state medical and public health authorities.
In the case of acute childhood leukemia in Columbus, Ohio (3 ), concern was for dis-
ease frequency in the city as a whole after eight cases were diagnosed during a
3-month period—twice the maximum number seen before. However, after further
investigation, no features were observed that distinguished these cases from others,
and a statistical analysis of time-space closeness indicated no evidence of unusual
clustering.
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The appearance of Burkitt’s tumor in Winchester, Virginia, presented a different
problem (4 ). This particular cancer is rare outside central Africa and New Guinea, and
the two initial cases occurred in children whose diagnoses were simultaneous and
who lived only two doors apart. The third patient, diagnosed 4 years later, lived
nearby. Although no other links were found among the three cases, the rareness of the
tumor, the time-space closeness of the first two cases, and the recurrent pattern sug-
gested by the third case required consideration of alternate explanations to that of a
chance event.
Interest in cancer case clusters has been evident in the medical literature since the
late 19th century. Leukemia has received particular attention, perhaps because clus-
ters suggest infectious disease outbreaks and because white cell elevations are asso-
ciated with infection. The focus on leukemia intensified in the 1960s when tumor
virologists, after demonstrating that leukemia viruses exist in other species, initiated
an extensive search for such viruses in humans. During the 1960s and 1970s, CDC
played a prominent role in that search by working closely with the National Cancer
Institute in field investigations of leukemia case clusters. One of the earliest of these
investigations involved eight cases of childhood leukemia in the Chicago suburb of
Niles, Illinois (5 ). Seven of those cases were associated with one particular school
where a parallel pattern of rheumatic-like illness had simultaneously appeared. The
neighborhood was newly created, a situation later recalled when observations con-
cerning a childhood leukemia cluster in the United Kingdom (UK) suggested that risk
might be heightened in newly established communities (6 ).
Epidemiologic work continued at CDC into the 1980s, with several field investiga-
tions conducted each year in cooperation with various local and state health depart-
ments (7 ). Most studies involved time-space clusters of childhood leukemia cases in
residential communities; however, some work involved adult leukemias, cancers of
other types in both adults and children, multiple-case families, associations between
human and animal cancers (i.e., pets and farm animals), and cancers occurring within
acquaintance networks (e.g., former school mates). In addition, occasional situations
were studied in which case clusters involved congenital malformations or chronic
neurologic disease. Over time, emphasis gradually moved away from infectious dis-
ease hypotheses and increasingly focused on environmental exposures (e.g., hazard-
ous waste sites, water pollution, and ionizing radiation).
In recent years, interest has been revived about clusters of childhood leukemia in
residential communities. Much of the impetus has come from studies in the UK where
a cluster of five cases occurred in a small town affecting children of men employed at
a nearby nuclear fuel-reprocessing plant. Extensive epidemiologic studies confirmed
this local increase in incidence and suggested a possible relation to increased paternal
exposure to low levels of ionizing radiation in the workplace before the children were
conceived (8 ).
Although studies in other human and experimental settings have not confirmed
this association, nationwide studies of childhood leukemia in the UK have suggested
that risk may be increased in newly settled towns, such as the one near the nuclear
reprocessing plant. This observation has led to the hypothesis that infectious disease
patterns among children in such new towns may be less stable than in more settled
communities and may, on occasion, be reflected in unusual patterns of childhood leu-
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kemia as a rare sequel to certain infections (6 ). Again, this concept recalls the earlier
Niles, Illinois, experience.
Despite frequent attention over the years to individual cancer case clusters and
despite the various hypotheses generated, there has been no instance yet where a
biologic cause for clustering has been convincingly demonstrated. In the rare instance
when causation has been proven from studies of small groups of cases (9 ), virtually
all have involved rare tumors in occupational settings where exposures were high and
where reasonable evidence existed to establish individual exposure levels. The most
striking example involved vinyl chloride monomer exposures causing hepatic
angiosarcomas in vinyl chloride polymerization workers (10,11 ). No comparable set
of data can be cited for exposures hypothesized in residential settings.
There are clear reasons why community cluster studies are generally inconclusive.
When known carcinogens are in question (either chemicals or ionizing radiation),
exposures are usually very low. Many situations, however, focus on exposures, such
as nonionizing radiation, for which firm evidence of carcinogenicity is lacking at any
dose. Studies also are limited by the long and irregular latency of cancer, the clinical
nonspecificity of cancer cases (e.g., our inability to assign specific causes to individual
cases), and the relative rareness of disease at any one point in time, resulting in very
small numbers on which to base epidemiologic analyses. Nonetheless, public health
departments must respond in some manner when cancer case clusters come to their
attention. The first step is to respond quickly and openly so that communication with
community residents is effective and concerns are not neglected. The second step
is to confirm the accuracy of reported diagnoses and to compare the number of
observed cases with the number to be expected. Often investigations need go no fur-
ther. If more work is needed, however, the next step is either to interview affected
patients or their families in search of common life features or to design and conduct a
more formal epidemiologic study, usually a case-control design. Here the work may
not be worth the effort unless a reasonable etiologic hypothesis exists or community
concern is exceptionally high. The methodologic difficulties become all too apparent,
especially the weakness of such studies, limited as they are by very small numbers.
Environmental studies also should be approached with caution because of their weak-
ness in establishing clear case-exposure relations and because of their great expense.
Despite these analytic limitations, cancer case clustering deserves research atten-
tion. With the possibility of molecular marker techniques, which in the future may help
determine the etiologies of individual cancer cases, it may be possible to conduct use-
ful studies of selected clusters, whether the hypotheses are infectious or environ-
mental. Still, the rarity of nonchance clusters must always be considered. Area-wide
statistical techniques designed to measure the degree to which cases may cluster in
time and space have failed to document any consistent tendency, except perhaps in
childhood cancers (12–14 ). If further knowledge is to develop in this difficult area of
public health practice, it is among childhood cancers that work should focus (15 ).
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Infant Metabolic Alkalosis and Soy-Based Formula — United States
Infant Metabolic Alkalosis MMWR 1979;28:358–9 (August 3, 1979)
Three cases of a Bartter-like syndrome in infants were reported to CDC from Mem-
phis, Tennessee, on July 26, 1979. The infants were less than 10 months of age and
were failing to gain weight. They had poor appetites, and one had a history of consti-
pation. All were hypochloremic and hypokalemic, with varying degrees of alkalosis
and microhematuria. The 3 infants were taking the same brand of soy-based formula.
To further investigate this possible association, CDC surveyed a sample of pediatric
nephrologists throughout the country for cases of metabolic alkalosis diagnosed since
January 1, 1979, in infants with a history of failure to thrive, anorexia, or constipation.
Infants known to have pyloric stenosis, cystic fibrosis, or diuretic therapy were ex-
cluded.
An additional 15 cases were ascertained through the survey, and another 16 cases
were determined from other sources. Cases were scattered throughout the country.
The infants ranged in age from 2 to 9 months; none died. There was no unusual sex
distribution.
Feeding history was available in 27 of the 31 cases. Of these, 26 were on Neo-Mull-
Soy (Syntex, Palo Alto, California), the same formula used by the 3 index cases. Neo-
Mull-Soy represents 10%–12% of the soy-based formula market. After diagnosis of the
alkalosis, infants who were placed on chloride supplement responded favorably;
those who, after treatment for and recovery from the alkalosis, went back on the
formula—but without chloride supplementation—had a recurrence.
The manufacturer of Neo-Mull-Soy has voluntarily stopped manufacturing this
product, halted its distribution to wholesalers, and requested that wholesalers stop
sales to retailers. Syntex has also issued a mailgram to pediatricians and pediatric
residents notifying them of the problem.
Reported by: JS Levy, MD, Memphis-Shelby County Health Dept, Memphis, Tennessee; S Roy,
MD, Memphis; RH Hutcheson Jr, MD, State Epidemiologist, Tennessee State Dept of Public
Health; AB Gruskin, MD, Philadelphia, Pennsylvania; S Hellerstein, MD, Kansas City, Missouri;
M Linshaw, MD, Kansas City, Kansas; S Alexander, MD, JD Liberti, MD, Portland, Oregon;
H Harrison, MD, Louisville, Kentucky; G Lum, MD, Denver, Colorado; LJ Cunningham, MD,
Galveston, Texas; EH Garin, MD, Gainesville, Florida; Div of Nutrition, Bur of Foods, Food and
Drug Administration; Birth Defects Br, Chronic Diseases Div, Bur of Epidemiology, CDC.
Editorial Note: Bartter syndrome is characterized by hypochloremic, hypokalemic
alkalosis; normal blood pressure; and increased serum levels of renin and aldos-
terone. The onset is usually during the first year of life. The pathogenesis is not
known.
The high percentage of affected infants on Neo-Mull-Soy formula and the fact that
infants who were switched to other soy formulas did not have recurrence both sup-
port the casual association between Neo-Mull-Soy formula and this outbreak.
Insufficient intake of chloride is a known cause of metabolic alkalosis. The cause of
this outbreak is not yet clear, but it is possible that the chloride concentration in this
formula falls below the daily requirement for infants, if they are not also receiving
chloride from other dietary sources. The current tendencies to delay the addition of
solids to infants’ diets and to remove sodium chloride from commercial and home-
prepared baby foods might be additional contributing factors.
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There are no regulations pertaining to the optimal level of chloride in infant formu-
las. The Committee on Nutrition of the American Academy of Pediatrics recommends
a minimum of 11 milliequivalents per liter in infant formula (1 ).
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At the time of this cluster of cases of hypochloremic metabolic alkalosis, infant for-
mula was regulated under 21 CFR 105.65, Infant Foods. This regulation specified
minimum levels of certain nutrients for infant formulas, including protein, fat, and
some vitamins and minerals; a level for chloride was not specified. If the specified
levels of nutrients were not present in the formula, the label was required to state that
the diet should be supplemented. The incident described in this report prompted the
Infant Formula Act of 1980*—the amendment of the federal Food, Drug, and Cosmetic
Act that established a new section 412 (21 U.S.C. 350a) and created a separate cate-
gory of food designated as infant formula. Section 412 requires that infant formulas
meet specified standards of quality and safety and contain all required nutrients, in-
cluding chloride, at specified levels. The Infant Formula Act of 1980 was the first in a
series of major legislative and regulatory steps taken to ensure the safety of infant
formulas
†
 (1,2 ). 
This episode underscores the need for regular and adequate testing of infant for-
mulas. Several events may have contributed to the formula chloride deficiency,
including removal of sodium chloride from the formula for the purpose of reducing
the sodium content of infant diets. The cummulative effect of these contributing
events led to a deficiency that was not recognized because regular testing for chloride
content was not conducted.
In follow-up to the investigation in 1979, CDC established a registry of children who
developed hypochloremic metabolic alkalosis following consumption of chloride-
deficient Neo-Mull-Soy and Cho-Free, another soy-based formula manufactured by
Syntex. Based on these data, the National Institutes of Health conducted a follow-up
study to determine whether the risk for developmental delays or deficiencies was in-
creased in these children (3 ). The study determined that by age 9–10 years, the chil-
dren appeared to have recovered from their early growth failure and to have achieved
normal cognitive development. However, these children remained at potential risk for




This investigation highlights the critical importance of developing and using appro-
priate case definitions for surveillance and in investigations of outbreaks of both infec-
tious and noninfectious origin. The original diagnosis of these cases was Bartter
syndrome, a condition that causes metabolic alkalosis from renal loss of potassium
and requires a large replacement dose of potassium chloride throughout life to main-
tain metabolic homeostasis. The children who had hypochloremic metabolic alkalosis
as the result of consuming chloride-deficient formula quickly recovered following
treatment with small doses of potassium chloride. This clinical response provided a
clue to the physician who reported the first three cases that the formula might be the
cause of the metabolic alkalosis. As a result, CDC’s survey of pediatric nephrologists
was used to search for cases of metabolic alkalosis resembling Bartter syndrome,
rather than confirmed cases of that condition. If the case definition in this survey had
been restricted to Bartter syndrome only, the association may not have been detected.
The outbreak described in this report highlights the value of a rapid response capa-
bility for local and state health departments and the Public Health Service and the
important role played by clinicians in identifying public health emergencies. The
sequence of problem recognition, investigation, and response unfolded rapidly: on
July 26, 1979, CDC was notified of the three cases from Memphis and of the causal
hypothesis related to infant formula as suggested by the attending physician. On July
27, two of CDC’s Epidemic Intelligence Service (EIS) officers reported for their first day
of work on assignment to CDC’s Birth Defects Branch and assisted in developing a
strategy for collecting information about feeding histories of children with metabolic
alkalosis. On July 30, the nationwide survey of pediatric nephrologists was conducted.
On August 1, one EIS officer traveled to the manufacturer’s corporate headquarters to
meet with company officials and three pediatricians. The company tested several for-
mula batches before the meeting and found that none contained sufficient chloride.
On August 2, after meeting with representatives of the Food and Drug Administration,
the company halted manufacture of the formulas, initiated a voluntary recall of the
products, and notified health-care professionals throughout the country about the
problem. The MMWR  article describing the occurrence was released to the news me-
dia that same day, only 7 days after CDC received notification of the first three cases
from Memphis.
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Temporal Trends in the Incidence of Birth Defects — United States
Birth Defects MMWR 1979;28:401–2 (August 31, 1979)
Through CDC’s Birth Defects Monitoring Program (BDMP), a total of 161 categories
of birth defects are analyzed quarterly to determine increases or other unusual trends.
Sixteen of these malformations have been selected for review in this report because
they occur in sufficient numbers to provide relatively stable rates, the coding catego-
ries for them are relatively homogenous, and they represent defects of different organ
systems.
Data on the incidence of these 16 malformations in the United States in 1970-1971
and in 1976-1977 were compared, and the geometric mean percentage change in rates
that occurred in the 6-year interval between these periods was calculated (Table 1). Six
malformations changed an average of 5% or more per year. Anencephaly and spina
bifida—2 of the most common, serious, and easily diagnosable defects—decreased
5.4% and 6.7% per year, respectively (Figure 1). The cause of this decrease is un-
known.
The reported incidence of ventricular septal defect doubled, and that for patent
ductus arteriosus tripled (Figure 1). A substantial search for the cause of these in-
creases was done in the greater Atlanta area, but it could not be determined whether
these increases were due to biologic factors or reporting methods (1,2 ).
The incidence of congenital hip dislocation (without central nervous system
anomalies) increased an average of almost 25% per year. Part of the increase was
artifactual: a coding change in 1974 assigned hip dysplasia to the hip dislocation
category. In addition, the diagnosis of this defect lacks clear, reproducible criteria.
Changes in the manner of newborn examinations can, therefore, make substantial
changes in reported incidence.
The reported incidence rate of renal agenesis increased an average of 9.7% per
year. This increase—as yet unexplained—is under investigation.
Reported by Birth Defects Br, Chronic Diseases Div, Bur of Epidemiology, CDC.
Editorial Note: The BDMP is conducted by CDC’s Birth Defects Branch with data pro-
vided under contract by the Commission on Professional and Hospital Activities
(CPHA) in Ann Arbor, Michigan. BDMP’s primary purpose is to monitor the incidence
of birth defects and other newborn conditions. Abstracts of hospital discharge sum-
maries are coded by medical records staff from participating hospitals and submitted
regularly to CPHA for data processing. CPHA uses some of the data on newborns to
produce monitoring reports and other tabulations; these are sent to CDC for analysis.
Since 1970, the tabulations have covered the births of 8 million infants. The present
annual number of births covered, from 1,130 hospitals, is 975,000—about one-third of
the births in the country.
The advent of new means for the prevention of birth defects or of a widespread
exposure to a powerful new teratogen would likely be followed by substantial
changes in the incidence of birth defects. Rh hemolytic disease, for example,
decreased following the widespread availability and use of rhesus immune globulin
(RhIG) (3 ). In the period covered in this report, the incidence of the majority of birth
defects neither substantially decreased nor increased. The paucity of decreasing rates
indicates the need for discovering and implementing prevention strategies for birth
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defects—the cause of nearly 20% of infant mortality in the United States. The paucity
of increases suggests that few, if any, widespread and powerful new teratogens were
introduced. The possibility of such an introduction requires continuing surveillance of
the incidence of birth defects in the United States.
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TABLE 1. Incidence of selected malformations reported to the Birth Defects Monitoring
Program, 1970-1971 and 1976-1977
Malformation
Cases Rates* Mean annual
percent change1970-1971 1976-1977 1970-1971 1976-1977
Anencephaly   949   833  5.48  3.94 – 5.4
Spina bifida without
anencephaly 1,306 1,053  7.55  4.97 – 6.7
Hydrocephalus without
spina bifida   833   925  4.81  4.37 – 1.6
Transposition of great vessels   131   175  0.76  0.83 + 1.5
Ventricular septal defect   770 1,889  4.45  8.92 +12.3
Patent ductus arteriosus   686 2,804  3.96 13.25 +22.3
Cleft palate without
cleft lip   873 1,093  5.05  5.16 + 0.4
Cleft lip with or without
cleft palate 1,715 1,890  9.91  8.93 – 1.7
Clubfoot without
CNS†  defects 4,756 4,912 27.49 23.21 – 2.8
Reduction deformity   547   705  3.16  3.33 + 0.9
Hip dislocation without
CNS defects 1,382 6,407  7.99 30.27 +24.9
Tracheo-esophageal fistula   289   327  1.67  1.54 – 1.3
Rectal atresia and stenosis   648   679  3.75  3.21 – 2.6
Renal agenesis   123   263  0.71  1.24 + 9.7
Hypospadias 3,565 5,036  40.02‡  46.22‡ + 2.4
Down’s syndrome 1,413 1,590  8.17  7.51 – 1.4
*Cases per 10,000 total births.
†Central nervous system.
‡Cases per 10,000 male births.
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*Rates per 10,000 total births.
FIGURE 1. Trends in reported incidence* of 4 birth defects reported to the Birth
Defects Monitoring Program, by quarter of birth, January 1970 through June 1978
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Editorial Note—1997
Godfrey P Oakley, MD, Director, Division of Birth Defects and Developmental Disabilities, Na-
tional Center for Environmental Health, CDC.
Birth defects are the leading cause of infant mortality in the United States  (1,2 ),
and 18 of the most common birth defects account for annual expenditures of $8 billion
(2 ). Even though the prevention of birth defects improves the health of children, pre-
vention efforts have been hampered because the specific causes of most (75%) are
unknown. CDC’s involvement in the surveillance for birth defects began in late 1967
when Clark Heath, M.D., Chief of the Leukemia Section, Viral Diseases Branch,
Epidemiology Program, and Epidemic Intelligence Service Officer Allan Ebbin, M.D.,
with the support of CDC Chief Epidemiologist Alexander Langmuir, M.D., and Arthur
Falek, M.D., and Suzanne Schimpler of the Georgia Mental Health Institute, estab-
lished birth defects surveillance in metropolitan Atlanta (3 ). This local surveillance
program provided not only excellent surveillance data but also the foundation on
which CDC built a group of public health scientists dedicated to determining the
causes of birth defects and to preventing birth defects.
One purpose of birth defects surveillance is to provide an early warning of an
“emerging” birth defects problem. Moreover, an important rationale for birth defects
surveillance is that appropriate surveillance programs might have enabled more rapid
identification of the birth defects associated with maternal use of thalidomide in
Europe during the late 1950s and early 1960s and, thereby, might have contributed to
a more timely ending of that tragic epidemic. However, subsequent epidemics of birth
defects cannot be predicted, and a single local surveillance system, while providing
useful information about exposures that are distributed relatively equally throughout
the country, cannot provide data about other regions. For these reasons, in the early
1970s, Virginia Apgar, M.D., and her colleagues at the March of Dimes/Birth Defects
Foundation articulated the need for a national birth defects surveillance system. After
discussions with Dr. Apgar and her colleagues, CDC’s William Flynt, M.D., with fund-
ing from the National Institute for Child Health and Human Development, established
the national BDMP in 1973 (4 ).
In the August 31, 1979, issue of MMWR, BDMP rates for 16 birth defects during
1970–1971 were compared with those during 1976–1977; the results indicated that the
reported rates for most birth defects were stable, although rates for some were either
increasing or decreasing. These findings indicated that the epidemiologies of various
birth defects can be as different as the varying epidemiologies of different infectious
diseases. The figure presented in the 1979 MMWR  showed declines in the rates of
spina bifida and anencephaly—two common and severe birth defects with many simi-
lar epidemiologic findings. These declines were consistent with improvement in the
environment (e.g., improved nutrition and fewer exposures to harmful chemicals).
During the weeks surrounding publication of the 1979 MMWR,  CDC staff members
learned of a study in England suggesting that one or more vitamins might prevent
spina bifida and anencephaly (5 ). At the same time, CDC’s David Erickson, D.D.S., and
colleagues were designing the Atlanta birth defects case-control study to assess the
increased risk for birth defects among children of Vietnam veterans (6 ); the design
included questions about the mothers’ use of vitamins before and during the early
weeks of pregnancy. Findings of this study included a strong association between
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regular maternal consumption of multivitamins before and during early pregnancy
and a reduction in risk for having a child with spina bifida and/or anencephaly (7 ).
In 1991, the results of a randomized clinical trial from the United Kingdom estab-
lished that folic acid was the specific vitamin associated with prevention of spina
bifida and anencephaly (8 ). Following publication of those results, the CDC birth de-
fects group assisted in fostering a science-based public policy for this “emerged” pre-
vention opportunity. In particular, CDC guidelines for high-risk women (i.e., those with
a previous spina bifida- or anencephaly-affected pregnancy) were published in
MMWR  2 weeks after the publication of the randomized clinical trial (9 ). Findings of
earlier case-control studies (7 ) supported the Public Health Service (PHS) recommen-
dation published September 11, 1992, that all women of reproductive age consume
400 µg of folic acid each day to prevent neural tube defects (10 ). In the United States,
these two recommendations have served as the foundation for intervention programs
subsequently implemented by industry, public health organizations, and voluntary
agencies (e.g., the March of Dimes Birth Defects Foundation and the Spina Bifida As-
sociation of America). In 1996, the Food and Drug Administration issued regulations
that required “enriched” cereal-grain products to be fortified with folic acid no later
than January 1, 1998 (11 ). As a result of this fortification, the consumption of folic acid
by U.S. women will increase by 100 µg per day.
Birth defects surveillance data are important in evaluating the effectiveness of pre-
vention programs. The BDMP was discontinued during the mid-1990s because of
changing technology, but was replaced by a network of state-based surveillance sys-
tems. In 1992, Congress mandated that CDC establish such a network to collect, ana-
lyze, and share data needed to prevent birth defects. By 1996, CDC assistance to states
had included the establishment of the National Birth Defects Prevention Network
(NBDPN), with a mission of creating and maintaining a national network of state- and
population-based programs for birth defects surveillance and research. These pro-
grams assess the impact of birth defects on children and families; identify factors that
can be used to develop primary prevention strategies; and assist families and their
health-care providers in secondary prevention of disabilities. NBDPN recently re-
ported on data from 21 states (12 ). These surveillance systems will be used to assist
health officials in assessing efforts to prevent folic acid-preventable birth defects and
in providing surveillance data for etiologic research. 
State-based birth defects surveillance systems have not yet detected changes
in the rates of spina bifida and anencephaly. Conversely, surveys of folic acid con-
sumption indicate that approximately 45 million women of reproductive age still do
not consume sufficient folic acid to protect the children they may have from neural
tube defects (13 ). During the next 10 years, additional programs to increase the
amount of folic acid consumed by women of reproductive age could result in the pre-
vention of most folic-acid preventable spina bifida.
In 1996, CDC intensified efforts to prevent birth defects by establishing a new pro-
gram comprising eight Centers for Birth Defects Research and Prevention (CBDRP).
These eight centers collaborate in epidemiologic studies to provide a timely, continu-
ing source of information on potential causes of birth defects. Each center also will
maintain center-specific, investigator-initiated research projects. This new program
should assist in advancing the prevention of birth defects by identifying modifiable
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causes of birth defects, just as earlier epidemiologic studies identified folic acid as the
agent that can prevent serious birth defects in thousands of children each year.
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Smoking-Attributable Mortality and Years of Potential Life Lost —
United States, 1984
Smoking-Attributable Mortality MWR 1987;36:693–7 (October 30, 1987)
Cigarette smoking has been identified as the chief avoidable cause of death in the
United States (1 ). Several estimates of mortality attributable to cigarette smoking
have been reported, including 270,000 deaths for 1980 (2 ) and 314,000 deaths for 1982
(3 ). Published estimates vary considerably because of changing mortality rates, de-
creasing smoking rates, and differences in methods used. Smoking-attributable mor-
tality and years of potential life lost (YPLL) for 1984 are analyzed in this report.
Relative risk (RR) estimates for smoking-related diseases and prevalence estimates
of current, former, and never smokers among adults ≥20 years of age were used to
calculate the smoking-attributable fraction (SAF) and smoking-attributable mortality
for 19 underlying causes of death (2 ) (Table 1).* Age-, sex-, and race-specific mortality
data for 1984 were obtained from National Center for Health Statistics reports. Age-,
sex-, and race-specific smoking prevalence rates were obtained from the 1985 Current
Population Survey (Supplement) of the Bureau of the Census (Office on Smoking and
Health, CDC, unpublished data). Years of potential life lost were calculated to age
65 according to previously described methods (6 ). Age-adjusted smoking-attributable
mortality and YPLL rates were calculated by the direct method, with the 1984 U.S.
population used as the standard.
For deaths among adults, the disease-specific SAFs are derived from RR estimates
for current and former smokers that are weighted averages from four prospective
studies (7–10 ). RR estimates for women based on these studies may be lower than the
current RRs for many of the specific smoking-related diseases among women. How-
ever, the SAF for lung cancer among women (0.75) has been updated based on RR
estimates from more recent mortality data (11 ). Race-specific RR estimates for
smoking-attributable diseases were not available.
For four pediatric diagnoses, the mortality attributed to maternal smoking during
pregnancy for children <1 year of age was determined. These calculations used RR
estimates from McIntosh (12 ) and current smoking prevalence among women
20–64 years of age as a proxy for the percentage of pregnant women who smoke. The
RR (1.50) for sudden infant death syndrome from McIntosh (12 ) was used, but the RR
(1.76) for total infant mortality reported by McIntosh was used to calculate the SAF for
only three specific infant death categories (short gestation/low birthweight, respira-
tory distress syndrome, and other respiratory conditions).
An estimated 315,120 deaths and 949,924 YPLL before age 65 years resulted from
cigarette smoking in 1984 (Table 2). The smoking-attributable mortality rate among
men is more than twice the rate among women, and the rate among blacks is 20%
higher than the rate among whites (Table 3). The smoking-attributable YPLL rate
*The equation for calculating the smoking-attributable fraction of each disease category is:
SAF=[p0 + p1(RR1) + p2(RR2)] - 1/[p0 + p1(RR1) + p2(RR2)] where p0=percentage of never smokers,
p1=percentage of current smokers, p2=percentage of former smokers, RR1=relative risk for
current smokers (relative to never smokers), and RR2=relative risk for former smokers (relative
to never smokers) (4 ). This formula is derived from the standard attributable risk (AR) formula
(5 ): AR=p(RR - 1)/[p(RR - 1) + 1].
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among men is more than twice the rate among women, and the rate among blacks is
more than twice the rate among whites (Table 3).
Reported by: Office on Smoking and Health, Center for Health Promotion and Education, CDC.
Editorial Note: The total smoking-attributable mortality and YPLL reported here is
similar to that cited in previous reports (2,3 ), showing that the disease impact of
TABLE 1. Total mortality, weighted smoking-attributable fractions (SAF), and




 SAM†Disease Category* Deaths SAF SAM Deaths SAF SAM
Adults ≥20 years old
Neoplasms:
140-149 Lip, oral cavity, pharynx  5,754 0.688  3,958  2,689 0.413  1,110  5,068
150 Esophagus  6,310 0.589  3,717  2,345 0.536  1,257  4,974
151 Stomach  8,468 0.172  1,455  5,772 0.254  1,467  2,922
157 Pancreas 11,513 0.300  3,459
 11,634
 0.142  1,653  5,112
161 Larynx  2,959 0.806  2,385    664 0.413    274  2,660
162 Trachea, lung, bronchus 82,459 0.796 65,659 36,227 0.750  27,170  92,829 
180 Cervix uteri      0 0.0       0  4,562 0.369  1,685  1,685
188 Urinary bladder  6,597 0.371  2,447  3,114 0.274    853  3,299
189 Kidney, other urinary  5,424 0.243  1,319  3,403 0.118    403  1,722
Circulatory diseases:
401-405 Hypertension 13,464 0.156  2,099 17,855 0.148  2,645  4,744
410-414 Ischemic heart disease
 <age 65 78,340 0.285 22,362 27,000 0.181  4,892  27,253 
410-414 Ischemic heart disease
 ≥age 65
211,003 
0.159  33,461 
224,756
 0.075  16,816  50,276 
427.5 Cardiac arrest 19,392 0.399  7,745 17,296 0.344  5,950  13,695 
430-438 Cerebrovascular disease 59,185 0.096  5,692 88,285 0.139  12,228  17,920 
440 Arteriosclerosis  9,235 0.238  2,200 15,216 0.315  4,797  6,996
441 Aortic aneurysm 10,323 0.624  6,444  4,791 0.468  2,244  8,689
Respiratory Diseases:
480-487 Pneumonia, influenza 28,774 0.208  5,986 28,935 0.093  2,679  8,664
491-492 Chronic bronchitis,
 emphysema 10,708 0.850  9,097  5,517 0.694  3,831  12,928 
496 Chronic airways obstruction 31,240 0.850 26,541 16,625 0.694  11,545  38,085 
Digestive diseases:
531-534 Ulcers  3,251 0.479  1,556  3,365 0.445  1,497  3,053
Pediatric diseases, <1 year old
765 Short gestation, 
 low birthweight  1,729 0.182    314     33 0.182    279    593
769 Respiratory distress syndrome  2,178 0.182    396  1,379 0.182    251    647
770 Other respiratory conditions 
 of newborn 1,982 0.182    360 1,515 0.182    275    636
798.0 Sudden infant death syndrome 3,176 0.128    405 2,069 0.128    264    669
Total
†
209,057 106,063 315,120 
* International Classification of Diseases, Ninth Revision.
† Sums may not equal total because of rounding.
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smoking in the United States continues to be enormous despite recent declines in the
prevalence of smoking. These figures do not include mortality and YPLL due to periph-
eral vascular disease (for which specific RR estimates are generally lacking), cancer at
unspecified sites, cigarette-caused fires, or involuntary (passive) smoking. In 1984, an
estimated 1,570 deaths were attributed to cigarette-initiated fires (13 ); an estimated
3,825 nonsmokers per year die from lung cancer attributed to involuntary smoking
(14) . When the figures for fires and involuntary smoking are included, the estimated
total of smoking-attributable deaths in the United States in 1984 is 320,515, or 15.7%
of all (2,039,369) U.S. deaths. Total smoking-attributable YPLL (949,924) represents
8.1% of all (11,761,000) U.S. YPLL before age 65 (excluding YPLL due to cigarette-
caused fires or involuntary smoking).
Among blacks, the smoking-attributable mortality (32,779) represents 13.9% of to-
tal 1984 mortality (235,884), whereas the smoking-attributable mortality for whites
(279,636) was 15.7% of total 1984 mortality (1,781,897), excluding deaths due to fires
or involuntary smoking. However, the smoking-attributable mortality rate and YPLL
rate were higher among blacks than among whites. These differences in rates reflect
a higher prevalence of smoking and a higher mortality rate from smoking-related dis-
eases among blacks. Higher YPLL rates among blacks may also reflect more smoking-
attributable deaths at earlier ages. Because blacks tend to smoke fewer cigarettes per
day than whites (15,16 ), the difference in smoking-attributable mortality and YPLL
rates between blacks and whites may be slightly overestimated. On the other hand,
the RR of smoking-related diseases among blacks may be higher than the RR esti-
mates used here because of increased interactions between smoking and other risk
TABLE 2. Estimated smoking-attributable mortality and years of potential life lost
(YPLL)*, by race and sex — United States, 1984
Mortality YPLL
Males Females Total† Males Females Total†
Whites 184,296  95,340 279,636 489,827 199,590 689,418
Blacks  22,647  10,131  32,779 129,952  63,473 193,425
Total population§ 209,057 106,063 315,120 661,651 288,273 949,924
*YPLL before age 65.
†Sums may not equal total because of rounding.
§Includes whites, blacks, and racial category “other.”
TABLE 3. Age-adjusted smoking-attributable mortality rates* and years of potential
life lost (YPLL) rates†, by race and sex — United States, 1984
Mortality rate YPLL
Males Females Total† Males Females Total
Whites 189.7 64.2 119.0  5.56 2.17 3.81
Blacks 236.5 75.5 143.2 12.07 4.85 8.14
Total population§ 192.6 68.0 133.2  6.53 2.71 4.56
*Per 100,000 persons (population data from 1984 U.S. Census).
†YPLL before age 65/1,000 persons <65 years (population data from 1984 U.S. Census).
§Includes whites, blacks, and racial category “other.”
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factors, different tar and nicotine exposures, or different smoking patterns. Still,
these findings support previously cited concerns regarding the increased burden of
smoking-related disease among blacks (17 ).
Smoking prevalence for 1985 was used to calculate the SAFs in this study. How-
ever, the 1984 smoking-related mortality is a result of a higher smoking prevalence
during the 1950s, ’60s, and ’70s, the decades during which these diseases were devel-
oping. Therefore, the SAFs used here are conservative.
CDC has examined YPLL before age 65 years since 1979 (6 ). In this study, most
smoking-related deaths (218,691, or 69.4%) occurred among persons ≥65 years of age.
Thus, the smoking-attributable YPLL among persons <65 reported here (949,924) is
substantially lower than the 3.6 million smoking-attributable YPLL calculated when
the average life expectancy in the United States is used for calculating YPLL for 1984.
Group-specific calculations such as these are possible for states and other defined
populations if mortality and smoking prevalence data for those populations are avail-
able. A computer program has recently been developed to aid in calculating mortality
and YPLL attributed to cigarette smoking (18 ). CDC is now collaborating with all
50 state health departments, Puerto Rico, and the District of Columbia to perform
similar studies. Results from this project will be reported in 1988.
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Editorial Note—1997
Ann M Malarcher, PhD, Jeffrey H Chrismon, Gary A Giovino, PhD, Michael P Eriksen, ScD, Office
on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion,
CDC.
In 1987, CDC published the preceding report that provided a detailed and compre-
hensive estimate of the number of deaths attributed to cigarette smoking in the United
States. Using the attributable fraction, which measures the magnitude of a public
health problem accounted for by an etiologic agent, CDC was able to quantify the
impact of smoking. This method established that smoking was the leading cause of
preventable deaths in the United States (1 ). As a result, increased emphasis was
placed on decreasing the health burden caused by tobacco use and on reducing ciga-
rette smoking. Since this SAM estimate was published in 1987, continued research
has increased understanding of the health risks associated with tobacco use, includ-
ing nicotine addiction and the recognition that addiction begins in childhood. Public
health programs have responded by focusing on preventing tobacco use among ado-
lescents, assisting in tobacco-use cessation, and protecting nonsmokers from
environmental tobacco smoke. This contemporary editorial note reviews previous
SAM estimates, presents new SAM estimates for 1990–1994, and discusses future im-
plications.
SAM and YPLL estimates for the United States published since the first estimate for
1984 include 390,000 deaths for 1985, 434,000 deaths and 6 million YPLL before age 85
for 1988, and 418,000 deaths and 5 million YPLL to life expectancy for 1990 (2 ). SAM
and YPLL also have been estimated for all 50 states and the District of Columbia for
1985 and for 1990 (3 ). Although all estimates were calculated by the same equation
used for the SAF, the data sources, study populations, and causes of death have
changed. The Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAM-
MEC) software program has also been used for calculating these estimates (2 ).
Since 1989, RR estimates for calculating SAM and YPLL have been obtained from
the American Cancer Society’s Cancer Prevention Study II (CPS-II) for 1982–1986 (4 ).
The CPS-II was selected, in part, because it is the largest prospective U.S. study that
has collected data on the relation between smoking and mortality (4 ). Recent SAM
estimates for adults have been limited to persons aged ≥35 years because the CPS-II
study population was restricted to this age range. Deaths from stomach cancer and
ulcers were dropped from the calculation of SAM because a causal relation has not
been established (4 ). Conversely, the cardiovascular and respiratory disease catego-
ries were expanded to include the International Classification of Diseases, Ninth Revi-
sion  [ICD-9], codes 390–398, 415–417, 420–429, 442–448, 010–012, and 493. The CPS-II
data also enabled the calculation of the RR for smoking and cerebrovascular disease,
which declines with age (4 ), for two age groups (35–64 years and ≥65 years). 
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Cigarette smoking remains the leading preventable cause of death in the United
States. The same methods and data sources that were used to calculate the 1990 SAM
and YPLL (2 )† were used for the 1990–1994 calculations, which indicated that
2,153,700 deaths (1,393,200 men and 760,400 women; total annual average: 430,700
deaths) were attributed to smoking (19.5% of all deaths). A total of 906,600 of these
deaths resulted from cardiovascular diseases; 778,700, from neoplasms; 454,800,
from nonmalignant respiratory diseases; 7900, from diseases among infants; and
5500, from smoking-related fires. Lung cancer (616,800 deaths), ischemic heart dis-
ease (IHD) (490,000 deaths), and chronic airway obstruction (270,100 deaths) ac-
counted for most deaths. During 1990–1994, cigarette smoking resulted in 5,732,900
YPLL before age 65 years and in 28,606,000 YPLL to life expectancy.
During 1990–1994, estimates of SAM were higher among men than among women,
reflecting their longer duration and higher prevalence of smoking and greater num-
bers of cigarettes smoked per day (6 ). Annual SAM rates will probably remain stable
if current trends in smoking prevalence among adults continue. Although the preva-
lence of smoking among persons aged ≥35 years decreased from 1985 to 1990 (28.4%
to 24.1%), during 1990–1994, smoking prevalence remained relatively constant—at
23.6%–24.8% (CDC, unpublished data). However, the prevalence of smoking among
U.S. adolescents has been increasing since 1992 (7 ). If these smoking patterns con-
tinue into adulthood, SAM and YPLL are expected to increase. Assuming that one
third of adult smokers, 10% of former smokers, and 5.3 million persons aged <18 years
die from smoking and that current smoking patterns continue, an estimated 25 million
persons alive today will die prematurely from smoking-related illnesses (7,8 ). 
Lung cancer has been and probably will continue to be the leading cause of SAM
because, although lung cancer death rates are decreasing among men, rates are con-
tinuing to increase among women (9 ). Among women, death rates for lung cancer
have surpassed those for breast cancer since 1987 (9 ). In addition, because recent
trends indicate a slowing of the decline in IHD mortality, IHD will probably remain a
major contributor to SAM  (9 ).
SAM and YPLL may be underestimated for several reasons (2 ); recent studies have
addressed two of these reasons. First, SAM and YPLL estimates are based on the
prevalence of current and former smokers in the current year; however, the deaths
that occur during a given year are primarily among persons who began smoking 30–
50 years earlier (10 ), many of whom have quit smoking (10 ). Including these persons
in the prevalence estimates of former smokers may decrease the SAF because the
summary measure of risk for former smokers does not reflect their increased likeli-
hood of dying from a smoking-related disease (4 ). Among whites, expanding the clas-
sification of smoking to include information on duration and number of cigarettes
smoked per day resulted in 10% larger SAM estimates for IHD than SAM estimates in
which smoking was categorized as current, former, and never (10 ). Second, the SAM
estimates do not include mortality caused by cigar smoking, pipe smoking, or smoke-
less tobacco use. Approximately 1000 deaths were attributable to pipe smoking in
1991 (11 ). 
†Except for the prevalence of smoking among pregnant women in the United States for 1992
through 1994, which was estimated from the 1992–1993 National Pregnancy and Health Survey
(5 ).
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Although SAM and YPLL estimates are not adjusted for confounders (2–4 ), a recent
study has documented little change in SAM estimates after adjustment for confoun-
ders (12 ). Among whites, SAM estimates for the combined disease categories of lung
cancer, IHD, bronchitis/emphysema, chronic airway obstruction, and cerebrovascular
disease were 2% higher than age-adjusted estimates after adjustment for relevant
confounders including age, education, alcohol intake, diabetes, and hypertension
(12 ) .
Cigarette smoking has resulted in approximately 10 million deaths since the first
Surgeon General’s report on smoking and health in 1964 (2,4,13 ). In 1993, $50 billion
in medical costs were attributable to smoking (14 ). The human and economic costs of
smoking will continue to accumulate until the completely effective implementation of
public health efforts to prevent initiation, to promote cessation, and to protect non-
smokers from the adverse effects of environmental tobacco smoke. Examples of such
efforts include Food and Drug Administration regulations to restrict youth access to
tobacco and to reduce the appeal of cigarette advertising to youth (7 ); comprehensive
state-based efforts, including tax increases and earmarked funding for tobacco-use
prevention and mass media campaigns similar to those in Massachusetts and Califor-
nia (15 ); physician adherence to the Agency for Health Care Policy and Research’s
smoking cessation guidelines (8 ); institutional adoption of the Guidelines for School
Health Programs to Prevent Tobacco Use and Addiction (16 ); and clean indoor-air
policies that protect nonsmokers. 
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